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Abstract 
 
Vaccinia virus (VACV) strain Western Reserve gene A40R encodes a type II 
membrane glycoprotein with a C-type lectin-like domain at the C terminus. The A40 
protein is not incorporated into virions, is nonessential for virus replication in cell 
culture and does not affect virus virulence in a murine intranasal model of infection. 
However, A40 does affect the outcome of infection in an intradermal infection model 
in which the virus lacking gene A40R produced smaller lesions and alterations in the 
host immune response.  
 
A40 has amino acid similarity to C-type lectins, such as NKG2A and DC-
SIGN. This observation together with its location on the infected cell surface and its 
ability to bind to the surface of cells of the immune system is consistent with A40 
functioning as an immunomodulator. It is possible that A40 might function by 
mimicking native host lectins or by modulating recognition of VACV-infected cells by 
cells of the immune system. 
 
 To investigate the mechanism by which A40 affects the outcome of infection in 
vivo, a cloning and experimental strategy was devised to search for its ligand(s) and try 
to determine its structure in collaboration with protein crystallographers. To achieve 
these goals, the recombinant A40 protein has been produced in E. coli, mammalian 
cells, and from insect cells infected with recombinant baculoviruses. Bacterially 
expressed recombinant A40 was used to generate an antibody specific to A40 and this 
was then purified, characterised and used to further the characterisation of A40. The 
potential for A40 to interact with a ligand on the surface of another cell was 
investigated by a cell binding assay using recombinant A40 protein. This protein was 
produced in a mammalian system and was found to bind to the surface of immune cells 
but not to epithelial cells. In cytotoxicity assays, the absence or over-expression of A40 
was found to modulate the ability of NK cells to kill VACV infected cells.  
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NKC   NK-gene complex 
NKR   NK receptor 
nM   nano molar 
NO   nitric oxide  
NP-40   nonidet P-40 
NYCBH  New York City Board of Health 
OAS   oligoadenylate synthetase 
OD   optical density 
OEP   overlapping extension PCR 
OMCP   Orthopoxvirus MHC class-I-like protein 
OPV   Orthopoxvirus 
ORF   open reading frame 
PAGE   polyacrylamide gel electrophoresis 
PAMP   pathogen-associated molecular patterns 
PBMC   peripheral blood mononuclear cell 
PBS   phosphate buffered saline 
PBSF   phosphate buffered saline containing 10% FBS 
PCR   polymerase chain reaction 
pDC   plasmacytoid dendritic cells 
PE   phycoerythrin  
PEG   polyethylene glycerol 
PEI   polyethylenimine 
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PFA   paraformaldehyde 
p.f.u   plaque forming unit(s) 
p.i.   post infection 
PI3K   phosphatidyltinositol 3-kinase 
PK   proteinase K 
PKR   protein kinase RNA-dependent 
PLC-γ   phospholipase C-γ 
PMN   polymorphonuclear neutrophilic leukocytes 
PNGase F  Peptide: N-Glycosidase F 
PRR   pathogen recognition receptor 
PSA   prostate-specific antigen 
RANTES  regulated on activation normal T cell expressed and secreted 
Rae   retinoic acid early transcript 
Rb   rabbit 
RCMV  Rat cytomegalovirus 
RCTL   rat C-type lectin 
Rev   revertant 
RG   Rosetta gami 
RIG   retinoic acid-inducible gene 
RK-13   rabbit kidney cells 
RNA   ribonucleic acid 
RNase   ribonuclease 
rpm   revolutions per minute 
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RPMI   Roswell Park Memorial Institute (medium) 1640 
RPXV   Rabbitpox virus 
RT   room temperature 
RT-PCR  reverse transcriptase polymerase chain reaction 
s   second(s) 
SAP   shrimp alkaline phosphatase 
SCR   short consensus repeat 
SD   standard deviation 
SDS   sodium dodecyl sulphate 
SEL   synthetic early/late promoter 
SEM   standard error of mean 
SeMet   selenomethionine 
SH2   SRC homology 2 
SHIP   SH2-containing inositol polyphosphate 5-phosphatase 
SHP   SH2-domain-containing protein 
sLe
x
   sialyl-Lewis X (sLe
x
) 
s6Le
x
   sialyl 6-sulpho Lewis X 
SOC   salt optimized broth with carbon 
SPI   serine protease inhibitor 
ss   single-stranded 
STAT   signal transducers and activators of transcription 
STING  stimulator of interferon genes 
Syk   spleen tyrosine kinase 
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TAA   tumour-associated antigens 
TAB   TAK-1 binding protein 
TAE   Tris/Acetate/EDTA buffer 
TAK   TNF-associated kinase 
TANK   TRAF-associated NF-κB activator 
Taq   Thermus aquaticus 
TB   Terrific broth 
TBK   TANK-binding kinase 
TBS   tris buffered saline 
TCA   trichloroacetic acid 
TCR   T cell receptor 
TE   Tris/EDTA buffer 
TEMED  N,N,N‟,N‟-Tetramethylethylenediamine 
TF   transcription factor 
6-TG   6- thioguanine 
TGF   transforming growth factor 
TGN   trans-Golgi network 
Th1   T helper cell type 1 
TIR   Toll/IL-1 receptor 
TK   thymidine kinase 
TLR   toll-like receptors 
TM    transmembrane domain 
TNF   tumour necrosis factor 
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TRAF   TNF receptor-associated factor 
TRAM   TRIF-related adaptor molecule 
TRIF   TIR domain containing adaptor inducing IFN-β 
Tris   tris-hydroxymethylamino methane (C4H11NO 3) 
TRITC   tetramethyl rhodamine isothiocyanate 
TYK   tyrosine kinase 
UL   unique long 
ULBP   UL16-binding protein 
UV   ultraviolet 
VACV   Vaccinia virus 
VARV   Variola virus 
vCKBP  viral CC chemokine binding protein 
VCP   virus complement control protein 
VETF   vaccinia early transcription factor 
VGF   virus growth factor 
VIG   VACV immunoglobulin 
VITF   vaccinia intermediate transcription factor 
VLTF   vaccinia late transcription factor 
VOTE   Vaccinia-lac Operon-T7-Encephalomycocarditis virus  
    upstream translational enhancer element 
v/v   volume/volume 
WHO   World Health Organisation 
WR   Western Reserve 
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WT   wild-type 
w/v   weight/volume 
X-gal   5-bromo-4chloro-3-indoly-β-Dgalactopyranoside 
Ζ   zeta 
ZAP-70  zeta-chain-associated protein kinase 
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Chapter 1. Introduction 
1.1 Introduction to poxviruses and their historical significance 
 The Poxviridae are a family of complex enveloped viruses with double-stranded 
(ds) DNA genomes, which replicate entirely in the cytoplasm of infected cells (Moss, 
2007). Vaccinia virus (VACV) is the most extensively studied member of the 
Poxviridae, which comprise 2 subfamilies, the Chordopoxvirinae and the 
Entomopoxvirinae, which infect chordates and insects respectively. The 
Chordopoxvirinae is divided into 8 genera (Table 1.1) and VACV is the prototype 
species of the Orthopoxvirus (OPV) genus, whose members include Variola virus 
(VARV) (Moss, 2007), the causative agent of smallpox. 
 
 Table 1.1 Poxvirus classifications.  
 Prototypical viruses are underlined and viruses with sequenced genomes are in bold. 
Subfamily Genus Member viruses 
Chordopoxvirinae Avipoxvirus 
fowlpox, canarypox, 
turkeypox 
 Capripoxvirus 
goatpox, sheepox, lumpy 
skin disease 
 Lepripoxvirus myxoma, rabbit fibroma 
 Molluscipoxvirus molluscum contagiosum 
 Orthopoxvirus 
camelpox, cowpox, 
ectromelia, monkeypox, 
taterapox, vaccinia, variola 
 Parapoxvirus 
orf, bovine papular 
stomatitis 
 Suipoxvirus swinepox 
 Yatapoxvirus 
yaba monkey tumour, 
tanapox, yaba-like disease 
Entomopoxvirinae Alphaentomopoxvirus melontha melontha 
 Betaentomopoxvirus 
amsacta moorei, melanoplus 
sanguinipes 
 Gammaentomopoxvirus chironomus luridus 
Unclassified poxviruses  crocodilepox, deerpox 
 
 In 1798, Edward Jenner exploited the immunological cross-reactivity between 
OPVs and started the process of vaccination (Jenner, 1798; Baxby, 1979; Baxby, 
1996). Smallpox is the only human disease to have been eradicated through human 
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intervention. By the 16
th
 century, smallpox was endemic in Europe and through 
European colonisation spread to other parts of the world. It was a greatly feared disease 
with up to 40% mortality and those who survived were usually left with deep-pitted 
scars (Mack, 1972; Fenner, 1993). The last known natural case occurred in 1977 in 
Somalia and the World Health Organisation (WHO) certified the disease as eradicated 
in 1980 (Fenner et al., 1988). Eradication was achieved through vaccination but the 
precise mechanisms of protection remain largely unknown. 
 The most commonly used VACV strains in the WHO eradication program were 
Lister and Elstree in Europe, New York City Board of Health (NYCBH), Dryvax and 
Wyeth in the United States, EM-63 in Russia and Temple of Heaven (Tian Tan) in 
China (Fenner, 1977). Of the many VACV strains isolated, VACV strains Copenhagen 
(Cop) (Goebel et al., 1990), Western Reserve ((WR), a derivative of NYCBH strain 
adapted by serial brain passage in mice) and International Health Division (IHD)-J 
(Parker, 1941) are the most commonly utilised laboratory strains. VACV has a broad 
host range although its origin and natural host remain unknown (Baxby, 1977).  
 Despite the eradication of smallpox more than 3 decades ago VACV continues 
to be a focus of research because its many interactions with the host cell and immune 
system have provided an insight into virology, cell biology and immunology. It was 
developed as an expression vector in 1982 (Mackett et al., 1982; Panicali & Paoletti, 
1982) and became widely used as a recombinant expression vector for laboratory 
research and vaccine development (Moss et al., 1983; Paoletti et al., 1984). As an 
expression vector it has several useful properties, such as the relative ease of 
constructing recombinant VACV, a large capacity for exogenous DNA (Smith & Moss, 
1983), relatively high levels of expression and a wide range of cells that can be targeted 
(Panicali & Paoletti, 1982; Moss et al., 1983; Mackett & Smith, 1986). Recombinant 
VACVs expressing genes from other pathogens, such as influenza virus (Panicali et al., 
1983; Smith & Moss, 1983) or hepatitis B virus (Smith et al., 1983), have induced in 
vaccinated animals immune responses against the foreign antigen expressed by the 
virus making VACV a potential vaccine vector. Attenuated strains of VACV, such as 
modified virus Ankara (MVA) (derived from chorioallantois virus Ankara (CVA) 
(Meisinger-Henschel et al., 2007)), are being developed with the aim of producing 
vaccines that induce protection but which are safer, causing fewer side-effects and 
complications. 
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1.2 Genome structure of OPVs 
 VACV has a linear, AT-rich (67%) dsDNA genome (Goebel et al., 1990; Moss, 
2001) which is approximately 190 kilobase pairs (kbp), although this varies depending 
on the strain. For instance, MVA is 165 kbp, (Antoine et al., 1998) and Duke is 199 
kbp (Li et al., 2006). The two DNA strands are covalently linked at the termini by 
incompletely base-paired hairpin loops into one continuous molecule (Baroudy et al., 
1982). The VACV strain Copenhagen genome contains about 200 open reading frames 
(ORFs) (Goebel et al., 1990; Johnson et al., 1993) and no introns have been identified. 
 Bioinformatic analyses of poxvirus genomes that have been sequenced revealed 
approximately 90 proteins are conserved in all chordopoxviruses and about half of 
these are present in all poxviruses (Upton et al., 2003; Gubser et al., 2004). The 
conserved genes are usually essential for replication and virion assembly and cluster in 
a central region of the genome, whilst genes that are non-essential and involved in 
immunomodulation or host range are usually located in the more variable terminal 
regions (Fig. 1.1).  
 At either end of the genome there are inverted terminal repeats (ITR) that 
consist of identical but oppositely orientated sequences. The ITRs of different VACV 
strains and OPVs vary in length (Gubser & Smith, 2002) due to various deletions, 
tandem repeat sequences and transpositions (Wittek & Moss, 1980). A highly 
conserved sequence is located near the terminal hairpin loops and is essential for the 
resolution of concatemeric DNA intermediates formed during DNA replication 
(DeLange & McFadden, 1987; Merchlinsky & Moss, 1989; Merchlinsky, 1990). 
 
 
 
Fig. 1.1 Diagrammatic representation of an OPV genome 
 
Variable VariableConserved
Approx. 30 – 60 kb Approx. 30 – 60 kbApprox. 80 -100 kb
ITR ITR
Terminal
loop
Terminal
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 The first sequence of a VACV genome was determined for the Copenhagen 
strain (COP) (Goebel et al., 1990) and with its publication, a genetic nomenclature was 
adopted in which the VACV ORFs were named according to their relative position (left 
to right) in the 16 fragments produced upon digestion of the VACV-COP genome with 
HindIII restriction endonuclease. The fragments were labelled A to P, with A being the 
largest fragment and P the smallest and the transcriptional orientation of each ORF was 
denoted by an L or R. Exceptions to this rule included ORFs in fragment C, which are 
located in the highly variable left end and which are numbered right to left. More 
recently, ORFs in the sequenced poxviruses have been numbered continuously along 
the genome, left to right, but the original nomenclature established for VACV 
Copenhagen remains a useful nomenclature for poxvirologists. 
 
1.3 Virion structure 
 VACV virions are large (360 x 270 x 250 nm), brick-shaped particles 
(Hollinshead et al., 1999; Cyrklaff et al., 2005) that are visible by light microscopy and 
lack the symmetry seen with other viruses such as helical and icosahedral capsids. 
VACV produces three distinct types of virion: intracellular mature virus (IMV), 
intracellular enveloped virus (IEV) and extracellular virions that include both the cell-
associated enveloped virus (CEV) and the extracellular enveloped virus (EEV). These 
different virions have different structures, locations, abundance and roles in the virus 
life-cycle. Some authors also refer to these virions as mature virus (MV) for IMV, 
wrapped virus (WV) for IEV and extracellular virus (EV) for both CEV and EEV 
(Moss, 2006). 
 All the virions are composed of a viral core surrounded by an IMV membrane. 
The core contains the genome associated with numerous viral structural proteins and 
enzymes required for early transcription (Munyon et al., 1967). The core is surrounded 
by the core wall, with a biconcave structure formed by separation of the core wall from 
the IMV membrane (Condit et al., 2006). The bilateral concavities are filled by 
amorphous masses termed „lateral bodies‟(Dubochet et al., 1994). IEV is formed by the 
wrapping of IMV with a double membrane derived from early endosomes or trans-
Golgi network (Tooze et al., 1993; Schmelz et al., 1994). IEV are transported on 
microtubules to the cell surface where its outer membrane fuses with the plasma 
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membrane to form CEV on the cell surface (Blasco & Moss, 1992) or EEV that is 
released from the cell. IMV represents the majority of progeny but remains inside the 
infected cell until cytolysis and is important for long-term stability in the environment 
and transmission between hosts. In contrast, EEV is important for in vivo dissemination 
of the virus (Payne, 1980).  
 
1.4 VACV life cycle 
 An overview of the VACV lifecycle is shown in Fig. 1.2 and can be divided 
into several steps: virus binding, entry, uncoating, gene expression, DNA replication, 
virion assembly and virion release. 
 
1.4.1 Virus binding 
 The binding of VACV to permissive cells is the primary step in establishing 
infection. Poxviruses are notable for their omission from a summary of the known 
cellular receptors of viruses (Sieczkarski & Whittaker, 2005). VACV can infect many 
diverse cell types, suggesting that either the viral receptor is ubiquitously expressed on 
cells or that the virus can bind to many different receptors (Moss, 2001). Several 
studies have shown that cell surface glycosaminoglycans (GAGs) can bind to distinct 
virus proteins but these interactions are not essential for VACV entry (Carter et al., 
2005). Several other types of molecules including cholesterol (Chung et al., 2005) and 
laminins (Chiu et al., 2007) may affect VACV binding and its subsequent entry. 
 
1.4.2 Virus entry 
 Due to the morphological differences between the two infectious forms of 
VACV, the IEV and EEV enter cells by different mechanisms (Vanderplasschen et al., 
1998a). Studies on IMV entry suggest there are several possible routes. IMV binds to 
cells and the IMV membrane fuses with the plasma membrane releasing the core into 
the cytoplasm (Carter et al., 2005). Fusion and entry may also take place within 
endosomes at low pH (Townsley & Moss, 2007) and a recent study supports a role for 
macropinocytosis (Mercer & Helenius, 2008) as an alternative pathway in the entry of 
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IMV. IMV fusion is mediated by a large fusion complex consisting of at least 9 
essential viral proteins (Senkevich et al., 2004; Brown et al., 2006). 
 The entry of EEV is complicated by the presence of an additional outer 
membrane, for simple fusion of the outer EEV membrane with the plasma membrane 
would release an IMV into the cell, which would still require removal of the IMV lipid 
envelope to obtain access of the core to the cytosol. Two models of EEV entry have 
been proposed and their relative importance may depend on the cell type being studied. 
In a process termed ligand-dependent non-fusogenic dissolution (Law et al., 2006), the 
EEV can interact with GAGs on the plasma membrane causing disruption of the outer 
membrane and exposure of the IMV to the cell surface. The IMV can then fuse to 
plasma membrane and release the core into the cytoplasm, leaving the outer membrane 
as a shroud over the fusing virion. In an alternative method, EEV is endocytosed by the 
cell and the EEV membrane is disrupted by acidification within an endosome, exposing 
the IMV. The IMV is then able to fuse with the endosomal membrane to release the 
core into the cytoplasm (Ichihashi, 1996; Vanderplasschen et al., 1998a). 
 
1.4.3 Gene Expression 
 Following entry into the cytoplasm, the viral core moves on microtubules (MT) 
deeper into the cell (Carter et al., 2003) and initiates a highly regulated temporal 
cascade of transcription and genome replication, all of which occur in the cytoplasm 
(Broyles, 2003). VACV genes are transcribed in a strictly controlled order that can be 
defined by four temporal gene classes: immediate-early, early, intermediate and late 
(Assarsson et al., 2008) and viral messenger RNAs (m RNAs) are capped and 
polyadenylated like eukaryotic mRNAs (Kates & Beeson, 1970; Wei & Moss, 1975).  
 
1.4.3.1 Immediate-early genes 
 The core contains all the necessary enzymes for early transcription associated 
with the genome (Golini & Kates, 1985; Rohrmann & Moss, 1985) including a DNA-
dependent RNA polymerase (Kates & McAuslan, 1967; Munyon et al., 1967), 
methylation capping enzyme, poly-A polymerase and various transcription factors (TF) 
(Yuen et al., 1987; Broyles et al., 1988). Recent genome-wide analysis of mRNA 
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expression from VACV WR revealed a set of 35 genes exhibiting immediate-early 
expression (Assarsson et al., 2008). This class of genes is characterised by expression 
within 0.5 h post infection (h.p.i.) and maximum expression was reached by 2 h.p.i 
before declining. Immediate early genes include those involved in virulence, immune 
evasion and DNA replication.  
 
1.4.3.2 Early genes 
 Early genes make up the largest class of ORFs, with 73 genes (as classified by 
(Assarsson et al., 2008). Expression is detectable within 1 h.p.i. and reaches maximum 
levels at 2 h.p.i. The early genes include proteins involved in transcription, DNA 
replication, immune evasion proteins and host cell modulators (Broyles, 2003). Early 
VACV promoters are approximately 15-bp long and lie at positions -28 bp to -13 bp 
upstream of the RNA start site. These promoters have the consensus sequence, 
AAAAATGAAAAAAA/TA, separated by a T-rich spacer sequence, (-12 to -2) from a 
7-bp region (-1 to +6) within which initiation occurs, usually at a purine (Davison & 
Moss, 1989a). Transcription of early genes terminates 30 – 50 bp downstream of a 
TTTTTNT signal (N represents any nucleotide), on the non-template strand of the 
DNA (Yuen & Moss, 1987; Piacente et al., 2008). 
 As yet there is no functional or genetic evidence for the subdivision of early and 
immediate-early genes. Intermediate-early and early transcription occurs within the 
core and the viral mRNA is extruded through pores in its surface and when the core is 
disassembled early transcription ceases. The uncoating of the viral genome from the 
core requires the proteolysis of some viral proteins and hydrolysis of the virion 
phospholipid (Zaslavsky, 1985) and is dependent on the novel synthesis of at least one 
early viral protein (Pedersen et al., 2000).  
 
1.4.3.3 Intermediate genes 
 Once DNA replication has started, intermediate transcription is initiated and 
requires several virus-encoded proteins including virus intermediate transcription 
factors (VITFs). (Sanz & Moss, 1999; Katsafanas & Moss, 2004). Intermediate genes 
encode proteins including late TFs (Keck et al., 1990; Zhang et al., 1992; Baldick & 
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Moss, 1993; Broyles, 2003). Intermediate transcripts are detected after 1.5 h.p.i. and 
peak at 2 h.p.i before declining. Intermediate promoters contain two elements, a 14 bp 
A/T rich upstream element separated by 10 or 11 bp from a TAAA initiator sequence, 
giving an overall core element with the sequence (A/T)8N12TAA(T/A)GG (Baldick & 
Moss, 1993).  
 For both intermediate and late genes, a 5‟ untranslated poly(A) leader sequence 
of about 35 bases is created by slippage of the VACV RNA polymerase on the AAA 
sequence of the transcription initiation motif (Schwer et al., 1987). During the 
intermediate and late phases of infection, the mRNAs are heterogeneous in length and 
do not have a defined 3‟ end (Mahr & Roberts, 1984; Baldick & Moss, 1993) due to a 
failure to terminate at the early termination sequences, which are no longer recognised 
by the RNA polymerase. 
 
1.4.3.4 Late genes 
 Late gene transcription is detected after 2 h.p.i and synthesis continues 
throughout the replication cycle (Baldick & Moss, 1993). Transcription begins once the 
necessary transcription factors and newly synthesised RNA polymerase are available 
(Broyles, 2003). Late gene products include the majority of structural proteins, the 
enzymes and TFs required for early transcription that become assembled into the 
virion, as well as some virulence factors that enhance viral immune evasion (Broyles, 
2003; Assarsson et al., 2008). In addition, late gene products are responsible for the 
resolution of the DNA concatemers into single genomes that are packaged into new 
virions  
 The late gene promoter is also bipartite, with the overall core sequence 
(A/T)6N9TAAAT, consisting of an upstream A/T-rich core region of around 20 bp and 
a conserved TAAAT element within which transcription initiates (Davison & Moss, 
1989b). This is often followed by a G with the resultant ATG acting as the translation 
start codon. 
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1.4.4 DNA replication 
 DNA replication occurs after early gene expression, within the cytoplasm at 
discrete sites termed viral factories. Individual infectious particles have the ability to 
initiate a separate factory and thereby, the number of factories in a cell is proportionate 
to the multiplicity of infection (MOI) (Moss, 2001). Several VACV proteins are 
required for synthesis of DNA precursors and for DNA replication. These include a 
DNA polymerase (Challberg & Englund, 1979; Earl et al., 1986), DNA helicases 
(Koonin & Senkevich, 1992), DNA ligase (Kerr & Smith, 1989), and enzymes for the 
synthesis of new nucleotides including ribonucleotide reductase (Slabaugh et al., 1988), 
thymidine kinase (Weir et al., 1982), thymidylate kinase (Smith et al., 1989a) and 
enzymes involved in proofreading such as deoxyuridine triphosphate (Broyles, 1993).  
 Replication starts approximately 1-2 h.p.i, with the introduction of a nick into 
one of the DNA strands near the terminal hairpin. The nick exposes a free 3‟OH group 
that acts as a primer for the initiation of replication (Moyer & Graves, 1981) and allows 
DNA polymerase to copy the hairpin and elongate to the end of the genome. The newly 
synthesised strand is self complementary and folds back on itself, allowing the DNA 
polymerase to continue along the genome and round the opposite hairpin so forming 
concatemers. These are resolved by specific nucleases (Shuman & Moss, 1987; 
DeLange, 1989; Garcia & Moss, 2001; Eckert et al., 2005) into monomers after late 
gene expression.  
 
1.4.5 Virus assembly, maturation & release 
 Virion assembly also occurs in the viral factories and involves a series of 
complex stages. The viral DNA and core proteins (Cassetti et al., 1998) are surrounded 
by membrane crescents which gradually extend into spherical immature virions (IV). 
These structures are then converted to a brick-shaped IMV particle by maturation via 
proteolytic cleavage of some capsid proteins (Moss & Rosenblum, 1973; Yang, 2007), 
loss of the scaffold protein D13 and condensation of the nucleoprotein core into the 
IMV particles.  
 The origin and number of the crescent membranes surrounding the IMV have 
been protractedly disputed since the mid 1990s. In the early 1960s Dales and co-
workers proposed that the membrane is a single lipid bilayer that is not associated with 
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cellular organelles. This theory has been supported by a large amount of EM data 
(Hollinshead et al., 1999; Heuser, 2005). A second proposal (Sodeik et al., 1993) 
suggested that the membrane was two tightly opposed membranes that originated from 
the immediate compartment between the endoplasmic reticulum (ER) and the Golgi. 
The one membrane model theory is now accepted in the field and is consistent with the 
membrane fusion mechanism for IMV entry (Carter et al., 2005). The debate as to 
whether the virion membrane is derived from de novo biogenesis (Dales & Mosbach, 
1968) or derived from pre-existing intracellular membranes (Sodeik et al., 1993; 
Sodeik & Krijnse-Locker, 2002) still rages (reviewed in (Roberts & Smith, 2008).  
 The majority of IMV are released from the infected cell during lysis but a 
proportion undergoes further morphogenesis to form EEV. This occurs predominantly 
in early stages of infection, as wrapping membranes can become depleted later in 
infection. IMV are transported out of virus factories on MTs (Sanderson et al., 2000; 
Ward, 2005) to near the microtubule organising centre (MTOC) where they become 
wrapped in a double-layer of membrane derived from the endosomes (Tooze et al., 
1993) or trans Golgi network (TGN) (Schmelz et al., 1994) to form IEV. The IEV are 
transported to the cell surface on MTs, utilising a kinesin-dependent mechanism 
(Hollinshead et al., 2001; Rietdorf et al., 2001; Ward & Moss, 2001), where the outer 
membrane fuses with the plasma membrane to form CEV that remain on the cell 
surface (Blasco & Moss, 1992) or is released from the cell as EEV (Smith et al., 
2002a). Actin nucleation, below the plasma membrane, induced by CEV propels the 
virion away from the infected cell and into surrounding cells or the extracellular space 
(reviewed in (Smith & Law, 2004).  
 
1.5 Effect of VACV on host cells 
 VACV infection induces early changes in cell morphology, adhesion properties 
and metabolism and eventually results in death of the infected cells. These changes are 
collectively termed the cytopathic effect (CPE). Effects include the inhibition of host 
protein synthesis (Bablanian et al., 1981), alterations to the extracellular matrix of cells 
leading to Ca
2+
-independent adhesion (Sanderson & Smith, 1998), cell rounding in a 
reversible and microtubule-dependent manner (Schepis et al., 2006) and virus-induced 
cell motility (Sanderson et al., 1998).  
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Fig. 1.2 Overview of the VACV lifecycle 
A cartoon diagram illustrates the VACV lifecycle. Extracellular enveloped virions (EEV, 1) and 
intracellular mature virions (IMV, 2) bind to and enter the cell, releasing the core into the cytoplasm. The 
core is translocated (3) by microtubules (MT) deeper into the cell to a perinuclear site. Production of 
early mRNAs (4) leads to uncoating of the core, release of the genome (5) and following replication of 
the viral genome (6), the production of intermediate (7) and late mRNAs (8). These are translated into 
structural proteins and early gene transcription machinery (9). Within the viral factories, a single genome 
interacts with the early transcription machinery plus structural proteins and these are assembled within 
membrane crescents to form immature virions (IV, 10). The IV undergoes nucleoprotein condensation 
and proteolytic cleavages of structural proteins to form IMV (11). Many IMV build up in the cell and are 
released upon cell lysis (12). However, a proportion undergo further morphogenesis. The IMV are 
transported on MT to sites of wrapping (13) by the trans golgi network (TGN) or early endosomes. IMV 
particles are wrapped by a double membrane (14) to form intracellular enveloped virions (IEV, 15). IEV 
are transported to the cell surface on MT (16). The outer IEV membrane fuses with the plasma 
membrane (17) to form cell-associated enveloped virions (CEV) on the cell surface. Actin 
polymerisation beneath the CEV forms actin tails (18), driving CEV towards neighbouring cells or 
releasing EEV that can infect either neighbouring or distant cells. 
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1.6 Use of VACV in medical research 
 The ability to generate recombinant VACV that express foreign genes (Mackett 
et al., 1982; Panicali & Paoletti, 1982) or delete VACV genes (Earl et al., 2001) has 
numerous applications in research. Recombinant VACVs are being used as a gene 
delivery agent (Guo & Bartlett, 2004), a vaccine vector for delivery of exogenous 
antigens for presentation to the immune system (Sutter & Staib, 2003; Gherardi & 
Esteban, 2005) or an oncotherapeutic agent (Shen & Nemunaitis, 2005). The use of 
VACV in these ways has been enabled by advances in the understanding of VACV‟s 
interaction with its host. 
 Recombinant VACV are generated by the construction of a plasmid containing 
the gene of interest under the control of a VACV promoter, flanked by VACV 
sequences that determine the site of insertion into the virus genome. Homologous 
recombination between the plasmid and the virus genome gives rise to recombinant 
VACV. The inclusion of selective markers such as β-galactosidase (Chakrabarti et al., 
1985), fluorescent proteins such as green fluorescent protein (GFP) (Dominguez et al., 
1998), or drug-selective proteins such as Escherichia coli (E. coli) guanine 
phosphoribosyltransferase (Ecogpt) (Boyle & Coupar, 1988) can be used to positively 
select for the recombinant viruses (Carroll & Moss, 1997). Alternative methods include 
in vitro ligation of a foreign gene into the virus genome (Merchlinsky & Moss, 1992), 
the rescue of infectious virus using the bacterial artificial chromosome (BAC) system 
with a non-replicating helper virus such as fowlpox virus (Domi & Moss, 2002; 
Cottingham et al., 2008) and the use of lepripoxviruses to aid recombination (Yao & 
Evans, 2003). 
 As well as being able to study the function of individual genes such as C12L  
(Symons et al., 2002a) or N1L (Bartlett et al., 2002) by null mutants for non-essential 
genes, techniques for inducible gene expression allow essential genes to be studied and 
can provide a system for replication control (Rodriguez & Smith, 1990; Ward et al., 
1995).  
 
1.6.1 VACV-based vaccines 
 After the success of VACV in the vaccination against and elimination of 
smallpox, research has turned to its use as a gene delivery system for heterologous 
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antigens. VACV has been used in a variety of clinical trials as vaccines for treatment of 
infectious agents such as rabies (Wiktor et al., 1984; Pastoret et al., 1988; Brochier et 
al., 1991) in which a recombinant VACV-rabies vaccine was developed for oral 
vaccination of foxes against rabies. Field trials proved safe and efficacious and 
eradicated rabies in areas of Europe where it was used.  
 Apprehensions about the safety profile of VACV are being addressed by the 
generation of attenuated vectors, focusing especially on MVA. MVA has lost the 
ability to replicate in most mammalian cells, is apathogenic even in immunodeficient 
animals and is safe in humans considered at risk from conventional VACV vaccines 
(Mayr & Danner, 1978; Blanchard et al., 1998; Sutter & Staib, 2003; Harrer et al., 
2005). In animal models, MVA vaccines have been shown to be immunogenic and 
protect against various infectious agents including influenza virus (Breathnach et al., 
2004; Veits et al., 2008), flaviviruses (Men et al., 2000; Nam et al., 2002), plasmodium 
parasites (Schneider et al., 1998; Moorthy et al., 2001) and simian immunodeficiency 
virus (Smith et al., 2004; Van Rompay et al., 2005; Martinon et al., 2008), either alone 
or as part of a heterologous prime-boost protocol.   
 Clinical trials in humans have confirmed that MVA is safe in 
immunocompromised patients and that MVA-based prime-boost strategies can induce 
T cell responses against human immunodeficiency virus (HIV) (Mwau et al., 2004; 
Goonetilleke et al., 2006) or tuberculosis specific (Hawkridge et al., 2008) antigen. 
Whilst these trials are encouraging, the need to improve the vectors has been 
recognised due to the failure of large scale phase II trials using MVA-malaria vaccines 
(Bejon et al., 2007a; Bejon et al., 2007b). Several strategies are being studied including 
the removal of immunomodulatory proteins from MVA (Staib et al., 2005) or the co-
expression of stimulatory molecules (Abaitua et al., 2006) as well as refining the choice 
of antigen to help induce a more potent immune response. 
 
1.6.2 VACV-based oncotherapy 
 VACV has been used in the treatment of cancer in three ways: as a vector for 
the delivery of anti-cancer genes to tumour cells, a vector for tumour-associated 
antigens and co-stimulatory molecules and as an oncolytic agent to selectively lyse 
tumour cells. The aim of the first two strategies is to stimulate immune responses that 
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target and eliminate active tumour cells. A recombinant VACV expressing the tumour 
suppressor p53 was generated using the Lister strain as a backbone (Timiryasova et al., 
1999; Fodor et al., 2005) and showed in vivo, the synergistic effect of combining an 
anti-tumour antigen with the co-expression of cytokines and co-stimulatory molecules 
such as interleukin (IL)-2 and IL-12 (Chen et al., 2000) to inhibit tumour growth. 
Recombinant VACV expressing specific tumour antigens have also been developed. 
Immune responses are often repressed by tumour-induced immune anergy, and VACV-
based vectors expressing tumour-associated antigens (TAAs) are designed to re-
stimulate the immune response to these cells. Some TAAs are expressed at low levels 
in normal tissues but over-expressed in a particular cancer including carcinoembryonic 
antigen (CEA) (Greiner et al., 2002; Schmitz et al., 2002), prostate-specific antigen 
(PSA) (DiPaola et al., 2006) and mucin 1 (Scholl et al., 2000). Other vaccines target 
TAAs that are involved in carcinogenic viral lifecycles such as MVA-E2, where 
antibodies to human papillomavirus (HPV) E2 target macrophages to destroy tumour 
cells (Rosales et al., 2000).  
 VACV itself is capable of directly lysing tumour cells in which it replicates. 
Oncolytic therapeutic strategies exploit the naturally high level of VACV replication in 
tumour cells or alternatively VACV may be modified to target it preferentially to 
tumour cells (McCart et al., 2001; Mullen & Tanabe, 2002; Thorne et al., 2005). 
 
1.7 Innate immune response to VACV infection 
 At the onset of infection, VACV is confronted by the innate and subsequent 
adaptive immune response that contains and eventually eliminates the viral infection. In 
response to this threat, VACV has evolved numerous ways to modulate the immune 
response and its immune evasion mechanisms have become the subject of intense study 
in recent years.  
 In animal models of VACV infection, infection occurs through exposure at the 
subcutaneous layer of the skin or through mucus membranes in the airways and the first 
host immune response is mediated by innate leukocytes and non-specific mechanisms 
of microbial recognition. VACV induces, and thereby needs to modulate, innate 
immune mechanisms including the complement system, macrophages, natural killer 
(NK) cells, γδ T cells and the antiviral state induced by interferons (IFNs).  
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1.7.1 Complement 
 The complement system is an important effector component of both the 
adaptive and innate response. The complement system is made up of at least 30 plasma 
and cell surface proteins and includes 3 activation pathways. The main function of 
these pathways is to mark targets permanently for destruction, to recruit other proteins 
and cells that facilitate the target‟s destruction and in the case of some bacteria and 
viruses to participate directly in the destructive process by osmotic lysis. Many of the 
proteins of the activation pathways are proteinases and activation occurs in a cascade 
by proteolytic activation of one zymogen that then activates the next zymogen in the 
pathway. Antigen-antibody complexes provide the activating signal for the classical 
pathway of complement activation. Sequential activation of complement components 
C1, C4 and C2 produces the key enzyme C3 convertase which acts to cleave and 
activate C3. C3 cleavage results in a small C3a fragment, a potent anaphylatoxin that 
induces mast cell degradation, promotes inflammation and recruits phagocytotic cells, 
and the larger C3b fragment that covalently attaches to the activating antigen, marking 
it for destruction. C3b acts as a site for activation and assembly of the complement 
membrane attack complex (MAC), a self-assembling pore-forming complex formed 
from plasma membrane proteins C5, C6, C7, C8 and C9 that kills targets by osmotic 
lysis. C3b also acts as an opsonin, enhancing phagocytosis by binding complement 
receptors on neutrophils and macrophages.  
 The second pathway, the alternative pathway, is activated without antibody 
(Ab) by microbial structures that neutralise inhibitors of spontaneous complement 
activation via C3bBb, the alternative pathway convertase. This leads to the deposition 
of C3b and the activation of MAC. The mannan-binding lectin (MBL) pathway utilises 
the MBL protein, a serum protein of the collectin family that is structurally and 
functionally similar to C1q of the classical pathway and binds to mannose-containing 
carbohydrates on microbial surfaces. This interaction activates MBL-associated serine 
proteases (MASP) 1 and 2 that activate C4 and thereby the remainder of the pathway. 
Recent studies have implicated a role for extrinsic proteases and coagulating molecules 
in the initiation of complement, expanding its role in the innate immune response 
(Atkinson & Frank, 2006; Markiewski et al., 2007). Activation of the complement 
system can lead to the lysis of virions, the neutralisation of virions through 
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opsonisation, membrane lysis of infected cells, increased phagocytosis and chemotaxis 
of neutrophils. 
 VACV encodes a 35 kDa secreted protein, related to the family of complement 
control proteins (CCP), called vaccinia complement control protein (VCP). It is most 
closely related to human C4b-binding protein (C4BP), contains multiple short 
consensus repeats (SCRs) and interacts with cells bearing C4b to prevent binding to the 
complement receptor 1 (Kotwal & Moss, 1988b). VCP also inhibits complement 
activation by both the classical and alternative pathways (Isaacs et al., 1992a). There 
have been three other VACV proteins proposed as complement modulates: B5 has 
amino acid (aa) similarity to factor H, a regulator of the alternative pathway, and two 
proteins from VACV strain rabbitpox (RPXV) that show significant aa similarity to 
complement proteins. RPXV B20 is similar to the complement component C5 whilst 
RPXV M2 shows similarity to C4a and C3 (Bloom et al., 1991).  
 VACV also resists complement-induced neutralisation by the incorporation of 
cellular modulators, cluster of differentiation (CD)55 and CD59 proteins, into the outer 
membrane of EEV (Vanderplasschen et al., 1998b). Host cells express these regulatory 
proteins to down-regulate complement activation and prevent unwanted damage to host 
tissues. CD55 inhibits the formation and accelerates the decay of C3-convertases 
involved in the classical and alternative pathways whilst CD59 prevents the formation 
of MAC. 
 
1.8 Innate immune cells 
 Phagocytic cells engulf pathogens and use intracellular vacuoles to focus toxic 
effector molecules such as nitric oxide (NO) and degenerative enzymes in an effort to 
destroy the organism. The major phagocytic cells are neutrophils, monocytes and 
macrophages and are crucial initiators and regulators of innate and adaptive immune 
responses. 
 
1.8.1 Neutrophils 
 Neutrophilic polymorphonuclear leukocytes (PMN) mediate their role in host 
defence after their rapid recruitment to sites of infection via chemotaxis, by the 
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phagocytosis of pathogens, secretion of the contents of their vesicles and production of 
reactive oxygen intermediates. Activated neutrophils also interact with dendritic cells 
(DC) to induce DC maturation (van Gisbergen et al., 2005). In this way, neutrophils 
may contribute indirectly to triggering adaptive responses via T cells. Activated 
neutrophils release neutrophil elastase (NE, also called Elastase 2), a powerful serine 
protease that along with its degenerative properties can induce inflammation (Korkmaz 
et al., 2008) through the modulation of cytokines (Bank & Ansorge, 2001) and up-
regulation of gene expression by the activation of IL-1R/Toll-like receptor (TLR) 
pathways. NE up-regulates IL-8 via TLR-4 (Walsh et al., 2001; Wiedow & Meyer-
Hoffert, 2005), and thereafter IL-8 attracts and activates neutrophils in a positive 
feedback loop.  
 Neutrophils can phagocytose radiolabelled VACV in vitro (West et al., 1987). 
In the intradermal (i.d.) infection model of VACV infection, granulocytes were seen to 
increase slightly by day 2 p.i and continue to increase to day 10 p.i. when their numbers 
began to decline (Jacobs et al., 2006). VACV also down-regulates the NE signalling 
cascade by interfering with the TLR signalling pathways (discussed in section 1.9.1) 
instigated by NE (Carroll et al., 2005). 
 
1.8.2 Macrophages 
 Macrophages have important functions as antigen presenting cells (APC) for the 
activation of NK and T cells, phagocytosis of pathogens and immunomodulation by the 
secretion chemokines, cytokines and components of the complement system (Fujiwara 
& Kobayashi, 2005). They also have an important role in cross-presentation of antigen 
to activated T cells (Ramirez & Sigal, 2002). Macrophages are a major cell population 
in most tissues in the body and their numbers increase further during inflammation, 
wounding and malignancy. In tissues with close contact to the environment, such as the 
skin, approximately 50% of murine leukocytes are macrophages (Dupasquier et al., 
2004) whilst they represent 95% of resident phagocytic cells in the respiratory tract and 
lungs (Curtis & Kaltreider, 1989).  
 Resident macrophages constitute a major subpopulation of leukocytes in mouse 
dermal tissue and early after VACV infection (day 4), increase in number (Jacobs et al., 
2006). Their importance in the control of VACV infection is illustrated by several 
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studies. When macrophages are depleted in a murine intranasal (i.n.) model of VACV 
infection, the overall severity of infection increased, with reduced clearance of VACV 
and a more pronounced weight loss (Luker et al., 2005; Rivera et al., 2007). VACV 
replication is abortive in activated macrophages (McLaren et al., 1976; Buchmeier et 
al., 1979; Natuk & Holowczak, 1985). In freshly isolated murine peritoneal 
macrophages, VACV infection induces nitric oxide synthase expression (Karupiah & 
Harris, 1995) and is important in control of VACV and ectromelia virus (ECTV) 
infection, inhibiting DNA replication and late protein synthesis (Karupiah et al., 
1998).Whilst in the murine macrophage cell line RAW 246.7, VACV inhibited NO 
production (Bellows et al., 2003). VACV infection of macrophages results in apoptosis 
via a mechanism that is dependent on early gene expression and is NO-independent 
(Humlova et al., 2002).  
 
1.8.3 Natural killer cells 
 NK cells are large granular lymphocytes that contribute to the early immune 
response to virus infection either by lysis of infected cells or by the release of antiviral 
cytokines in particular IFN-γ (Biron & Brossay, 2001; Mercer et al., 2005; Vivier et al., 
2008). During inflammation, viral infection and tumour growth, NK cells are rapidly 
recruited from the blood into injured tissues. They are activated by IFNs and 
macrophage-derived cytokines (IL-2 and tumour necrosis factor (TNF)-α) and may 
recognise infected cells either directly, through identification of alteration in expression 
of major histocompatibility complex (MHC), or via Fc receptors on bound Abs, leading 
to Ab-dependent cellular cytotoxicity (ADCC). 
 A balance between activating and inhibitory receptors from cellular interactions 
and soluble mediators control the cytolytic activity of NK cells, with their activation 
being stringently controlled by inhibitory receptors that act as a „fail-safe‟ to avoid 
inadvertent stimulation and consequential harm to normal cells. The susceptibility of 
target cells to natural killing is inversely related to their expression of MHC class I 
molecules. NK cells survey cells for down-regulation or over-expression of MHC class 
I or „missing-self‟ (Fig. 1.3), with activating receptors dampening or regulating signals 
depending on the target cell encountered. 
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1.8.3.1 NK cell receptors 
 Most activating and inhibitory NK cell receptors are encoded by genes in two 
genomic regions, the NK-gene complex (NKC, (Yokoyama et al., 1991; Yokoyama & 
Plougastel, 2003)) and the leukocyte-receptor complex (LRC (Wende et al., 1999)). 
While the receptors in the LRC belong to the immunoglobulin (Ig) superfamily, the 
NKC-encoded molecules encode lectin-like molecules.  
 The human killer Ig-like receptors (KIR), are a family of type I membrane 
proteins which possess two (2D) or three (3D) Ig domains, with either a long (L) or 
short (S) cytoplasmic domain. Each member interacts with a group of closely related 
human leukocyte antigen (HLA) class I molecules that are determined by the aa 
belonging to the C-terminal portion of the α1 helix of the MHC class I molecule 
(Boyington & Sun, 2002). KIRs with long cytoplasmic tails are inhibitory and contain 
immunoreceptor tyrosine-based inhibitory motif (ITIM) sequences, while those with 
short tails activate cytotoxicity via interactions with immunoreceptor tyrosine-based 
activation motif (ITAM) containing adaptor molecules by a charged aa residue in the 
transmembrane region (TM). 
 A second group of receptors known as immunoglobulin-like transcript (ILT) are 
also members of the Ig superfamily and are categorised into three groups: those with 
ITIM motifs, those with short cytoplasmic domains and a charged aa residue in the TM, 
and a member that contains no transmembrane segment (Borges et al., 1997). These 
receptors are expressed in monocytes, macrophages, DCs, B, T and NK cells (Colonna 
et al., 1999). ILT-2 is expressed on NK cells and is targeted by the human 
cytomegalovirus (HMCV) protein UL18, a MHC class I homolog (Cosman et al., 1997; 
Wilkinson et al., 2008). 
 Members of the NKC lectin-like family of NK receptors are dimeric type II 
transmembrane glycoproteins, with each chain comprising an extracellular C-type 
lectin-like domain (CTLD, (Drickamer, 1999)) connected by a stalk region of 25-75 
residues to transmembrane and cytoplasmic domains. These receptors include the 
murine Ly49 receptors (Wilhelm et al., 2002), the natural killer cell receptor protein 1 
(NKR-P1) receptors (Giorda et al., 1990), the human and murine CD94/NKG2 family 
of receptors (Boyington et al., 1999) and CD69 (Llera et al., 2001). The Ly49 family 
(Karlhofer et al., 1992; Wilhelm et al., 2002) comprise receptors with a single CTLD 
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and are expressed as disulphide-bonded homodimers. Ly49A, C and G2 contain 
cytoplasmic ITIMs and function as MHC class-I-specific inhibitory receptors 
(Matsumoto et al., 1998), although Ly49G2 has some peptide specificity (Brennan et 
al., 1996). Ly49D and Ly49H function as activating receptors, with a transmembrane 
arginine residue for association with the adaptor protein DNAX-activating protein of 
molecular mass 12 kDa (DAP12). Activating Ly49 receptors regulate lymphocyte 
function-associated antigen 1 (LFA-1) intercellular adhesion molecule 1 (ICAM-1) 
dependent adhesion between cytolytic cells and their target cells (Osman et al., 2007), 
and promote the delivery of cytotoxic granules towards target cells (Bryceson et al., 
2005). 
 The NKG2 family, like Ly49 and NKP-P1 families, contains activating 
(NKG2C, -E and –H) and inhibitory members (NKG2A and –B) (Plougastel et al., 
1996). NKG2 molecules must dimerise with the invariant CD94 molecule for 
expression at the cell surface and signalling functions (Lazetic et al., 1996). Human 
CD94/NKG2A and CD94/NKG2C recognise the non-classical MHC class I molecule 
HLA-E (Braud et al., 1998), while the murine CD94/NKG2A, -C and –E recognise the 
HLA-E related molecule Qa-1 (Vance et al., 1998). HLA-E and Qa-1 are similar to 
MHC class I molecules but bind and present leader peptides of classical MHC class I 
molecules and non-classical HLA-G. Thereby, NK cells can monitor individual HLA 
allele changes by KIRs but also the global expression of class I molecules and HLA-E 
itself by CD94/NKG2 heterodimers. CD94/NKG2 receptors are expressed on most NK 
cells, γδ T cells and a subset of effector/memory CD8+ γδ T cells  
 The activating receptor NKG2D is distinct from other NKG2 molecules as it is 
expressed as a disulphide-bonded homodimer by NK, NKT cells, γδ T cells, CD8+ T 
cells and macrophages (Bauer et al., 1999). There is also only limited sequence 
similarity between NKG2D and other NKG2 molecules (28% aa identity for the lectin-
like domain) whereas other NKG2 molecules are closely related to each other (~ 70% 
aa identity). In humans, the NKG2D ligands are MHC class-I-chain related protein 
(MIC) A, MICB, and the unique long (UL)16-binding protein (ULBP) family (Bauer et 
al., 1999; Cosman et al., 2001). The murine ligands are the minor histocompatibility 
molecule H-60 (Diefenbach et al., 2000), members of the retinoic acid early transcript 
(Rae) 1 family (Cerwenka et al., 2000) and mouse ULBP-like transcript 1 (Mult1, 
(Carayannopoulos et al., 2002; Diefenbach et al., 2003)). The NKG2D ligands are type 
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I transmembrane proteins related to MHC class I molecules but do not associate with 
β2-microglobulin (β2m), nor do they bind peptides. The NKG2D receptor thereby 
recognises self proteins that are inducible (Groh et al., 1996; Li et al., 2001) and up-
regulated on the surface of most tumours and many infected cells. Signalling pathways 
associated with infection, such as TLR signalling (see Section 1.9.1), lead to the up-
regulation of NKG2D ligands on macrophages (Hamerman et al., 2004). 
 The NKR-P1 family (Giorda et al., 1990; Mesci et al., 2006) includes NK1.1 
(NKR-P1C, (Ryan et al., 1992)), a serological marker of NK cells from C57Bl/6 mice. 
NKR-P1C acts as an activating receptor, with a charged residue at the TM and interacts 
with FcεRIγ. Only NKR-P1A (Lanier et al., 1994) has been identified in humans, and is 
found on only a subset of NK cells whilst murine NKR-P1C is expressed by all NK 
cells and a subset of T cells (NKT cells). Originally NKR-P1 receptors were thought to 
recognise carbohydrates (Bezouska et al., 1994) but physiological ligands were shown 
to comprise a group of C-type lectin-like proteins designated C-type lectin-related 
protein (Clr) (or Clec2 or Ocil (Plougastel et al., 2001; Zhou et al., 2001; Iizuka et al., 
2003; Carlyle et al., 2004)). Although they lack at least one of the conserved cysteines 
thought to form disulphide bridges in CTLDs, Clr-b can recognise certain GAGs in a 
Ca
2+
-independent manner (Plougastel et al., 2001). Only two ligands for the murine 
NKR-P1 receptors have been demonstrated: Clr-b is a ligand for the inhibitory NKR-
P1B and D receptors (Carlyle et al., 2004) and is expressed on a broad range of cells, 
whereas Clr-g is a ligand for the activating receptor NKR-P1F (Iizuka et al., 2003) and 
is expressed preferentially in activated NK cells. 
 Other molecules encoded by the NKC have been identified. These include the 
killer cell lectin-like receptor subfamily F1 (KLRF1, or NKp80, (Roda-Navarro et al., 
2000; Vitale et al., 2001)) and a human NKC-encoded lectin-like molecule that 
contains cytoplasmic tyrosine residues that are not typical of ITIM or ITAM and has no 
charged TM residues. The ligand of KLRF1 is another lectin-like receptor, human 
activation-induced C-type lectin (AICL, (Hamann et al., 1997; Welte et al., 2006)). 
KLRG1 (also known as mast cell function-associated antigen (MAFA)) was identified 
on rat mast-cells (Guthmann et al., 1995). Human and murine orthologues are 
expressed on NK and T cell subsets but not mast cells (Blaser et al., 1998; Corral et al., 
2000) and bind cadherin-E, -N and –R to inhibit lysis of cells expressing the cadherins 
(Ito et al., 2006). Human lectin-like transcript 1 (LLT1, (Boles et al., 1999)), AICL and 
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mouse Clr form another family, related to CD69 and are among the earliest cell-surface 
molecules induced during lymphocyte activation. 
 Each NK cell usually expresses only a selection of these receptors, so the NK 
cell population has a diverse repertoire of different MHC class I specificities and other 
ligands including DNA-damage or stress-induced ligands (Valiante et al., 1997; Kubota 
et al., 1999; Raulet et al., 2001). NK cells can also recognise target cells indirectly 
through CD16, a receptor specific for the Fc region of IgG, thereby activating ADCC 
towards these Ab-bound cells.  
 
1.1.1.1.1 Signalling from inhibitory and activating NK receptors 
 Inhibitory receptors mediate their effect through ITIM sequences (V/IxYxxL/V) 
in their cytoplasmic domains. When phosphorylated, ITIMs recruit and activate Src 
homology 2 (SH2)-domain-containing protein tyrosine phosphatases (SHP)-1, SHP2 
(Campbell et al., 1996; Olcese et al., 1996; Yusa & Campbell, 2003) or SH2-
containing inositol polyphosphate 5-phosphatase (SHIP), depending on the receptor 
analysed. The phosphorylation of SHP-1 or SHP-2 results in a decrease in 
phosphorylation of numerous intracellular proteins involved in activatory signal 
transduction, see below (Valiante et al., 1996; Palmieri et al., 1999; Stebbins et al., 
2003)). 
 Activating receptors lack an intracellular ITIM and instead have a charged 
residue in their TM domain that allows their non-covalent association with signalling 
adaptor molecules containing an intracytoplasmic ITAM. The ITAM is defined by the 
prototype sequence Yxx(L/I)x6-8Yxx(L/I) (Reth, 1989). NK cells express three ITAM-
containing adaptor proteins FcεRIγ (Hibbs et al., 1989), CD3δ (Anderson et al., 1989), 
and DAP12 (Lanier et al., 1998). The phosphorylation of the tyrosine residue recruits 
protein tyrosine kinases including spleen tyrosine kinase (Syk) and zeta-chain-
associated protein kinase 70 kDa (ZAP-70). Their recruitment and phosphorylation 
initiate several kinase cascades and the release of intracellular calcium to trigger the 
cytolytic cascade and cytokine release (McVicar et al., 1998). This response is coupled 
to a series of downstream regulators including phospholipase C-γ (PLC-γ), 
phosphatidylinositol 3-kinase (PI3K), extracellular-signal regulated kinase (ERKs), the 
Vav family guanine nucleotide exchange factor (Galandrini et al., 1999) and Rho-Rac 
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guanosine 5'-triphosphate (GTP)-binding proteins and their effectors, reviewed in 
(Colucci et al., 2002). The mouse NKR-P1C associates with the ITAM-containing 
adaptor protein FcεRIγ (Arase et al., 1997) while the human NKR-P1A receptor does 
not contain ITIM sequences nor does it contain a charged residue in the TM (Lanier et 
al., 1994). The human NKR-P1A receptor modulates NK cell function via the 
activation of acid sphinomyelinase and N-acyl-sphingosine (ceramide) generation, 
which can induce apoptosis, proliferation, and differentiation in cells (Pozo et al., 
2006). 
 In most cell lines NKG2D pairs with DAP10, which lacks an ITAM, and 
instead contains the tyrosine-based motif YxxM that binds to the p85 subunit of PI3K 
(Wu et al., 1999). In murine NK cells, NKG2D associates with DAP12 (Diefenbach et 
al., 2002; Gilfillan et al., 2002) and DAP12 is necessary for NKG2D-induced cytokine 
production (Diefenbach et al., 2002). This is due to mice having two isoforms of 
NKG2D, that are generated by alternative splicing and differ in the presence (NKG2D-
L) or absence (NKG2D-S) of 13 aa at the N terminus in the cytoplasmic domain 
(Diefenbach et al., 2002; Gilfillan et al., 2002). NKG2D activation can also activate 
Janus activated kinase (JAK) 2, signal transducers and activators of transcription 
(STAT) 5, ERK 1/2 and mitogen-activated protein kinase (MAPK) 1/2 (Sutherland et 
al., 2002).  
 
1.8.3.2 NK cell activity in OPV infection 
 Several observations suggest that NK cells play a role in defence against VACV 
infection. In mice, NK cells are recruited to the site of infection in mice as early as 6 
h.p.i. (Natuk & Welsh, 1987; Prlic et al., 2005). In the i.d. model of VACV infection, 
NK cells represented only <1% of the lymphocyte population in mock-infected ears, 
but increase after infection up to day 7 p.i. in infected ears (Jacobs et al., 2006). 
Depletion of NK cells renders mice more susceptible to VACV infection (Bukowski et 
al., 1983; Karupiah et al., 1991). In athymic nude mice, which lack functional T cells, 
NK activity was 3-fold higher than in control animals, perhaps to compensate for 
reduced CD8
+
 T cell activity (Karupiah et al., 1990). Following infection by ECTV, 
NK cells are necessary for initial recovery (Jacoby et al., 1989; Fang & Sigal, 2005). 
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 In humans, VACV provokes an increase in the susceptibility of cells to NK cell-
directed lysis ex vivo (Brooks et al., 2006; Chisholm & Reyburn, 2006). Direct action 
of type I IFN on NK cells, but not on DCs, is required for NK activation in response to 
VACV infection in vitro and in vivo, and this activation of NK cells can lead to 
efficient VACV clearance (Martinez et al., 2008), although in the context of VACV 
infection in vivo, DCs participate in the direct activation of NK cells (Raulet, 2004). As 
infection progresses, there is a reduction in cytolytic capacity of NK cells, indicating 
that NK cells are subject to infection themselves (Brutkiewicz et al., 1992; Kirwan et 
al., 2006), although it could be that down-regulation of their activity occurs by 
mechanisms other than direct infection. Some groups have seen sufficient down-
regulation of MHC class I molecules (Kirwan et al., 2006) or non-classical MHC class 
Ib molecules on the cell surface of infected cells to prevent KIR-mediated or NKG2A 
protection of the target cell respectively and NK cells exhibit increased lysis of VACV-
infected targets in vitro (Baraz et al., 1999).  
 Although deletion of the VACV genes N1L (Jacobs et al., 2008) or F3L 
(Froggatt et al., 2007) altered the NK cell responses in the i.n. model, VACV encoded 
proteins that directly prevent NK-mediated destruction of target cells, such as those 
encoded by human and murine cytomegalovirus (Krmpotic et al., 2002; Dunn et al., 
2003; Lodoen & Lanier, 2005) have not been reported.  
 In Cowpox virus (CPXV) and Monkeypox virus (MPXV), the orthopoxvirus 
MHC class I-like protein (OMCP) is secreted during infection and is a competitive 
antagonist of NKG2D, thereby inhibiting NKG2D-dependent NK killing of infected 
cells (Campbell et al., 2007). It has been hypothesised that OPVs will encode a 
modulator of NK function only if they modulate MHC expression excessively, as is 
seen with CPXV (Byun et al., 2007; Dasgupta et al., 2007) and some herpes viruses 
(Ziegler et al., 1997; Fruh et al., 2002; Trgovcich et al., 2006) but not VACV. MPXV 
does not down-regulate MHC class I or II in vitro but has been shown to inhibit T cell 
responses by a mechanism that requires cell-to-cell contact and is MHC class I and II 
processing/presentation independent (Hammarlund et al., 2008). 
 As well as modulating expression of host proteins including MHC class I 
molecules (van der Wal et al., 2002; Barel et al., 2003) and NKG2D ligands (Beck & 
Barrell, 1988; Dunn et al., 2003), some CMV encode decoy ligands to immune cell 
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receptors (Lodoen & Lanier, 2005). Whilst MHC class I homologs (Arase et al., 2002; 
Smith et al., 2002b) inhibit T and NK cell function in an MHC-dependent manner, rat 
CMV (RCMV) encodes the C-type lectin-like protein RCTL that acts as a decoy ligand 
for the inhibitory NK receptor NKR-P1B (Voigt et al., 2001; Voigt et al., 2007) in an 
MHC-independent manner. During RCMV infection, expression of NKR-P1B‟s 
cellular ligand, Clr-b, is rapidly down-regulated. RCTL subverts NK killing of infected 
cells by counteracting the loss of Clr-b. 
 
1.8.4 NKT cells 
 NKT cells are a subset of T lymphocytes that express NK markers (Bendelac, 
1995). The T cell receptor (TCR) consists of an invariant T cell α chain paired with one 
of the three β chains and NKT cells are regarded as non-specific innate cells. NKT cells 
recognise CD1d, a non-polymorphic MHC class I-like ligand which binds self- and 
foreign lipids and glycolipids. Upon activation, NKT cells are able to produce large 
quantities of IFN-γ, IL-4, granulocyte-macrophage colony-stimulating factor (GM-
CSF) and multiple other cytokines and chemokines (such as IL-2 and TNF-α) within 
minutes of activation (Ota et al., 2005). Both activatory and inhibitory NK receptors 
(Section 1.8.3.1) are expressed by subsets of T cells, including NKG2D, NKR-P1, 
KIRs, Ly49 and CD94/NKG2 receptors (Raulet, 2003; Vivier & Anfossi, 2004). 
 In the i.d. model of VACV infection, subsets of T cells expressing the NK cell 
marker NK1.1 were very low (<1%) in uninfected tissue and did not increase after 
infection, whilst a subset expressing the marker DX5 (CD49b) emerged p.i. and 
underwent >400-fold expansion in cell number. At day 9 p.i. 67% were 
DX5
+
CD3
+
CD4
+
 and 28% were CD8
+
. After day 10 p.i. the percentage and number of 
these cells had decreased corresponding with the observed decrease in lesion size 
(Jacobs et al., 2006). 
 
1.8.5 Importance of C-type lectins in immune response 
 C-type lectins are a group of Ca
2+
-dependent (C-type) carbohydrate-binding 
(lectin) proteins that contain a compact domain that mediates carbohydrate binding 
called the carbohydrate recognition domain (CRD). Comparison of different proteins 
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CRDs revealed conserved residues that are characteristic of the domain (Drickamer, 
1988; Drickamer, 1989). As the number of proteins identified with these motifs has 
grown it became apparent that not all proteins with CRDs can bind carbohydrates or 
Ca
2+
 and the term C-type lectin-like domain (CTLDs, (Drickamer, 1999)) was coined to 
describe such domains. The superfamily of proteins containing CTLDs is a large group 
of proteins with diverse functions. The classification of the family members is based on 
the overall domain architecture of the CTLD-containing proteins reviewed in 
(Drickamer & Fadden, 2002; Zelensky & Gready, 2005). The CTLD fold is a double-
loop structure (loop-in-loop), stabilised by two conserved disulphide bridges located at 
the bases of the loops formed by four cysteines (C1-C4). The second loop, (long loop 
region) is structurally and evolutionary flexible and is involved in Ca
2+
-dependent 
binding. These domains bind the hydroxyl groups of monosaccharides in complex with 
a Ca
2+
 ion, which is coordinated by a highly conserved Asp-Glu-Cys (EDC) motif. 
CTLDs can be divided into two groups depending on the presence (canonical) or 
absence (compact) of a long loop region. CTLDs that are not related to the classical 
fold by sequence, have been identified, such as the link-protein type module of CD44 
(Kohda et al., 1996) and the angiogenesis inhibitor protein endostatin (Hohenester et 
al., 1998). CRDs generally have a low affinity for their ligands but this is compensated 
by having multiple CRDs in a single peptide or oligomerisation of multiple single 
CRDs (Bouyain et al., 2001; Cambi & Figdor, 2005). 
 Whilst many CTLDs selectively bind carbohydrates, others bind proteins (NK 
receptors, (see Section 1.8.3.1), reviewed in (Natarajan et al., 2002)), lipids ((Sano et 
al., 1998; Shi et al., 2001), inorganic compounds (such as calcium carbonate (Geider et 
al., 1996)) and ice (Ewart et al., 1992). 
 The NK cell receptor group of CTLD-containing proteins (Group V lectins), as 
described in section 1.8.3.1 are all type II TM proteins containing divergent CTLDs. 
Group V not only contains the NK cell receptors but also structurally-related proteins 
such as the lectin-like oxidized low-density lipoprotein receptor (LOX-1), which plays 
an important role in leukocyte extravasation upon inflammatory stimuli and in 
scavenger function (Hayashida et al., 2002; Honjo et al., 2003) and Dectin-1. Dectin-1 
lacks cysteines in its stalk region, and therefore probably does not dimerise and has an 
ITAM in its cytoplasmic tail. Unusually, Dectin-1 recognises carbohydrates (β-glucan, 
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(Weis et al., 1998; Brown et al., 2003)) but lacks many of the conserved residues in the 
CRD indicative of carbohydrate binding in other lectins (Drickamer, 1999). 
 Another important family of C-type lectins are the selectins (E-, L- and P- 
selectin), which mediate adhesion and homing of leukocytes by the recognition of 
carbohydrates sialyl-Lewis X (sLe
x
) and sialyl 6-sulpho Lewis X (s6Le
x
), (Erbe et al., 
1992; McEver et al., 1995; Nelson et al., 1995; Bouyain et al., 2001). In a similar way, 
the macrophage mannose receptor (MMR) is multifunctional, acting as a scavenger 
receptor via carbohydrate binding (Leteux et al., 2000) and in phagocytosis of 
microbial pathogens (Weis et al., 1998) and under certain conditions, can mediate 
lymphocyte binding via L-selectin (Irjala et al., 2001). Another family of CTLD 
proteins involved in trafficking of leukocytes is the type II receptors which include DC-
specific ICAM-3-grabbing non-integrin (DC-SIGN), DC-SIGN receptor (DC-SIGNR) 
and DC immunoreceptor (DCIR). All the type II receptors contain one Ca
2+
-dependent 
CRDs. The interaction between DC-SIGN and ICAM-2 regulates the chemotaxis of 
DCs across resting and activated endothelium (Geijtenbeek et al., 2000a), mediates 
DC-T cell interactions (Geijtenbeek et al., 2000c; van Kooyk & Geijtenbeek, 2002) and 
acts as an antigen uptake receptor on DCs (Engering et al., 2002). The latter process is 
exploited by HIV (Geijtenbeek et al., 2000b; Geijtenbeek et al., 2000c). The CRD of 
DC-SIGN is separated from the TM region by a neck region, consisting of seven 
complete and one incomplete tandem repeat sequences. This neck region is required for 
oligomerisation (Mitchell et al., 2001) and ligand binding (Bernhard et al., 2004). 
 The collectins are a group of soluble C-type lectins that can neutralise a broad 
range of bacterial and fungal pathogens through aggregation or complement activation 
via the MBL pathway. Collectins can also induce the production of pro-inflammatory 
molecules, such as cytokines, and reactive oxygen species in phagocytes by interacting 
with other cell surface receptors or by scavenging of bacterial molecules, for example 
lipopolysaccharide (LPS). 
 Utilising a diverse superfamily of proteins, the host can distinguish self and 
non-self as well as drive cell trafficking to specific areas, as and when different cell 
populations are required. C-type lectins have been described in bacteria and viruses. 
Bacterial CTLD-containing proteins include toxins such as pertussis toxin (Stein et al., 
1994) whilst viral CTLD proteins include structural envelope proteins and have been 
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found in many viruses including VACV (Duncan & Smith, 1992; Wilcock et al., 1999), 
fowlpox virus (Afonso et al., 2000), African swine fever virus (ASFV, (Neilan et al., 
1999; Galindo et al., 2000)), Epstein-Barr virus (EBV, (Mullen et al., 2002)) and 
alcelaphine herpes virus (Ensser et al., 1997). Whilst bacterial CTLD proteins were 
assigned to the CTLD superfamily on the basis of structural similarity only, viral 
CTLD proteins contain a canonical CTLD and show similarity to mammalian CTLDs 
.  
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Fig. 1.3 Representation of NK cell-target interactions that can activate NK function 
Left panels depict the signalling components of the NK cell as a balance of contact-mediated inhibitory 
(polygons) and stimulatory (circles) signals. Innate cytokines (stars and sliding weight) can alter the 
equilibrium. Right panels schematise interactions between the two cell types. (a) A resting NK cell in 
contact with a normal uninfected target is inhibited, as inhibitory signals constitutively outweigh 
activating signals. Infected cells often down-regulate inhibitory MHC class I molecules (b) and up-
regulate ligands for activating receptors (c). They also induce „innate‟ cytokines that bias NK-cell ligand 
recognition and signalling in favour of triggering (d). Adapted from (Carayannopoulos & Yokoyama, 
2004)  
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Fig. 1.4 Natural killer cell receptors and their signalling pathways 
(A) Representation of the types of receptors and their domains present on human and mouse NK cells 
(Vivier & Anfossi, 2004) (B) Signal transmission from NK cell-receptors. (i) The recruitment and 
activation of ITIM-containing adaptors such as SHP-1, by inhibitory receptors leads to the 
dephosphorylation of proteins whose phosphorylation is necessary for conveying activating signals. (ii) 
Activating receptor complexes on NK cells associate with the ITAM-bearing adaptor molecule DAP12 
through charged residues in their transmembrane regions. The membrane adaptor protein DAP10 does 
not have an ITAM in its cytoplasmic region but has an YxxM motif that is a potential Src homology 2 
(SH2) binding domain. Activation of NK cells through ligation of these complexes leads to recruitment 
and activation of SH2 domain-containing protein tyrosine kinases, such as Syk or ZAP-70, except for 
NKG2D which recruits PI3-kinase. Adapted from (Borrego et al., 2002) 
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1.8.6 DCs 
 DCs are APCs that play an essential role in bridging innate and adaptive 
responses to infection by activating naïve CD4
+
 and CD8
+
 T cells. Immature DCs, such 
as Langerhans cells (LC), reside underneath the epithelia of peripheral tissues where 
they are ideally located to acquire antigens of invading pathogens. Pathogen structures 
such as LPS and endogenous signals from CD40-CD40L interactions and TNF-α 
production by NK cells mediate DC maturation. Mature DCs leave the peripheral 
tissues and migrate to lymph nodes to present MHC-bound antigen to T cells which in 
turn initiates T cells responses. A subset of DCs termed plasmacytoid DCs (pDCs) are 
responsible for the production of high levels of type I IFN in some viral infections that 
activate NK cells (Andoniou et al., 2005) and inducing an antiviral state in cells 
bearing IFN receptors (discussed in Section 1.9.3.1). 
 CD11c
+
MHC II
+
 APC cells (dermal DCs and LCs) increase only slightly post-
VACV infection and their number are comparable to the number seen in situ prior to 
infection (Jacobs et al., 2006) when they make up approximately 10% of the cell 
population in the mouse dermis (Dupasquier et al., 2004). Direct visualisation of 
sectioned lymph nodes by confocal microscopy showed direct presentation of VACV 
antigen to prime CD8
+
 T cells by infected DCs (Norbury et al., 2002). Depletion of 
DCs in mice abrogates the production of IFN-γ by T cells following MVA infection, 
suggesting DC-mediated antigen presentation is required for the induction of T cell-
mediated responses in vivo (Liu et al., 2008). Whilst MVA induces moderate activation 
of DCs (Drillien et al., 2004), VACV WR or VACV Cop inhibits maturation of 
immature DCs (Engelmayer et al., 1999; Drillien et al., 2000; Drillien et al., 2004) 
inducing delayed apoptosis ex vivo and infection of DCs by both strains is abortive 
(Drillien et al., 2004). Mature DCs seem to be more resistant to VACV-induced cell 
death and can induce naïve CD8
+
 T cell responses (Yates & Alexander-Miller, 2007). 
VACV infection inhibits their migration without altering surface expression of 
chemokine receptors or impairing cellular locomotion (Humrich et al., 2007). In vivo, 
VACV infection induces DC maturation but impaired DC antigen-presentation function 
by reducing MHC class II expression (Yao et al., 2007). Despite this modulation of DC 
function by VACV, uninfected bystander DCs may induce viral antigen-specific 
cytotoxic T lymphocytes (CTLs) by cross-presentation rather than by direct antigen 
presentation (Larsson et al., 2001; Ramirez & Sigal, 2002; Liu et al., 2008). 
61 
1.8.7 T cell receptor γδ cells 
 TCR γδ cells are a minor proportion of lymphocytes (<10%) in peripheral blood 
but are abundant in the epidermis (Asarnow et al., 1988) and are the first line of 
defence that is crucial for the control of viral infection (Bukowski et al., 1994; 
Ninomiya et al., 2000) including infection with VACV. In contrast to αβ T cells, γδ T 
cells can target antigens directly, not just via MHC presentation (Kaufmann, 1996). 
 In the i.d. model of VACV infection, γδ T cells were the major populations of 
lymphocytes up to day 4 p.i. with their number increasing up to this point but with no 
change relative to the percentage of the total leukocyte population until after day 4 
when their relative percentage began to decrease (Jacobs et al., 2006). In mice lacking 
γδ T cells, virus titres were significantly higher and these mice had increased mortality 
compared to normal mice (Welsh et al., 1997; Selin et al., 2001) attributed to enhanced 
VACV replication early after infection. Upon infection by VACV, there was a 4-fold 
increase in γδ T cells and 12% of the γδ T cells were producing IFN-γ compared to 1% 
in uninfected mice (Selin et al., 2001). In a VACV-challenge study on vaccinated 
patients, an expansion of VACV-specific γδ T cells was seen, indicating that a memory 
effector γδ T response was induced (Abate et al., 2005; Agrati et al., 2006). 
 
1.9 Pattern recognition receptors (PRRs) 
 The recognition of microbial „non-self‟ lies in the ability of the host to 
recognise conserved products of microbial metabolism that are unique to the microbial 
organism and not produced by the host, termed pathogen-associated molecular patterns 
(PAMPs) and these include nucleic acid, protein or lipid structures. These PAMPs are 
recognised by receptors called pattern recognition receptors (PRRs). PRRs can be 
secreted, membrane bound or soluble. Secreted PRRs bind to microbial cells and flag 
them for destruction by the complement system or phagocytosis, whilst membrane 
bound and soluble receptors activate signalling pathways that induce anti-microbial 
responses upon PAMP recognition. The importance of TLRs in the detection of viral 
infection and activation of antiviral effector mechanisms is highlighted by the ways that 
viruses have developed to modulate these signalling pathways. 
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1.9.1 Toll-like receptors (TLRs) 
 TLRs are a family of PRRs expressed particularly on macrophages and DCs but 
also on neutrophils, eosinophils and many epithelial cells. TLRs are present in the 
plasma membrane or endosomal membrane. There are at least 10 human TLRs and 12 
murine TLRs. Each TLR is a transmembrane receptor that contains a cytoplasmic 
Toll/IL-1 receptor (TIR) domain and an extracellular leucine-rich repeating (LRR) 
domain and recognises a unique subset of PAMPs (Takeda & Akira, 2007). Upon 
activation, the TIR domain recruits TIR domain-containing adaptors, myeloid 
differentiation factor 88 (MyD88) for TLR1, 2, 4-9 and TIR domain-containing adaptor 
inducing IFN-β (TRIF) for TLR 3 and 4. Both pathways lead to the activation of 
transcription factors such as nuclear factor – kappa –light chain-enhancer of B cells 
(NF-κB) and IFN-regulatory factors (IRFs). These regulate the expression of genes that 
encode IFNs and pro-inflammatory cytokines (Fig. 1.5). TLR 1, 2, 5 and 6 are mostly 
expressed on the plasma membrane. TLR4 is expressed on the plasma membrane and 
early endosomes and TLR3, 7, 8 and 9 are restricted to late endocytic components 
(reviewed in (Blander, 2007). 
 
1.9.1.1 TLR 2 
 TLR2 recognises a variety of components from microbial pathogens and have 
been shown to detect Gram-positive bacteria via lipopeptides. Infection of TLR2
-/-
 mice 
with VACV showed that the VACV-stimulated secretion of pro-inflammatory 
cytokines by DCs is dependent on the TLR2/MyD88 pathway and this pathway is 
required for activation of innate immunity to control of VACV in vivo (Zhu et al., 
2007). This pathway is also important in the development of effector and memory 
formation in VACV infection in vivo by survival of activated T cells (Quigley et al., 
2009). 
 
1.9.1.2 TLR3 
 TLR3 recognises dsRNA and thereby is expected to be a key component in host 
recognition of viruses. DNA viruses as well as RNA viruses can produce dsRNA due to 
hybridisation of complementary transcripts. In an i.n. model of VACV infection TLR3
-
/-
 mice were unexpectedly more resistant to infection than wild-type (WT) with less 
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weight loss and reduced morbidity and mortality (Hutchens et al., 2008a). These 
findings were attributed to the role of TLR3 in the recruitment of leukocytes to the site 
of infection and its role in the induction of cytokines including IL-6 and TNF-α, which 
may regulate the adverse affects of VACV in vivo.  
 
1.9.1.3 TLR4 
 The role of TLR4 in recognition of LPS, a major component of Gram-negative 
bacteria has been well characterised. TLR4 can also recognise components of the 
extracellular matrix produced in response to tissue damage. As well as MyD88-
dependent signalling, TLR4 can activate TRIF-dependent signalling and has been 
reported to limit replication of a number of viruses (Kurt-Jones et al., 2000; Georgel et 
al., 2007). TLR4 was shown to mediate protection against VACV in an i.n. infection 
when viral titre was compared inC3H/HeJ mice (with a TLR4 mutation) and WT mice 
(Hutchens et al., 2008b).  
 
1.9.1.4 TLR7, 8 and 9 
 TLRs7, 8 and 9 recognise single stranded (ss)RNA, nucleotide analogues and ss 
CpG-DNA, respectively, within endosomal compartments. The role of TLR9 in VACV 
infection was demonstrated using TLR9-deficent mice and highlighted the importance 
of TLR9 in DC recognition of poxviruses. MVA and ultraviolet (UV)-inactivated CVA 
activated DCs in normal mice whilst infectious CVA inhibited TLR9 recognition. 
MVA was less efficient at inducing maturation of TLR9-deficient DCs, suggesting 
MVA has lost some of the immune inhibitory components and this recognition utilises 
a TLR9-dependent component (Samuelsson et al., 2008). 
 TLR7 and TLR8 have also been postulated to play a role in the innate response 
to VACV infection (Miller et al., 2008) via the recognition of non-host nucleic acids by 
macrophages and DCs (Bauer et al., 2008), but these responses have not been fully 
characterised. 
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1.9.1.5 Modulation of TLR signalling by VACV 
 The intracellular VACV protein A52 inhibits the activation of NF-κB by 
multiple TLRs via its association with interleukin 1 receptor associated kinase 2 
(IRAK2) and TNF receptor-associated factor 6 (TRAF6) (Harte et al., 2003). This 
association displaces TNF-associated kinase (TAK)-1 binding protein (TAB1) from the 
TRAF6 complex and MyD88 adaptor-like (MAL) from the IRAK2 complex.  
 A46 targets host TIR adaptors such as MyD88 and TRIF (Stack et al., 2005) 
and thereby inhibits the translocation of NF-κB into the nucleus. A46 also interacts 
with two other TIR adaptor proteins MAL and TRIF-related adaptor molecule (TRAM) 
and thereby down-regulates TRIF-dependent pathways that induce IRF3 activation 
leading to expression of IFN-β. 
 The roles of A46 and A52 are not redundant as demonstrated by the attenuated 
phenotype resulting from deletion of either gene (Harte et al., 2003; Stack et al., 2005). 
Furthermore, both proteins are needed to efficiently shut down TLR3 signalling, whilst 
only A46 is required for the inhibition of TLR-induced MAPK activation (Stack et al., 
2005).  
 NF-κB modulates the expression of many genes that are critical for the innate 
and adaptive immune response to infection and can be stimulated by multiple pathways 
including TLRs and by cytokines such as IL-1 and TNF-α (reviewed in (Perkins, 
2007)). The importance of this molecule in controlling virus infection is exemplified by 
the number of VACV proteins that modulate its function or signalling pathways leading 
to its activation. 
 VACV protein B14 is an intracellular virulence factor made early during 
infection (Chen et al., 2006). B14 interacts with the inhibitor of kappa B (IκB) kinase 
(IKK) complex via IKK-β, thereby inhibiting the activity of the IKK complex and 
preventing NF-κB activation from multiple signalling pathways (Chen et al., 2008). 
 M2 inhibits the phosphorylation of ERK2 and subsequent NF-κB activation 
(Gedey et al., 2006). Unlike the aforementioned modulators of NF-κB, M2 is located 
exclusively at the ER and this localisation is necessary for its function (Hinthong et al., 
2008). It has been postulated that M2 could inhibit the ER-localised protein, stimulator 
of interferon genes (STING, (Ishikawa & Barber, 2008)), which is involved in NF-κB 
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and IRF3 activation and the subsequent induction of IFN, although this hypothesis has 
yet to be investigated (Barber, 2008). 
 K1L is a VACV protein that prevents the degradation of IκBα (Shisler & Jin, 
2004) and thereby the translocation of NF-κB into the nucleus. It also has a role in 
VACV host cell restriction and allows replication in rabbit cell lines (Bradley & 
Terajima, 2005). The significance of its NF-κB-regulatory function in this host 
restriction and the mechanism by which it inhibits IκBα degradation is not well defined. 
 VACV K7 is a cytosolic protein that inhibits induction of IFN-β (Schroder et 
al., 2008) by interacting with the RNA helicase protein DEAD-box protein 3 (DDX3) 
(Kalverda et al., 2009) preventing TANK-binding kinase (TBK) 1 and IKKε from 
activating IRF3. 
 
 
Fig. 1.5. Representation of TLR signalling and VACV modulation of these pathways 
Adapted from (Akira & Takeda, 2004). 
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1.9.2 Soluble PRRs 
 The cytosol is also equipped with PRRs capable of detecting viral infections. 
 
1.9.2.1 DNA sensing molecules 
 The DNA-dependent activator of IFN regulatory factors (DAI) protein binds 
cytosolic Z-DNA (Takaoka et al., 2007). Upon binding, the protein undergoes 
homodimerisation and phosphorylation and recruits TRAF-associated NF-κB activator 
(TANK)-binding kinase (TBK)1 and IRF3 and induces type I IFN expression (Wang et 
al., 2008). Wang et al., also demonstrated the presence of additional cytosolic DNA-
sensing molecules, by suppressing the DAI protein, but these remain unidentified. 
 
1.9.2.2 RNA sensing molecules 
 The RNA helicases retinoic acid-inducible gene 1 (RIG-1) and melanoma 
differentiation-associated gene 5 (MDA-5) mediate recognition of viral RNA (Asahina 
et al., 2008; Takeuchi & Akira, 2009). Both proteins contain two N-terminal cysteine-
aspartic acid protease (caspase) activation and recruitment domains (CARDs) and a C-
terminal DexD/H box RNA helicase domain. Whilst RIG-1 recognises the 5‟-
triphosphate end of RNA and MDA-5 senses dsRNA both proteins associate with the 
adaptor protein IFN-β promoter stimulator 1 (IPS-1) via its CARD (Kawai et al., 2005). 
IPS-1 then associates with TRAF3, which recruits TBK1 and IKKε leading to 
phosphorylation of IRF-3 and IRF-7 leading to type I IFN production. 
 The dsRNA-dependent PKR contains two dsRNA binding domains and a 
serine-threonine kinase domain that phosphorylates eukaryotic initiator factor (eIF) 2, 
leading to an arrest in translation of both cellular and viral mRNAs (Garcia et al., 
2007). PKR also functions downstream of TLR3 signalling to amplify the signal by 
interaction with TBK1. PKR can transmit these signals to eIF2 but also to the STAT 
protein family, IRF1, c-Jun N-terminal kinases (JNKs), p38 MAPK and NF-κB (Deb et 
al., 2001; Takada et al., 2007) and can also induce apoptosis (Lee & Esteban, 1994).  
 The dsRNA-dependent enzyme 2‟5‟-oligoadenylate synthetase (2‟5‟-OAS) 
converts adenosine triphosphate (ATP) to 2‟5‟-linked oligoadenylates with a 
2‟5‟phosphodiesterase bond instead of 3‟5‟ (Hovanessian, 1991). These molecules 
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activate the endoribonuclease RNase L, which cleaves mRNA and rRNA, thereby 
leading to inhibition of protein synthesis.  
 The VACV E3 protein contains an N-terminal domain with similarity to the Z-
DNA binding domain of DAI (Kim et al., 2003). This domain contributes to virus 
virulence in a murine intracranial model (Brandt et al., 2005), can inhibit apoptosis and 
gene transactivation (Kwon & Rich, 2005), but its involvement in the DAI pathway 
remains unconfirmed. The effect of E3 on the RNA-independent induction of IFN-α via 
the phosphorylation of IRF3 and IRF7 (Smith et al., 2001) could be explained by a 
down-regulation of the DAI pathway. 
 E3 also has a role in the modulation of dsRNA sensing by its C-terminal 
domain that binds and sequesters dsRNA (Rice & Kerr, 1984; Chang & Jacobs, 1993; 
Beattie et al., 1995). E3 inhibits the activity of PKR (Chang et al., 1992) and OAS 
(Rivas et al., 1998), thereby inhibiting the IFN antiviral response to VACV. 
 The role of the VACV K3 protein overlaps with E3 but accomplishes the 
inhibition of translation by a different mechanism. K3 has aa similarity to a domain of 
eIF2α and acts as a pseudo-substrate for PKR thereby preventing the phosphorylation 
of eIF2 (Beattie et al., 1991; Davies et al., 1992; Davies et al., 1993; Kawagishi-
Kobayashi et al., 1997). Both K3 and E3 influence VACV host range. The importance 
of E3 and K3 varies depending on the cell type and level of different viral nucleic acid 
sensors (Shors et al., 1997; Langland & Jacobs, 2002). 
 
Fig. 1.6 Modulation of soluble PRR signalling by VACV infection 
Representation of soluble PRRs involved in the innate immune response to VACV infection and the 
targets of VACV immune evasion proteins E3 and K3. 
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1.9.3 Soluble mediators of immune response 
1.9.3.1 Interferon (IFNs) 
 IFN plays a crucial role in host defence against virus infection and can induce 
direct antiviral effects, growth-inhibitory effects, as well as promote adaptive immune 
responses such as promoting T helper cell type 1 (Th1) responses (Muller et al., 1994). 
IFN was discovered more than 50 years ago as an agent that inhibited the replication of 
influenza A virus (Isaacs & Lindenmann, 1957). The IFNs now refer to a family of 
structurally-related cytokines and three classes of IFN (IFN I, II and III) as well as IFN-
like cytokines have been identified.  
 Type I IFNs (Pestka et al., 2004; Langer, 2007) include IFN-α, β, κ (LaFleur et 
al., 2001), ε, ω, τ (Roberts et al., 1999), δ (Lefevre et al., 1998) and ξ (limitin) (Oritani 
et al., 2000) and bind a common receptor complex composed of two subunits, IFNAR1 
and IFNAR2 (Abramovich et al., 1994). IFNs α and β are the best characterised and are 
induced by PRRs and their downstream signalling cascades. IFNs are among the 
earliest host molecules up-regulated upon viral infection. IFN-β induction leads to up-
regulation of IFN-α. The binding of type I IFNs to IFNAR can induce the induction of 
more than 300 IFN-stimulated genes (ISGs). Many of the gene products encode PRRs 
that detect viral molecules and modulate signalling pathways as well as TFs that form 
an amplification loop resulting in the generation of an anti-viral state in cells. Some 
ISGs encode proteins with direct anti-viral activity that catalyse cytoskeletal 
remodelling, induce apoptosis, induce shut-down of protein synthesis (including 
RNaseL and PKR), stimulate the expression of MHC class I molecules on the surface 
of the cell and induce more pro-inflammatory cytokines. 
 In contrast to type I IFNs, there is only one type II IFN, IFN-γ: IFN-γ does not 
have marked structural similarity to type I IFNs and binds a different dimeric receptor 
comprising IFNGR1 and IFNGR2. IFN-γ has direct anti-viral activity but is also 
associated with the adaptive immune response because it is secreted by T cells and 
promotes Th1 adaptive responses. IFN-γ is also secreted by macrophages and NK cells 
and leads to the activation of further inflammatory cells. Many ISGs are regulated by 
both type I and II IFNs, whereas others are selectively regulated by distinct IFNs. 
 Type III IFNs (IFN-λ1-3) were discovered more recently (Kotenko et al., 2003) 
and have antiviral properties. Type III IFNs signal through a receptor composed of 
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IFNLR1 and IL-10Rβ. They can induce similar outcomes to type I IFNs but are less 
widely expressed than type I IFNs although they are abundant in dermal tissues.  
 
1.1.1.1.2 Classical IFN signalling pathway 
 Exposure of cells to viruses or dsRNAs induces the production of IFN-α, IFN-β 
and IFN-ω through the activation of PRRs especially the TLRs, cytosolic dsRNA and 
DNA sensors as discussed above. Each of the IFN receptor subunits interact with a 
member of the JAK family (Darnell et al., 1994). The IFNAR1 subunit associates with 
tyrosine kinase (TYK) 2 whereas IFNAR2 is associated with JAK1, whilst for the type 
II IFN receptor, IFNGR1 and IFNGR2 associate with JAK1 and JAK2, respectively. 
For all three types of IFNs, the initial step in signalling is the dimerisation and 
autophosphorylation of the associated JAKs, which in turn phosphorylate members of 
the STAT family, including STAT1 and STAT2 (Ihle & Kerr, 1995; Darnell, 1997). 
Tyrosine phosphorylation of the STATs leads to homo or heterodimerisation and the 
formation of transcriptional activator complexes. These complexes translocate to the 
nucleus where they bind to specific DNA sequences. An important transcriptional 
complex that is induced by type I IFNs is ISG factor 3 (ISGF3), comprised of a 
heterodimer of phosphorylated STAT1, STAT2 and IRF9. ISGF3 binds to specific 
elements known as IFN-stimulated response elements (ISREs), (Kessler et al., 1990) 
that are present in certain ISGs. The IFN-γ-activated factor (GAF) is a homodimer of 
STAT1, which binds to IFN-γ-activated sequence (GAS) (Decker et al., 1991; Lew et 
al., 1991). Of the hundreds of known ISGs, some have only ISREs or only GAS 
elements in their promoters, whereas others have both. 
 Although IFN-γ signals through a distinct receptor, constitutive sub-threshold 
IFN-alpha/beta signalling is critical for eliciting strong responses to IFN-γ (Takaoka et 
al., 2000) and IL-6 (Mitani et al., 2001). Type I IFNs also influence the adaptive 
immune response via the activation of T cells. T cells lacking IFNAR1 cannot respond 
efficiently to antigen stimulation and the CXCR3 chemokine system is regulated by 
IFN-α/β in CD8+ T cells, and it is critical for efficient cell activation (Ogasawara et al., 
2002).  
70 
 Type III IFNs are induced upon viral infection and mediate anti-viral activity 
through the induction of ISGs such as OAS, PKR and MxA leading to the formation of 
ISGF3 (Onoguchi et al., 2007). 
 Although the JAK/STAT pathway is the primary component in IFN-induced 
signal transduction, additional signal transducers support IFN signalling via STAT-
dependent and STAT-independent ways. Examples of these components are ERK2, 
which is required for STAT-dependent effects of IFN-β (David et al., 1995) and SHP-2 
which becomes phosphorylated upon IFN-α/β stimulation (You et al., 1999). The p38 
MAPK pathway also functions in the induction of type I IFN-mediated signals in a 
variety of cell lines (Goh et al., 1999; Uddin et al., 1999; Uddin et al., 2000).  
 
1.1.1.1.3 VACV modulation of IFN signalling 
 Several lines of evidence indicate that IFNs play a crucial role in controlling 
VACV infection. An early study showed that rabbit IFN protected rabbits from an 
intradermal VACV infection if administered before inoculation (Isaacs & Westwood, 
1959). More recently, infection of transgenic mice lacking IFNRs or downstream 
signalling components showed enhanced sensitivity to OPV infection (Xu et al., 2008). 
In macaques, a rapid up-regulation of genes involved in the type I and II IFN response 
to VARV infection was demonstrated (Rubins et al., 2004).  
 As discussed above, VACV proteins E3 and K3 block the functions of IFN-
induced proteins such as PKR and OAS. In addition, there are several other VACV 
proteins that modulate IFN pathways by acting as IFN decoy receptors or blocking IFN 
signalling. The VACV WR B18 protein is a secreted type I IFN receptor, which binds 
IFN-α and IFN-β (Colamonici et al., 1995; Symons et al., 1995). B18 binds to human 
and rabbit IFN-α with high affinity, while it has a reduced affinity for bovine and rat 
IFN-α. Its affinity for murine IFN-β is low (nM range) but loss of the B18R gene 
(vΔB18R) still attenuates the phenotype of VACV infection in the i.n. model (Symons 
et al., 1995). 
 B8 is a soluble IFN-γ receptor from VACV WR and has aa sequence similarity 
to the IFN-γ binding domain of cellular IFN-γ receptor. B8 is expressed early in 
infection and binds to IFN-γ, thereby preventing the IFN-γ-IFN-γR interaction (Upton 
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et al., 1992; Alcami & Smith, 1995). B8 has broad species specificity for IFN-γ and can 
inhibit human, bovine, equine, ovine and rat IFN-γ but not murine (Alcami & Smith, 
1995; Mossman et al., 1995a; Symons et al., 2002b) whilst the myxoma virus M-T7 
binds and inhibits only rabbit IFNγ (Mossman et al., 1995b).  
 VACV also modulates IFN functions by blocking IFN signalling at the level of 
STAT phosphorylation. The H1 phosphatase, termed VH1, (Liu et al., 1995), blocks 
IFN-γ-stimulated presentation of antigen in VACV-infected cells by dephosphorylating 
the STATs (Najarro et al., 2001). H1 can inhibit the phosphorylation of STAT1 and 
STAT2 in response to either type I or type II IFNs and VACV can also block STAT1-
independent IFN-induced gene expression, suggesting that VACV encodes other 
proteins that block additional IFN-mediated signalling pathways (Mann et al., 2008).  
 
 
Fig. 1.7 Type I and II IFN signalling pathways and their modulation by VACV 
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1.9.3.2 Other cytokines 
 IL-18, first known as the IFN-γ-inducing factor, mediates NK and T-cell 
activation via the induction of IFN-γ production in NK and T cells. IL-18 acts with IL-
12 to promote Th1-mediated responses. IL-18 is produced by activated macrophages as 
an inactive precursor that is processed by caspase 1, IL-1β-converting enzyme (ICE), 
and the mature form is secreted from cells and binds IL-18R. Humans and mice express 
soluble proteins that can bind to IL-18 called IL-18BP that regulates IL-18 activity. 
VACV expresses a related protein called C12 that binds IL-18 and  reduces NK and T 
cell cytotoxic activity, IFN-γ production and NO activity (Calderara et al., 2001; 
Symons et al., 2002a; Reading & Smith, 2003b). The importance of this pathway is 
highlighted by VACV modulating it in several ways. As well as targeting IL-18 itself, 
VACV A46 and A52 (discussed in Section 1.9.1.5) inhibit signalling from the IL-18R 
and encode an inhibitor of caspase 1, VACV B13(Kettle et al., 1995; Kettle et al., 
1997). B13 (or serpin protease inhibitor (SPI)-2), is an intracellular protein, expressed 
early in infection and inhibits caspase 1. B13 also prevents maturation of IL-1β and IL-
18 and has a role in apoptosis (discussed in Section 1.10). 
 VACV also modulates the IL-1β signalling pathway by secreting a soluble IL-
1β receptor encoded by gene B15R in the VACV strain WR (Smith & Chan, 1991; 
Alcami & Smith, 1992; Spriggs et al., 1992a). B15 binds to IL-1β to inhibit febrile 
response during systemic infection. In the MVA background, the absence of B15 
enhanced CD8
+
 T cell memory responses (Staib et al., 2005). 
 VACV also encodes a protein, C16 (Fahy et al., 2008), with a short peptide 
sequence that was identified in the IL-1 receptor antagonist (IL-1Ra) (Kluczyk et al., 
2002; Kluczyk et al., 2004). IL-1ra is secreted from cells binds to the IL-1R but does 
not induce signal transduction, thereby acting as an antagonist. However, the C16 
protein is intracellular and so must have a different function. 
 Several orthopoxviruses also encode modulators of TNF, such as soluble or cell 
surface TNFRs. Although most VACV strains do not express TNFRs, 3 strains, Lister, 
USSR and Evans, were identified that did and each expressed more than 1 TNFR 
(Alcami et al., 1999; Reading et al., 2002). VACV also expresses intracellular 
inhibitors of TNF mediated signalling, such as B14 (see section 1.9.1.5). 
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1.9.3.3 Chemokines 
 Chemokines are small (8- to 13-kDa) heparin-binding proteins that are grouped 
according to shared structural characteristics. These include the presence of cysteines in 
conserved locations that are essential to forming a characteristic tertiary fold, termed a 
„Greek key‟, and are classified into C, CC, CXC or CX3C subfamilies. Chemokines and 
chemokine receptors play a critical role in the host defence against viruses by 
mobilising leukocytes to sites of infection, injury and inflammation. Chemokines 
mediate their actions via seven-transmembrane G-protein-coupled receptors expressed 
by different subsets of leukocytes. The cellular distribution of different receptors 
determines the leukocyte subset that predominates in the inflammatory response. In 
general, CC chemokines attract macrophages and T cell populations and CXC 
chemokines attract neutrophils, while lymphotactin (XCL1) attracts T and NK cells. 
Soluble fractalkine (CX3CL1, the only CX3C chemokine) attracts monocytes, T cell 
subsets and NK cells. Large DNA viruses, such as poxviruses and herpes viruses have 
evolved several strategies for exploiting or subverting chemokine networks. 
 VACV expresses a secreted protein that binds CC chemokines with high 
affinity and is termed the viral chemokine inhibitor (vCCI) or viral CC chemokine 
binding protein (vCKBP) (Alcami et al., 1998; Beck et al., 2001; Seet et al., 2001; 
Reading et al., 2003b). The VACV vCCI binds RANTES (regulated on activation 
normal T cell expressed and secreted) a CC-motif ligand (CCL) 5) chemokine (Alcami 
et al., 1998)], macrophage-inflammatory protein 1α (MIP-1α, CCL3), macrophage 
chemotactic protein 1 (MCP-1, CCL2) and eotaxin (CCL11) and thereby blocks the 
recruitment of inflammatory cells to the lungs of VACV-infected mice (Graham et al., 
1997; Reading et al., 2003b). 
 The VACV A41 protein is a secreted glycoprotein that shares sequence 
similarity with vCCI (Ng et al., 2001) and blocks the binding of some CC chemokines 
to GAGs (Bahar et al., 2008). Although it has relatively low affinity for a subset of CC 
chemokines and consequently does not block the interaction of chemokines with their 
receptors, it can still function in vivo by blocking the establishment of a chemokine 
concentration gradient on endothelial cells and thereby inhibiting leukocyte 
chemotaxis. The deletion of the A41L gene from VACV reduces virulence, but induces 
stronger CD8
+
 T cell response and confers better protection against subsequent 
challenge (Clark et al., 2006). 
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1.9.3.4 Vaccinia growth factor 
 VACV growth factor (VGF) (Brown et al., 1985; Twardzik et al., 1985), is 
related to the epithelial growth factor (EGF) family of cytokines that stimulate 
epithelial cells to divide. By mimicking EGF, VGF induces proliferation of uninfected 
cells surrounding the site of infection, so that as the virus spreads it encounters cells 
with high metabolic activity that support virus replication. The importance of EGF for 
virus virulence was demonstrated by the attenuated phenotype of the deletion mutant 
(Buller et al., 1988). 
 
1.10 Apoptosis 
 Apoptosis or programmed cell death plays an essential role in development, 
tissue homeostasis and the elimination of pathogen-infected cells. In response, viruses 
have evolved several mechanisms to block apoptosis and allow completion of the 
replication cycle before cell death. Apoptosis can be induced by extracellular stimuli, 
such as TNF or Fas-binding, or by intracellular stimuli that cause DNA damage, and 
mitochondrial dysfunction or signal microbial invasion. Central to apoptosis are the 
caspases and B-cell lymphoma 2 (Bcl-2) proteins. The caspase family comprise 
aspartic proteases, which are present as inactive pro-enzymes that are activated in a 
proteolytic cascade and contain an N-terminal death domain (DD), either a CARD 
(caspases 1, 2, 4, 5, 9 and 11) or a death effector domain (DED, caspases 8 and 10). 
They can be activated by extracellular stimulation such as Fas ligand that binds to Fas. 
Binding induces trimerisation of the receptor and binding of adaptor proteins such as 
Fas-associated protein with death domain (FADD) via DDs. The adaptor proteins also 
contain a DED that recruits and activates caspase 8. This initiating step induces a 
cascade of proteolytic caspase cleavage that leads to the eventual disassembly of 
cellular structures and dys-regulation of homeostatic cellular activity.  
 Alternatively, apoptotic stimuli can be sensed intracellularly by the 
mitochondrion, ER or Golgi complex. These signals converge the mitochondrion, and 
result in the loss of membrane potential and the release of pro-apoptotic proteins such 
as apoptosis inducing factor, second mitochondria-derived activator of caspases 
(SMAC), endonuclease G and cytochrome c. Cytochrome c initiates caspase 9 
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recruitment and activation via its interaction with the adaptor molecule protease 
activating factor 1 (APAF-1). 
 The mitochondrial „checkpoint‟ of apoptosis is regulated by pro- and anti-
apoptotic members of the Bcl-2 family. These proteins are characterised by up to four 
domains termed Bcl-2 homology (BH) domains and can function as homo- or 
heterodimers to regulate apoptosis. The relative levels of pro- and anti-apoptotic 
members within a cell modulate the balance between apoptosis and cell survival.  
 VACV modulates apoptosis in several ways including interference with 
caspases, interference with Bcl-2 proteins and alterations in Ca
2+
 homeostasis, reviewed 
in (Taylor & Barry, 2006). For instance, VACV strain WR protein B13 is a serpin that 
inhibits caspase 1 activity (Kotwal & Moss, 1988a; Smith et al., 1989b) and seems to 
inhibit cell death during VACV infection (Dobbelstein & Shenk, 1996; Kettle et al., 
1997). VACV encodes a second serpin, B22 (also called SPI-1, (Kotwal & Moss, 
1988a; Smith et al., 1989b; Kettle et al., 1995), which acts as a pseudo-substrate for 
target proteases and thereby modulates apoptotic signalling. Deletion of B22R from 
RPXV restricts host range and in the cells that become non-permissive, the restriction 
is due to the induction of apoptosis (Brooks et al., 1995). B22 was shown to interact 
with cathepsin G, a serine proteinase, via serpin motifs and thereby modulate apoptosis. 
In an intraperitoneal model, lack of B13 or B22 induced stronger T helper and 
cytotoxic responses (Legrand et al., 2004). 
 The VACV proteins F1 and N1 are Bcl-2-like proteins that inhibit the activity 
of pro-apoptotic BCl-2signalling (Cuconati & White, 2002). F1 localises to the 
mitochondrion, via a single transmembrane domain (Stewart et al., 2005), where it 
inhibits the release of cytochrome c and thereby regulates the initiation of the apoptotic 
cascade (Wasilenko et al., 2003; Taylor et al., 2006). This inhibition may be due to the 
direct interaction of F1 with the BH3 domains of the Bcl-2 proteins (Fischer et al., 
2006). VACV N1 is a virulence factor in the i.d., i.n. and intracranial models of 
infection (Bartlett et al., 2002; Abrahams et al., 2005; Jacobs et al., 2008). Structurally 
N1 is a Bcl-2-like protein (Aoyagi et al., 2007; Cooray et al., 2007) and interacts with 
pro-apoptotic Bcl-2 proteins to protect infected cells against staurosporine-induced 
apoptosis (Cooray et al., 2007). The structure of F1 also showed a Bcl-2 protein with 
an open surface groove for binding BH3 peptides. 
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1.11 Adaptive immune responses to VACV infection 
1.11.1 Humoral responses 
 The importance of an Ab response to VACV infection is shown by the many 
ways in which Ab binding can help clear the infection. Anti-VACV Ab can bind 
directly to VACV particles, causing aggregation and inhibiting virus binding and entry 
to cells. Ab-binding to virions can also initiate complement-mediated lysis or 
opsonisation. Ab can also bind to infected cells, leading to ADCC.  
 The relative contributions of humoral and cellular immunity to VACV infection 
were assessed in mice that were B-cell deficient or CD4
+
 T cell depleted that were 
unable to clear a VACV infection (Xu et al., 2004).The Ab response is primarily CD4
+
 
T cell-dependent (Xu et al., 2004) and is predominantly of an IgG2a isotype (Fogg et 
al., 2004). IgM appears by 7 days p.i. and IgG by day 14 (Spriggs et al., 1992b) and Ab 
levels peak around 6 weeks p.i. (Wyatt et al., 2004; Meseda et al., 2005) and can be 
maintained for more than 3 months (Coulibaly et al., 2005; Meseda et al., 2005) in 
mouse models. 
 Vaccination studies in humans demonstrate a strong Ab response is elicited 
after primary vaccination. Abs are not detected before day 10 post vaccination 
(McCarthy et al., 1958; McClain et al., 1997) but are apparent by day 13/14 
(Greenberg et al., 2005) and Ab levels continue to rise until approximately day 28 
(Frey et al., 2003; Greenberg et al., 2005). Re-vaccination elicits a more rapid Ab 
response, with Ab levels peaking approximately day 14, considerably earlier than after 
primary immunisation and re-vaccination also boosts previous Ab levels (McCarthy et 
al., 1958; Frey et al., 2003; Greenberg et al., 2005). 
 Ab levels decrease slowly to a steady level but are long-lived, being maintained 
up to 50 years post-vaccination (Fenner et al., 1988; Hammarlund et al., 2003; Putz et 
al., 2005). VACV-specific memory B cells are also generated after smallpox 
vaccination (Crotty et al., 2003). At 4 weeks to 6 months post-vaccination, 1% of 
circulating IgG
+
 memory B cells were VACV-specific and a moderate correlation was 
seen between memory B cells and serum Abs, indicating that multiple factors may be 
involved in Ab maintenance (Slifka et al., 1998; Crotty et al., 2003). 
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1.11.1.1 Important immunogens in the humoral response 
 In animal and human studies, approximately 10 immunodominant antigens have 
been identified by immunoblotting (Wilton et al., 1986; Cheliapov et al., 1988; 
Demkowicz et al., 1992; Jones-Trower et al., 2005) and proteome arrays (Davies et al., 
2005a; Duke-Cohan et al., 2009). In general the major targets are core proteins such as 
A4, E3 and A10, IMV surface antigens such as H3, D8, D13, and A27 and EEV-
specific antigens such as A56, B5, A33 and F13. There was some variation in strength 
of targeting to a particular antigen between species. The targets for neutralising Ab 
activity are the IMV and EEV surface antigens. IMV targets include H3 (Chertov et al., 
1991; Demkowicz et al., 1992; Lin et al., 2000; Davies et al., 2005b), D8 (Hsiao et al., 
1999; Sakhatskyy et al., 2006), A27 (Rodriguez et al., 1985; Hooper et al., 2003; 
Hooper et al., 2004), L1 (Fogg et al., 2004; Wyatt et al., 2004), A17 and F9 whilst B5 
is the only EEV target for neutralising Abs in the absence of complement (Putz et al., 
2006). However, anti-A33 Ab can neutralise EEV in the presence of complement (Fogg 
et al., 2004) 
 EEV antigens A33 and A56 are not targets for neutralising Abs without 
complement but A33-specific Abs can inhibit comet tail formation (Galmiche et al., 
1999; Lustig et al., 2004) and A33 is important for Ab-resistant direct cell-to-cell 
spread (Law et al., 2002). In the presence of complement, A33-specific Abs induce 
EEV membrane lysis, exposing the IMV which can be neutralised (Lustig et al., 2004). 
A56 is the viral haemagglutinin (HA) protein but A56-specific Abs have not been 
shown to neutralise EEV (Law & Smith, 2001; Putz et al., 2006). 
 
1.11.2 Cellular response 
 There have been many studies of cellular immunity to VACV infection, 
utilising proliferation assays, cytotoxic killing assays and detection of IFN-γ and other 
cytokines. 
 
1.11.2.1 T cell response 
 In mice, both CD4
+
 and CD8
+
 T cell responses are elicited following VACV 
infection (Xu et al., 2004). Kinetic analysis of infection shows that VACV induces a 
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potent primary CD8
+
 T cell response as well as long-term memory in vivo. As early as 
day 5 p.i., a IFN-γ positive CD8+ T cell response was detected and peaked at day 7, 
with 30% of CD8
+
 T cells in the spleen being VACV-specific. There was also a strong 
CTL response by day 7 (Harrington et al., 2002). Despite the large CD8
+
 response, in 
CD8
+
-depleted or null mice, virus was cleared at similar rates to the control, suggesting 
that the activated CD8
+
 T cells were not essential for virus clearance following acute 
infection in the intraperitoneal model (Xu et al., 2004) and subcutaneous model 
(Spriggs et al., 1992b) of infection. However, in the absence of CD4
+
 T cell response, a 
partial function of CD8
+
 T cells was demonstrated (Xu et al., 2004).  
 The CD4
+
 T cell response displayed similar kinetics to that of CD8
+
 T cells but 
at  lower frequencies (Harrington et al., 2002). The response peaked at day 7 p.i., with 
3% of the CD4
+
 T cell being VACV-specific. When compared to CD8
+
 T cells, a 
higher percentage of CD4
+
 T cells produced IL-2, demonstrating an increased 
proliferative response compared to the CD8
+
 T cell compartment. This is consistent 
with CD4
+
 T cells as T helper cells. Although the response declined by approximately 
90% by day 30, it was maintained for over 300 days (Harrington et al., 2002). 
 Within the i.d model, the lymphocyte populations from the adaptive immune 
response was observed later p.i. with CD4
+
 T cells, increasing in percentage even up to 
day 17 p.i. despite most lesions having resolved by this time-point. In contrast, the 
percentage of CD8
+
 T cells started to decrease after day 7 p.i. and the absolute number 
for both subsets started to decrease after day 10 p.i. The CTL activity against EL4 cells 
infected with VACV WR at 10
4
 plaque forming units (p.f.u) was detected by day 7 p.i. 
(Jacobs et al., 2006). 
 The influence of the mouse strain, on the immune responses is highlighted by 
the resistance of C57BL/6 mice to VACV (and ECTV) compared to BALB/c mice. 
BALB/c mice are more susceptible and exhibit a type II polarised (IL-4) cytokine 
response. In contrast, C57BL/6 mice are more resistant and exhibit a type I polarised 
(IFN-γ, IL-2, TNF) cytokine response. Depletion of CD8+ T cells in a type II bias 
environment results in greater susceptibility (Belyakov et al., 2003). The Th1 skewed 
response in C57BL/6 mice indirectly indicates an important role in innate immunity. 
Recombinant VACV expressing IFN-γ (Kohonen-Corish et al., 1990) or IL-2 
(Ramshaw et al., 1987) were less virulent whereas IL-4 expressing recombinant VACV 
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(Sharma et al., 1996) was more virulent and expression of IL-2 activates NK cells and 
CD4
+
 T cells. 
 Overall, these data from murine studies indicate that Abs, CD4
+
 T cells and 
CD8
+
 T cells are not essential for survival but all make valuable contributions. Whilst 
Abs contribute to the prevention of infection, in the absence of Abs, T cells are 
necessary and sufficient for survival. In a more virulent OPV infection, such as ECTV, 
both humoral and cellular responses become necessary for recovery and survival 
(Chaudhri et al., 2004). 
 In humans, strong CD4
+
 and CD8
+
 T cell responses are elicited following 
smallpox vaccination. In general, CD8
+
 T cell responses are of a greater magnitude (2-
to 4-fold higher) after immunisation (Amara et al., 2004; Rock et al., 2006) but CD4
+
 T 
cell responses
 
are maintained for a greater length of time at higher frequencies 
(Hammarlund et al., 2003; Amara et al., 2004; Rock et al., 2006). VACV-specific 
CD4
+
 T cells were detected in the majority (82-100%) of individuals vaccinated up to 
75 years previously unlike CD8
+
 responses (Hammarlund et al., 2003; Amara et al., 
2004). The importance of CD4
+
 T cells was highlighted by the outcome of vaccination 
in HIV positive individuals. In the USA, after a review of approximately 300 HIV-
infected military personnel, the smallpox vaccine is not recommended for individuals 
with a CD4
+
 T cell count below 200 cells/mm
3 
(Bartlett, 2003). In one case, an HIV 
positive vaccinee developed progressive vaccinia which was treated successfully with 
VACV immunoglobulin (VIG) (Redfield et al., 1987). 
 
1.1.1.1.4 T cell epitopes 
 The investigation of not only the global T cell response to VACV infection, but 
also the specific T cell epitopes has been important, especially for future vaccine 
development. Approximately 50 murine MHC-I-restricted (Mathew et al., 2005; 
Tscharke et al., 2005; Moutaftsi et al., 2006; Tscharke et al., 2006) and human HLA-
A/B-restricted VACV epitopes (Drexler et al., 2003; Terajima et al., 2003; Oseroff et 
al., 2005; Pasquetto et al., 2005) have been identified. The 49 HLA-restricted human 
epitopes are from 35 different proteins, spanning almost 20% of predicted ORFs and 
are recognised by PBMCs from vaccinated humans (Oseroff et al., 2005). Overall, the 
proteins involved are usually greater than 100 aa in size and approximately 50% are 
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made early during infection and 50% late during infection. Furthermore, there was no 
obvious bias towards a particular function or location of the protein containing the 
epitope. 
 In mice, analysis of MHC-II-restricted epitopes showed that the pattern of 
antigens recognised by CD4
+
 T cells differs substantially from the pattern of antigens 
recognised by CD8
+
 T cells (Moutaftsi et al., 2007). In humans, 122 VACV proteins 
elicited CD4
+
 T cell responses (Jing et al., 2008) and the proteins recognised most 
frequently tended to be virion structural proteins, with higher molecular weights and to 
be expressed late during infection. 
 
1.12 Vaccination 
 Apart from trying to determine important immune responses for prevention and 
elimination of an OPV infection, many studies have also investigated what factors are 
important for protection from a secondary infection. In general, protection conferred by 
licensed vaccines such as measles/mumps/rubella, hepatitis B or yellow fever vaccines 
is due to the production of neutralising or binding Abs (Burton, 2002; Zinkernagel & 
Hengartner, 2006) that can neutralise a pathogen immediately. In contrast, T cell 
activation can take several days to develop and consequently, are more involved in 
clearance and recovery. This is also the case for protection against OPV. In humans, the 
correlates of protection remain uncertain but animal studies have helped elucidate 
possible mechanisms. 
 Primary vaccination in humans, by i.d. inoculation with replication-competent 
VACV strains results in local viral replication followed by complete virus elimination. 
Vaccination is via scarification of the epidermal layers of the upper deltoid region of 
the arm. VACV replicates in the basal layer of the skin where a papule appears at the 
site of vaccination within 3 – 5 days and develops into a pustular vesicle, following a 
vigorous inflammatory and adaptive infiltrate, which reaches maximum size within 8 – 
10 days. A scab then forms, which separates after 17 -21 days, leaving a vaccination 
scar (Fenner, 1989). Aside from the primary site lesion, most vaccinees experienced a 
mild fever and localised discomfort but local responses could include erythema, pain 
and swelling following the release of cytokines and chemokines from necrotic and 
infected cells (Fenner, 1989; Frey et al., 2002; Orr et al., 2004; Artenstein et al., 2005; 
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Greenberg et al., 2005). Systemic responses included fever, fatigue, malaise, 
headaches, nausea, diarrhoea and vomiting (Frey et al., 2002; Orr et al., 2004). 
 On rare occasions, severe complications were observed after vaccination. These 
were commonly associated with virus escape from the site of vaccination and included 
accidental infection of the eye, eczema vaccinatum, generalised vaccinia, postvaccinial 
encephalitis, progressive vaccinia and myopericarditis (Kempe, 1960; Neff et al., 
1967a; Neff et al., 1967b; Lane et al., 1969; Bray & Wright, 2003). Accidental 
infection of a secondary site such as the eye were more common in children, occurring 
at a rate of 25-529 cases per million. Eczema vaccinatum (Babic, 2007) was observed 
in 10-40 cases per million, in people with skin disorders as a result of mechanical and 
blood borne viral dissemination. The outcome ranged from benign to fatal and human 
VIG was often used to treat such complications (Kempe, 1960). VIG was also used to 
treat generalised vaccinia, a condition where additional lesions form at secondary sites 
about 6-9 days after vaccination following blood-borne dissemination. Generalised 
vaccinia was observed in 23-241 cases per million (Vellozzi et al., 2005). Postvaccinial 
encephalopathy was more severe and often fatal, but had a lower incidence rate, 
occurring in 3-12 vaccinees per million (Kempe, 1960). The most severe complication 
of vaccination was progressive vaccinia (Bray & Wright, 2003), which occurred at a 
rate of 1 per million and resulted from an inability to control virus replication due to T 
cell deficiencies. The condition resulted in the expansion of the primary site and 
formation of additional lesions. Depending on the immune status of the vaccinee, the 
condition could be treated with several doses of VIG. Myopericarditis was only 
recognised as a complication following more recent military vaccine trials in the USA 
(Chen & Lane, 2003). 
 Protection induced by vaccination is shared between Ab and cellular immunity 
(Belyakov et al., 2003). In murine studies, B cell-deficient mice when immunised with 
either Wyeth vaccine or MVA were protected against challenge with VACV WR 28 
days later were protected (Wyatt et al., 2004; Xu et al., 2004), indicating that Abs are 
not essential for VACV immunity. However, Abs are sufficient for protection, as 
shown by passive transfer of sera from immunised animals (Boulter et al., 1961; Law et 
al., 2005). Likewise, T cells are not strictly necessary for protection. Depletion of CD8
+
 
T cells prior to challenge with VACV WR had no effect compared to control animals 
(Belyakov et al., 2003) nor did challenge in β2m-/- mice (Wyatt et al., 2004). In 
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contrast, CD4
+
-deficient mice (MHC II
-/-
) were not protected from challenge (Wyatt et 
al., 2004). Following adoptive transfer of CD4
+
 and/or CD8
+
 T cells from MVA-
immunised mice, naïve mice were not protected upon challenge with VACV WR 
(Wyatt et al., 2004). In a separate study, adoptive transfer of WR-activated memory 
CD8
+
 T cells resulted in a 100-fold reduction of virus in the ovaries (Xu et al., 2004). 
 The precise duration of protection afforded by vaccination is still unclear. 
Whilst Jenner originally claimed protection was life-long, the WHO estimated the 
duration of protection to be around 5-10 years (Henderson, 2003). In Europe between 
1950 and 1971, only 2%, 6% and 7% respective fatality rates were observed in 
individuals vaccinated 0-10, 11-20 and > 20 years previously and who subsequently 
became infected or exposed to VARV (Mack, 1972). Approximately 30% of today‟s 
population are contraindicated to the current smallpox vaccine, including individuals 
with eczema, HIV infection, those receiving immunotherapy and pregnant women, 
emphasizing a need for new and safer vaccines. To this end, the immune response to 
VACV infection and vaccination is crucial. 
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Table 1.2 Summary of VACV immune evasion proteins 
Protein Function 
 Complement modulation 
C3/VCP 
Binds C3 and C4b; inhibits the classic and alternative pathways of complement 
activation (Isaacs et al., 1992b) 
 PRR signal modulation 
A46 Targets IRAK2 and TRAF6 (Bowie et al., 2000; Stack et al., 2005) 
A52 Targets TIR adaptor proteins (Bowie et al., 2000; Harte et al., 2003) 
B14 NF-κB inhibitor; down-regulates IKK by targeting IKK-β (Chen et al., 2008) 
K1 
NF-κB inhibitor; suppresses IκB-α degradation. Host range gene (Shisler & Jin, 
2004; Bradley & Terajima, 2005) 
K7 Interacts with TBK1 and IKKε (Schroder et al., 2008) 
M2 NF-κB inhibitor (Hinthong et al., 2008) 
 IFN modulation 
E3 
Binds to dsRNA, preventing PKR and OAS activation (Langland & Jacobs, 2002; 
Kwon & Rich, 2005) 
K3 Pseudo-substrate of PKR (Davies et al., 1992) 
B8 Binds to and inhibits IFN-γ (Alcami & Smith, 1995; Symons et al., 2002b) 
B18 Binds to and inhibits IFN-α/β (Colamonici et al., 1995; Symons et al., 1995) 
H1 
IFN signalling inhibitor; dephosphorylates STAT1 (Najarro et al., 2001; Mann et 
al., 2008) 
 Cytokine & chemokine modulation 
A41 Chemokine binding protein (Clark et al., 2006; Bahar et al., 2008) 
B15 
Binds to and inhibits IL-1β (Alcamí & Smith, 1992; Spriggs et al., 1992a; Alcami 
& Smith, 1996) 
C12 
IL-18 binding protein; inhibits IL-18 induced IFN-γ production (Symons et al., 
2002a; Reading & Smith, 2003b) 
C16 Intracellular IL-1Ra-like protein; (Fahy, 2008) 
vCKBP/
CCI 
CC chemokine binding protein (Graham et al., 1997; Lalani et al., 1997; Alcami 
et al., 1998) 
CrmE Binds to and inhibits activity of TNF-α (Reading et al., 2002) 
 Apoptosis modulation 
B13 
Serpin; inhibits caspase 1 and thereby i) maturation of IL-1β and IL-18 and ii) 
TNF or Fas-induced apoptosis (Blake et al., 1995; Kettle et al., 1997) 
B22 Serpin (Blake et al., 1995) 
F1 
Interferes with cytochrome c release from mitochondria and apoptosis (Taylor et 
al., 2006) 
N1 Inhibits apoptosis (Cooray et al., 2007) 
 Other 
A39 Semaphorin glycoprotein (Gardner et al., 2001) 
A40 
Type II membrane glycoprotein that affects the murine i.d. (Tscharke & Smith, 
1999; Wilcock et al., 1999) 
A44 
3-β-hydroxysteroid dehydrogenase; synthesises steroid hormones that inhibit 
inflammatory response (Moore & Smith, 1992; Reading et al., 2003a) 
A55 Kelch-like protein that affects the murine i.d. (Beard et al., 2006) 
C2 Kelch-like protein that affects the murine i.d. (Pires de Miranda et al., 2003) 
F3 Kelch-like protein that affects the murine i.d. (Froggatt et al., 2007) 
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1.13 A40 
VACV WR gene A40R encodes a type II membrane glycoprotein with a C-type 
lectin-like domain at the C terminus. The A40 protein is expressed early in infection, is 
nonessential for viral replication and is not incorporated into virions (Wilcock et al., 
1999). VACV proteins required to provide precursors for macromolecular synthesis or 
having roles in evasion of host defences are often not required for viral replication in 
tissue culture cells. Wilcock et al. (1999) also reported that A40 partitioned to the 
membrane fraction when infected cells were treated with Triton X-114. Four proteins 
(18, 28, 35 and 38 kDa) were identified in lysates from VACV-infected cells but were 
absent from deletion mutant-infected cells by immunoblotting using an A40 specific 
Ab (Wilcock et al., 1999). In the presence of tunicamycin, only the 18 kDa protein was 
found indicating A40 contains N-linked carbohydrate. Furthermore, in preparations 
omitting ß-mercaptoethanol, one additional band at 70-76 kDa was identified and may 
represent homodimers of the glycosylated A40. 
 Wilcock et al. (1999) found the highest FASTA score (198) with a non-
poxvirus protein was against the human natural killer cell G2-A protein (accession no. 
P26715). The predicted CRD domain of A40 contains 5/14 invariant and 17/32 
conserved residues of the CRD consensus sequence (Duncan & Smith, 1992; Wilcock 
et al., 1999). However, it lacks one of the cysteine residues predicted to form 
intradomain disulphide bonds and residues equivalent to loop 2 and β sheet 5. Some 
lectins lacking several conserved residues and containing a deletion in the loop regions 
still may bind carbohydrate. The putative interaction between A40 and carbohydrates 
remains to be investigated further. 
In contrast to the conclusions of Wilcock et al., (1999), Palacios et al., (2005) 
reported that A40 was modified by sumoylation (SUMO-1) rather than glycosylation 
and was an intracellular protein that was not associated with membranes (Palacios et 
al., 2005). A number of proteins, mainly located in the nucleus, are sumoylated (Yeh et 
al., 2000; Muller et al., 2001; Seeler & Dejean, 2003). Sumoylation is a pathway 
similar to ubiquitination that modifies proteins reversibly and post-translationally and 
can alter a protein‟s intracellular location, activity, stability and interactions. Palacios et 
al., (2005) proposed that sumoylation of A40 prevents A40 forming polymers and a 
small amount of unsumoylated A40 could aid bringing ER membranes together before 
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they fuse to generate an ER envelope that is proposed to surround the virus factory 
(Sodeik & Krijnse-Locker, 2002). These differences were proposed to be due to a lack 
of specificity of the Ab used in the study by Wilcock et al., (1999). However, controls 
were provided and the Ab reacted with proteins in cells infected with WT and revertant 
viruses but not a virus mutant lacking the A40R gene or mock infected cells (Wilcock et 
al., 1999). In comparison, Palacios et al., 2005 did not show controls for the specificity 
of the peptide Ab and no inhibitor of glycosylation was used to support claims that the 
protein lacks N-linked glycans. If the peptide Ab used by Palacios et al., is binding 
A40, the presence of A40 in the ER may reflect its normal transport through the host 
cell‟s secretory pathway. 
 A recombinant VACV lacking the A40R gene (vΔA40R) was constructed and 
was found to replicate normally in cell culture (Wilcock et al., 1999). However, 
compared to WT and revertant (Rev) controls it was attenuated in a murine i.d. 
infection model (Tscharke et al., 2002) and induced a 30% reduction in lesion size 
compared to WT and Rev virus (Tscharke et al., 2002). This was observed in Balb/c 
and C57B1 mice. 
 The low but significant aa similarity of A40 to C-type lectins such as NKG2A 
and DC-SIGN, its location on the infected cell and the attenuation in the murine i.d. 
model of infection, suggest that A40 may function as an immunomodulator by 
mimicking native host lectins or modulating recognition of VACV-infected cells by 
cells of the immune system and consequently, interrupting host responses to the viral 
infection. 
 
1.14 Project Aims 
The project aims are to: 
1) identify the ligand(s) with which A40 interacts. 
2) understand the mechanism by which A40 modulates the host immune 
response. 
 To identify cell surface binding partners for A40, recombinant A40 proteins 
were produced and used in cell binding assays, with binding being assessed by flow 
86 
cytometry. Recombinant protein was produced in bacterial, mammalian and 
baculovirus systems. 
 Due to the poor affinity of the present anti-A40 Abs, a new A40 Ab  was 
produced and used to re-investigate the localisation, biochemical properties and to try 
to characterise the interacting partner(s) of A40. 
 To determine the structure of A40, in collaboration with Dave Stuart‟s group at 
Oxford, recombinant A40 was produced, purified and used in crystallisation trials. 
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Chapter 2. Materials & Methods 
2.1 Chemicals, reagents and rotors 
 All chemicals were obtained from VWR, UK, or Sigma-Aldrich Co., UK, 
unless otherwise stated. All centrifugation steps were performed in an Allegra 6R 
benchtop centrifuge with GH-3.8A rotor unless otherwise stated. 
 
2.2 Antibodies 
Table 2.1 Conditions for usage of Ab in immunoblotting and immunofluorescence 
Antibody Host 
species 
Specificity Dilution 
(immunoblot) 
Dilution 
(IF) 
Reference 
or supplier 
RAb A40 Rabbit VACV A40 1:1000 1:400 - 
mAb BAP 
(LX035-9) 
Mouse Biotin 
Acceptor 
Protein tag 
1:1000 1:400 Law M 
(Smith lab)  
mAb HA Mouse HA-tag 1:1000 - Covance 
Tetra-His  Mouse His-tag 1:1000 - Qiagen 
mAb MBP Mouse MBP-Tag 1:5000 - Sigma-
Aldrich 
mAb α-
tubulin 
Mouse α-tubulin 1:5000 - Upstate 
mAb 19C2 Rat VACV 
SCR2 of B5 
1:500 - (Schmelz et 
al., 1994) 
mAb AB 
1.1 
Mouse VACV D8 1:2000 - (Parkinson & 
Smith, 1994) 
RAb B14 Rabbit VACV B14 1:2000 - (Chen et al., 
2006) 
RAb K7 Rabbit VACV K7 1:2000 - Lucas S 
(Smith lab) 
mAb 15B6 Rat VACV F13 1:1000 - (Schmelz et 
al., 1994) 
α-Mouse 
IgG HRP 
Goat Mouse 1:1000 - Sigma- 
Aldrich 
α-Rabbit 
IgG HRP 
Goat Rabbit 1:1000 - Sigma- 
Aldrich 
α-Rat IgG 
HRP 
Goat Rat 1:2000 - GE 
Healthcare 
α-Mouse 
Alexa488 
Donkey Mouse  - 1:400 Sigma-
Aldrich 
α-Rabbit 
Alexa 488 
Donkey Rabbit - 1:400 Sigma-
Aldrich 
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Table 2.2. Conditions for usage of Ab in FACS analysis 
Antibody Host 
species 
Specificity Dilution 
 
Reference 
or  supplier 
B220 TC Rat Mouse B220 1:100 BD Biosciences 
CD14 FITC Mouse Human CD14 1:100 BD Biosciences 
CD3 FITC Rat Mouse CD3 1:50 BD Biosciences 
CD3 APC Rat Mouse CD3 1:100 BD Biosciences 
CD3 FITC Mouse Human CD3 1:100 BD Biosciences 
CD4 APC Rat Mouse CD4 1:100 BD Biosciences 
CD8 FITC Rat Mouse CD8 1:50 BD Biosciences 
CD8 APC Rat Mouse CD8 1:100 BD Biosciences 
CD11c PE Hamster Mouse CD11c 1:200 BD Biosciences 
CD16/CD32 
Fc γ receptor 
Rat Mouse 
CD16/CD32 
Fc γ receptor 
1:75 BD Biosciences 
CD20 FITC Mouse Human CD20 1:100 BD Biosciences 
CD25 PE Rat Mouse CD25 1:100 BD Biosciences 
CD45 FITC Rat Mouse CD45 1:100 BD Biosciences 
CD45 APC Rat Mouse CD45 1:20 BD Biosciences 
CD56 FITC Mouse Human 1:10 AbD Serotec 
CD69 FITC Hamster Mouse 1:100 BD Biosciences 
CD69 Mouse Human 1:50 BD Biosciences 
CD94 Mouse Human CD94 1:50 Abcam 
CD94 FITC Mouse Human 1:50 AbD Serotec 
CD209 PE Mouse Human 1:50 BD Biosciences 
F4/80 APC Rat Mouse F4/80 
receptor 
1:100 AbD Serotec 
Ly6G PE Rat Mouse 
granulocyte 
marker 
1:150 BD Biosciences 
MHC class II 
FITC 
Rat Mouse MHC 
class II  
1:50 AbD Serotec 
NK1.1 FITC Rat Mouse 
(C57Bl/6) 
NK1.1 
1:50 BD Biosciences 
TCRγδ PE Rat Mouse TCRγδ 1:50 BD Biosciences 
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2.3 Cell culture and transfection techniques 
2.3.1 Cell lines 
 RK13 (rabbit kidney, ATCC CL-37) cells, TK
-
143 (thymidine kinase negative 
human osteosarcoma) and BS-C-1 (African green monkey kidney, ATCC CL-26) cells 
were used for growth and titration of VACV. COS-7 (African green monkey kidney 
fibroblasts, ATCC CL-1651) cells were used for the production of recombinant 
proteins using mammalian expression systems. NK92MI (human natural killer cells, 
ATCC CRL-2408) cells, Jurkat E6.1 (human acute T cell leukaemia cells, ATCC TIB-
152) cells, RAW (mouse spleen lymphoma cells, ATCC TIB-50) cells, HEK-293T 
(human epithelial cells ATCC CRL-11268) cells, DG75 (human B lymphocytes ATCC 
CRL-2625) cells, AK31 (human B lymphocytes) cells, HeLa (human negroid cervix 
epitheloid carcinoma, ECACC 93021013) cells and B3Z (human T cell hybridoma) 
cells were used for protein binding studies. K562 suspension cells (human lymphoma, 
ATCC CCL-243) were used in in vitro cytotoxicity assays whilst Yac-1 (mouse 
lymphoma (induced by moloney murine leukaemia virus) cells, ATCC TIB-160) cells 
and EL4 (mouse (C57BL/6) lymphoma, ATCC TIB-39) cells were used as targets for 
NK and CTL cytotoxicity assays respectively. Sf9 (Spodoptera frugiperda derived cells 
(Novagen)) were used for production and growth of recombinant baculoviruses. Mouse 
hybridoma cells (LX035-9) were used to produce an anti-BAP mAb. AK31 and DG75 
cells were kindly provided by Professor Paul Farrell and B3Z cells were kindly donated 
by Dr. Keith Gould.  
 
2.3.2 Maintenance of cell stocks 
 All cells were maintained in medium supplemented with 50 IU/ml penicillin 
and 50 μg/ml streptomycin (Gibco BRL) unless stated. BS-C-1, TK
-
143, HEK-293T, 
K562 and EL4 cells were maintained in Dulbecco‟s modified Eagle‟s medium 
(DMEM, Gibco BRL) supplemented with 10% heat-treated (1 h, 56 ºC) foetal bovine 
serum (FBS, Gibco BRL) and 2 mM L-glutamine (Gibco BRL) referred to here as 
DMEM/10. COS-7 cells were maintained in DMEM/10 then adapted to DMEM 
supplemented with 2% FBS for protein production (DMEM/2). Jurkat E6.1 cells and 
B3Z cells were maintained in Roswell Park Memorial Institute medium (RPMI) 1640 
(Gibco BRL) supplemented with 10% FBS (RPMI/10). DG75, AK31 and YAC-1 cells 
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were maintained in RPMI 1640 supplemented with 10% superior serum (SS, 
BioWhittaker (RPMI/SS)). NK92MI cells were maintained in alpha – modified Eagle‟s 
medium (α-MEM, Gibco BRL) supplemented with 12% FBS, 0.1 mM ß-
mercaptoethanol, 0.2 mM inositol, 0.02 mM folic acid, (α-MEM complete). RK13, 
RAW and HeLa cells were maintained in minimum essential medium (MEM, Gibco 
BRL) supplemented with 10% FBS, 1% non-essential aa, and 2 mM L-glutamine 
(MEM/10). The LX035-9 hybridoma cell line was maintained in RMPI 1640, 
supplemented with 5% ultra low IgG foetal bovine serum (Invitrogen), 1% non-
essential aa, 0.2% peptone, 0.25% D-glucose, 100 IU/ml penicillin, 100 μg/ml 
streptomycin, 50 µM ß-mercaptoethanol (Integra medium, IM). The Sf9 cells were 
maintained in SF900 II SFM (SF900) (Gibco BRL) with 5% FBS (SF900/5). All cells 
except Sf9s were incubated in a humidified incubator (Heraeus) with 5% CO2 at 37 °C. 
The Sf9 cells were incubated as monolayer cultures in a humified incubator (Hera Cell, 
Heraeus) at 28 °C and as suspension cultures in a shaking incubator (Orbital Incubator 
S150, Stuart Scientific) at 28 °C. Cell culture and virus work were performed in a 
laminar flow hood (Microflow Biological Safety Level II) under biological safety level 
II conditions.  
 
2.3.3 Subculture of cells 
 For adherent cells, the supernatant was removed and cells were detached with 
0.5 mM EDTA/trypsin (Gibco BRL) at 37 °C. Trypsinisation was stopped by adding 
medium containing 10% serum and any cell clumps were disaggregated by pipetting 
gently several times. Cells were split as necessary. For suspension cells, the cells were 
collected by centrifugation at 1,000 x g for 5 min at 4 °C, resuspended in growth 
medium and seeded at the appropriate density. 
 
2.3.4 Cryopreservation of cells 
 Cells were harvested as described as above, and resuspended in freezing 
medium (90% FBS, 10% DMSO) at 1 x 10
7
 cells/ml. The cells were aliquoted into 
Cryo tubes (Nunc) and frozen slowly (-1 °C per h) then transferred to liquid nitrogen 
(CellBank).  
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2.3.5 Revival of frozen cells 
 Cells were thawed quickly in a 37 °C water bath and then added to 10 ml pre-
warmed medium in a sterile 50 ml Falcon tube. The cells were collected by 
centrifugation and resuspended in growth medium and transferred to a T25 flask 
(CellStar). 
 
2.3.6 Histological staining of extracted cell populations 
 Cells extracted from mouse tissues were cytospun onto Superfrost slides 
(VWR) by loading ~ 2x 10
4
 cells into the sample chamber of a disposable cytofunnel 
case. The cells were spun onto the slide for 10 min at 800 rpm. The slide was carefully 
removed from the cytofunnel and the cells air dried for 30 min before being fixed and 
stained using the Diff-Quik kit (Themoshandon) according to the manufacturer‟s 
instructions. Briefly, the slides were dipped slowly into the Diff-Quik fixative solution 
then solution 1 (xanthene) followed by solution 2 (thiazine) for 30 s each and finally 
washed in distilled water three times. The stained slides were air dried before mounting 
with DePex solution under coverslips and samples were examined with and 4 
representative fields were counted to check the percentage purity of the extracted cells.  
 
2.3.7 Transfection of COS-7 cells 
 Liposome-mediated transfection was employed for the transfection of COS-7 
cells (FuGene6 transfection reagent Roche). Cells were seeded at 50-70% confluency 
the day before transfection in DMEM/2%. The culture medium was replaced with pre-
warmed medium (1 ml for 6-well plates and 20 ml for a T175 flask). For transfection in 
6-well plates, 4 μl FuGene6 reagent (Roche) or 1.5μl polyethylenimine (PEI, Park 
Scientific Ltd) was added to 100 μl serum-free DMEM, then 1 μg plasmid DNA was 
added and the mixture was incubated at room temperature (RT) for 20 min and added 
to the cells. After 24 h the medium was replaced with DMEM/SF and 72 h later the 
supernatant was harvested and cell debris was removed.  
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2.3.8 Enrichment of cell populations 
 Peripheral blood mononuclear cells (PBMCs) were revived in RMPI with 10% 
human serum (heat inactivated) and human IL-2 (100 ng/ml) and seeded in a T75 tissue 
flask overnight. The lymphocyte enriched population (non-adherent) was harvested by 
carefully removing the supernatant and centrifugation at 1,000 x g for 5 min. The 
monocyte enriched (adherent) population was also harvested. The cell monolayer was 
gently washed with PBS and this was removed and replaced with PBS/0.5 mM EDTA 
and the cells incubated at 37 ºC for 5 min. The flask was gently tapped and the cells 
harvested by centrifugation at 1,000 x g for 5 min. The cells in each fraction were 
enumerated with trypan blue exclusion and a haemocytometer and re-suspended in 
binding buffer for cell binding assays or FACS buffer for antigen staining. 
 
2.4 Growth of vaccinia viruses 
2.4.1 VACV strains and mutants  
 VACV strain WR (Smith et al., 1991), the VACV mutants vΔA40, vA40HA 
(Wilcock et al., 1999) and vB14HA (Chen et al., 2006) and the recombinant VACV 
WR vT7lacIO (Ward et al., 1995) were all described previously. 
 
2.4.2 Maintenance of virus stocks 
 Viruses were kept at -70 °C as master stocks. These were used to seed sub-
master, which in turn were used to seed working stocks in RK13 cells. The master 
stocks were sonicated 3 times for 10 s at 20% power output (Sonicator 3000, Sonimix), 
diluted and used to infect a T175 cm
2
 flask of RK13 cells at 0.01 p.f.u/cell in 
DMEM/2.5% for 90 min at 37 °C. The infected cells were incubated at 37 °C in 
DMEM/10% until complete CPE developed (usually 2 -3 days). The cells were 
harvested into the medium by a few vigorous taps of the flasks and were collected by 
centrifugation at 2000 rpm for 10 min. The sub-master stock was resuspended in 2 ml 
DMEM/SF medium, sonicated, aliquoted and the virus titre assessed (section 2.4.3). 
This sub-master stock was used to infect 10 x T175 cm
2
 flasks of RK13 cells at 0.01 
p.f.u/cell as described for the sub-master stocks. After 2 days, the infected cells were 
harvested and the pellets were resuspended in chilled 10 mM Tris pH 9.0 (Tris 9.0 
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buffer) and left on ice for 15 min for the cells to swell. The cells were lysed on ice 
using a tight fitting dounce homogeniser (25 strokes) and the cell debris was removed 
by centrifugation at 2000 x g for 10 min at 4 °C. The pellet was resuspended in 10 ml 
Tris 9.0 buffer, re-dounced and centrifuged again. The supernatants were pooled and 
sonicated briefly before being loaded onto 18 ml 36% (w/v) sucrose solution in Tris pH 
9.0 buffer in Beckman Ultra-Clear tubes and centrifuged at 13,500 rpm for 80 min at 4 
°C using a Beckman L8M ultracentrifuge and SW28 rotor. The supernatant was 
removed by aspiration and the pellet was resuspended in 1 ml Tris 9.0 buffer, sonicated 
and stored at -70 °C. All viruses were titrated by plaque assay on BS-C-1 cells. 
 
2.4.3 Virus titration 
 The infectivity of the virus was determined by plaque assay. Sonicated virus 
stocks were diluted 10 or 100-fold through a dilution series in DMEM 2.5% in 
triplicate. One ml of the dilutions was used to infect 6-well plates of confluent BS-C-1 
cells. The plates were incubated at 37 °C and rocked gently every 30 min for 1.5 h. The 
inocula were aspirated and the cells were overlaid with 1.5 ml DMEM (2.5% FBS) 
containing 1.5% carboxymethylcellulose (CMC). After 48 or 72 h, the overlay was 
aspirated, the cells were rinsed in PBS and the cells were stained for 2 h with 0.01% 
(w/v) crystal violet in 15% (v/v) ethanol. Cells were rinsed by submersion in water and 
the plaques were counted. 
 
2.5 Recombinant vaccinia virus preparation 
2.5.1 Infection/transfection 
 A T25 flask of confluent CV-1 cells were infected at 0.05 p.f.u/ml with the 
vT7LacOI virus (Section 5.5). After 90 min incubation at 37 °C, cells were washed 
twice with DMEM/SF and then 2 ml DMEM/SF was added to each flask. One μg 
plasmid DNA in 50 μl DMEM/SF and 2 μl Lipofectamine 2000 in 50 μl DMEM/SF 
were incubated at RT for 15 min then combined and incubated for a further 20 min. 
This mixture was then added to the flask and cells were incubated for 4 h at 37 °C. The 
DMEM/DNA/Lipofectamine 2000 mix was replaced with DMEM/2.5% and cells were 
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incubated for two days at 37 °C. Cells were harvested by scraping, collected by 
centrifugation at 2000 x g for 5 min and resuspended in 500 μl DMEM. 
 
2.5.2 Plaque purification, selection and analysis of recombinant viruses  
 VACV recombinants expressing the E. coli guanine (-xanthene) phosphoribosyl 
transferase (Ecogpt) gene may be selected in the presence of mycophenolic acid 
(MPA) as described previously (Boyle & Coupar, 1988). MPA blocks VACV 
replication in most cell lines due to its inhibition of inosine monophosphate 
dehydrogenase in the de novo pathway of purine synthesis. If Ecogpt is expressed from 
a VACV promoter such as the P7.5 early/late promoter, the inhibition in purine 
synthesis is overcome if xanthine and hypoxanthanine, substrates for the purine salvage 
pathway, are added.  
 Confluent monolayers of BS-C-1 cells in 6-well plates were incubated for 4 h 
with DMEM containing 50 μg/ml MPA, 250 μg/ml xanthine and 15 μg/ml 
hypoxanthanine (HX). Hypoxanthanine stocks were prepared as 10 mg/ml stocks in 0.1 
M NaOH, so an equal volume of 0.1 M HCl was added to the medium. The medium 
containing MPA and HX was removed and cells were infected as described above 
(section 2.4.2) with 10-fold serial dilutions of the infection/transfection inoculum. 
Infected cells were overlaid with medium containing 1% low-melting point agarose 
(Sigma) in 2.5% FBS DMEM containing MPA, hypoxanthine and xanthine at the 
concentrations above. The agar was allowed to set and plaques were incubated at 37 °C 
for 2 days. Monolayers were then stained by the addition of 2 ml semi-solid overlay 
containing 33 mg/L neutral red solution (Sigma). After 1-4 h plaques were visualised as 
areas which have not taken up the red stain. These plaques were picked as a plug of 
agarose using a 200 μl blunt-ended micropipette tip and were transferred to a 1.5 ml 
microfuge tube containing 500 μl 2.5% FBS medium. 
 Plaque solutions were frozen and thawed twice to break open cells and then 
sonicated for 20 sec. A fraction of each plaque isolate (50 μl) was used to infect one 
well of a 96-well plate of confluent RK13 cells. After 90 min at 37 °C, 150 μl of 
MEM/10% FBS was added to each well and the cells were incubated for 2 days before 
proteinase K digestion (section 2.7.11) and PCR analysis (section 2.7.12). 
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 Recombinant viruses were plaque purified three times in BS-C-1 cells and  100 
μl of the final plaque isolate was used to infect a T25 flask of BS-C-1 cells. After three 
days, the cells were harvested by scraping, collected by centrifugation and resuspended 
in 1 ml DMEM. This was freeze-thawed three times and stored at -70 °C as a master 
stock. This master stock was used to infect a T175 flask of RK13 cells to create a 
submaster stock which in turn was used to create a working stock (Section 2.4.2). 
 
2.6 Recombinant baculovirus production 
2.6.1 Direct plaquing transfection 
 For each transfection mix, Sf9 cells were diluted to ~ 5 x 10
5
 cells/ml in 
prewarmed medium and were seeded at 2 ml per well of a 6 well-plate plus 5 ml in a 
T25 flask. The plates were gently rocked to ensure an even monolayer and left to attach 
at 28 °C for at least 20 min. 
 The transfection mix was prepared in a sterile 5 ml polystyrene bijou. One 
hundred ng BacVector-1000 Triple Cut Virus DNA was mixed with 500 ng transfer 
plasmid in a total volume of 25 μl with BacVector Insect Cell Medium (Novagen). In a 
separate bijou, 5 μl Insect GeneJuice Transfection Reagent (Novagen) was mixed with 
20 μl nuclease free water. This was added immediately to the plasmid/DNA/medium 
mix and swirled to mix and incubated at RT for 15 min. 
 During this incubation, the Sf9 cells were washed twice in SF900 medium, 
removing the second wash just prior to adding the transfection mix to the cells. After 
the incubation was completed, 0.45 ml BacVector Medium was added to the 
DNA/Insect GeneJuice mix and vortexed gently to become a 1/10 dilution. Then 0.4 ml 
BacVector Medium was added to to fresh tubes and using a fresh sterile tip for each 
dilution, 0.1 ml from the 1/10 was added to the first tube (1/50) and this mix was 
vortexed gently, then 0.1ml of this mix was added to the second tube (1/250).  
 The second wash medium was removed from the cells and 0.1 ml of 1/10, 1/50 
and the 1/250 dilution were added to the freshly drained wells in duplicate by slowly 
pipetting the dilution onto the centre of the monolayer. The plates were incubated for 1 
h at RT with rocking every 20 min. The residual 0.3 ml of the 1/10 dilution were added 
to the T25 flask as a back up to the direct plaquing transfection and incubated for 1 h at 
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RT. During this incubation, the agarose overlay was prepared from 3% BacPlaque 
melted agarose stock diluted 1:2 with pre-warmed SF900 II SFM/5%.  
 After the incubation, 2 ml agarose overlay was added to each well by pipetting 
slowly down the side of the well and allowed to solidify for 20 min at RT, after which 1 
ml SF900 II SFM/5% was added gently to the centre of each well. The plates were 
incubated at 28 °C for 4 days and monitored for plaque formation. 6 ml SF900/5% was 
added to the T25 and this was incubated for 4 days at 28 °C. 
 
2.6.2 Plaque staining and isolation 
 After incubation for 4 days, the transfections were monitored by staining 
plaques in the monolayer with neutral red staining. The liquid overlay was removed 
from the agarose and replaced with 1 ml diluted neutral red (0.33% [w/v] neutral red 
stock solution diluted 1:13 with sterile PBS just before use). The plates were incubated 
for 2 h at 28 °C, the staining solution was removed and the plates were incubated at RT 
for at least 3 h or overnight.  
 For each transfection, several well-isolated, independent plaques were picked 
and eluted into 1ml SF900 in a sterile screw-cap tube and the mixture was incubated 
overnight at RT to allow the virus to diffuse from the agarose. Each plaque pick was 
purified by replaquing onto freshly seeded Sf9 cells (Section 2.6.1) in duplicate.  
 
2.6.3 Preparation of high titre virus stocks 
 A seed stock was prepared from a well isolated plaque. For each virus stock, a 
T25 flask was seeded using 2.5 x 10
6
 cells obtained from an exponentially growing 
suspension culture of Sf9 cells. The flasks were incubated at RT for 20 min to allow the 
cells to attach, the medium was removed and 0.3 ml of virus suspension was added to 
the cells. The cells were incubated at RT for 1 h and the liquid rocked across the cells 
twice and 5 ml SF-900/5% medium was added to the flask and the infected cells were 
incubated at 28 °C until CPE was observed (3-5 days). The medium was then harvested 
as a seed stock of virus. This was then used to inoculate a T75 flask of SF9 cells seeded 
with 2 x 10 
7
 cells from an exponentially growing suspension culture. The seeding 
medium was removed from the flask and 0.5 ml seed stock was added to the cells 
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carefully and incubated for 1 h at RT. The inoculum was rocked across the cells twice 
during the incubation. To each flask, 10 ml of SF-900/5% was then added and 
incubated at 28 °C until CPE was observed (3-5 days). The medium was harvested into 
sterile 15 ml Falcon tubes and centrifuged (1000 x g for 10 min) to remove cell debris. 
The supernatant was removed to a fresh sterile tube and constituted the master stock of 
virus. As a backup, 0.9 ml of the master stock was added to 100 μl FBS and stored at – 
70 °C while the rest was stored at 4 °C. The master stock was titrated on freshly seeded 
Sf9 cells in duplicate and the plaques stained with neutral red solution. The master 
stock was then used to seed a high titre stock. Exponentially growing Sf9 cells at ~ 2 x 
10
6
 cells/ml in a suspension culture were infected at 0.01 p.f.u/cell. The culture was 
incubated at 28 ºC with shaking for 5 days and harvested by centrifugation at 2,000 rpm 
for 15 min at 4 ºC. The supernatant (high titre stock) was aliquoted into foil covered 
tubes and stored at 4 ºC. This stock was titred and then used to infect Sf9 cells to 
produce recombinant protein (sections 2.8.10 & 2.8.11). 
 
2.7 Manipulation of DNA & cloning techniques 
2.7.1 Quantification of DNA 
 The concentration of DNA was determined by measuring UV absorbance at 260 
nm (1 OD260=50 μg/ml dsDNA) using a NanoDrop ND-1000 spectrophotometer. The 
purity of the nucleic acids was assessed by the OD260/280 ratio. Pure DNA has a value 
between 1.8 and 2.0. 
 
2.7.2 Restriction enzyme digestion of DNA 
 Restriction digests were performed with 5 U of enzyme per μg DNA for 2 h 
under conditions recommended by supplier (Promega, Roche or New England Biolab). 
For SfiI (New England Biolabs, NEB) restriction was performed at 10 U of enzyme per 
μg DNA for 20 h at 50 °C. The products were purified by extraction from an agarose 
gel (Sections 2.7.13 & 2.7.14). 
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2.7.3 Dephosphorylation of 5’ends of DNA fragments 
 Dephosphorylation was performed at 1 U of shrimp alkaline phosphatase (SAP, 
Amersham Biosciences) per µg DNA for 1 h at 37 °C under conditions recommended 
by supplier. The reaction was terminated by heating at 65 °C for 15 min. 
 
2.7.4 DNA ligation 
 The molar ratio of insert to vector was 3:1 for sticky-end ligation. The reaction 
was performed in 30 μl containing the insert and vector DNA (50 ng), 1 x buffer (66 
mM Tris-HCl, 5 mM MgCl2, 5 mM DTT, 1 mM ATP, pH 7.5) and 1 U T4 DNA ligase 
(Roche) and the reaction mix was incubated at 16 °C for 20 h. 
 
2.7.5 Plasmids 
 Five DNA plasmid vectors, pSEL (Ahmad, 2003), pSecTag2C (Invitrogen), 
pET-28a (Novagen), pVOTE 1 (Ward et al., 1995), and pBac-2cp (Novagen) were 
used. pSecTag2C was used for the construction of mammalian expression clones of 
truncated A40 protein. pSEL was used to express full-length A40 protein tagged with 
BAP in VACV-infected mammalian cells. pET-28a was utilised to create truncated 
proteins expressed in E. coli whilst pBac-2cp was used to create recombinant 
baculoviruses containing truncated A40 protein tagged with His and BAP expressed 
from insect cells. pVOTE 1 was used to create recombinant VACV expressing full-
length A40 protein tagged with BAP and FLAG, and truncated A40 protein tagged with 
BAP under an isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible system.  
 
2.7.6 Transformation of bacterial cells 
 Transformation competent cells were thawed slowly on ice. Plasmid DNA (50 
ng) or ligation products (5 μl, described above) was added to the cells and left on ice 
for 30 min. The cells were heat-shocked at 42 °C for 2 min and cooled on ice for 10 
min. Two hundred μl of SOC (Invitrogen) was added and the transformation mixture 
was incubated at 37 °C for 1 h with shaking. One hundred μl of the transformation 
mixture was spread on agar plates containing 100 μg/ml ampicillin (Amp+) or 50 μg/ml 
kanamycin (Kan
+
) and the plate was inverted and incubated overnight.  
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2.7.7 Bacterial glycerol stocks 
 A single bacterial colony on an agar plate was inoculated into 5 ml Luria-
Bertani broth (LB) and incubated at 37 °C overnight with shaking. A 500 µl aliquot of 
the culture was mixed with an equal volume of glycerol solution (65% glycerol [v/v], 
10 mM Tris-HCl pH 8.0, 100 mM MgSO4) and stored at -80 °C. When required, the 
frozen glycerol stock was scraped using a sterile loop, streaked onto an agar plate to 
generate discrete colonies, and the plate was incubated overnight. 
 
2.7.8 Preparation of plasmid DNA: miniprep 
 This protocol was used to prepare good quality plasmid DNA for general DNA 
manipulations such as restriction enzyme digestion, sub-cloning and DNA sequencing. 
A commercial plasmid purification system, QIAprep Spin Miniprep Kit (Qiagen), was 
used following the supplier‟s instructions. Plasmids were eluted in double distilled 
water (ddH2O) and stored at -20 °C.  
 
2.7.9 Preparation of plasmid DNA: Maxiprep 
 This protocol was used to prepare up to 500 μg of high purity plasmid DNA for 
cell transfection using a commercial plasmid purification system, HiSpeed Plasmid  
Maxi Kit (Qiagen) following the supplier‟s instructions. The plasmid DNA was eluted 
in 1 ml of TE buffer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA) and stored at -20°C.  
 
2.7.10 DNA sequencing 
 DNA samples (200 ng of template dsDNA) were mixed with 32 pmol of 
oligonucleotide primer in a reaction volume of 10 μl. Samples were submitted to the 
MRC Sequencing Service, Hammersmith Campus, Imperial College London. The 
results were analysed using BioEdit software (Hall T.A) and the NCBI website 
(http://www.ncbi.nlm.nih.gov/).  
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2.7.11 Preparation of viral template DNA for PCR analysis 
 Confluent BS-C-1 cells were infected with 50 μl of plaque isolate medium 
(Section 2.5.2) for 48 h in a 96-well plate in the presence of selection drugs. The 
medium was removed and the cells washed in PBS once. Proteinase K solution [50μL 
(50 μg/ml Proteinase K (Fluka), 10x Mg free PCR buffer (Promega)] was added to each 
well and the plate was freeze - thawed once. The contents of each well was transferred 
into 0.2 ml eppendorf tubes and incubated at 56°C for 20 min, followed by 85 °C for 10 
min to inactivate the proteinase K.  
 For analysing recombinant baculoviruses, the virus was first lysed then treated 
with proteinase K. The high titre stock virus (section 2.6.3, > 1 x 10
8
 p.f.u/ml,) was 
added to 89 μl Baculo lysis buffer (10 mM Tris, pH 8.3, 100 μg/ml gelatine, 0.45% 
Triton X-100, 0.45% Tween-20, 50 mM KCl) and then 1 μl proteinase K (10.8 mg/ml) 
was added. The samples were incubated for 1 h at 60°C after which, the proteinase K 
was heat inactivated at 95 °C for 10 min and the samples were cooled on ice. A PCR 
was performed to determine the presence/absence of the required gene within the virus 
using 3 μl of template per PCR. 
 
2.7.12 Polymerase chain reaction (PCR) 
 PCR was used to amplify specific DNA sequences for cloning and to screen 
bacterial clones. For cloning, Platinum Taq DNA High Fidelity (HiFi Taq) (Invitrogen) 
was used whereas GoTaq (Roche) was used for screening. As an overall strategy, a 
standard PCR in a 50 μl reaction volume contained 10 to 100 ng of template DNA, 
oligonucleotide primers (50 pmol each), 200 μM dNTPs, 1 x PCR buffer (HiFi Taq: 60 
mM Tris-SO4 [pH 8.9], 18 mM ammonium sulphate; GoTaq:, 2 mM MgCl2 [HiFi Taq] 
and 2 U of thermal polymerase. PCR conditions used were (i) initial denaturation at 94 
°C for 2 min, (ii) 30 cycles of 94 °C for 30 s, annealing for 30 s, extension at 72 °C 
(HiFi Taq), 74 °C (GoTaq) for 2 min. The extension time for DNA sequences was 
approximately 1 min/kb. The PCR products were analysed by agarose gel 
electrophoresis and where necessary purified from the excised fragment of agarose 
(section 3.5.12 and 3.5.13).   
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2.7.13 Resolution of DNA by agarose gel electrophoresis 
 DNA fragments were resolved by agarose gel electrophoresis. Samples were 
mixed with 1/5 vol of 6 x loading buffer (30% glycerol [v/v], 0.25% bromophenol blue, 
0.25% xylene cyanol FF) before loading into an agarose gel. The concentration of 
agarose in 1 x TAE (40 mM Tris-acetate, 1 mM EDTA) was selected according to the 
size of DNA fragments to be resolved (0.7% agarose for DNA fragment sizes between 
800 bp and 12 kb, 1% for 500 bp to 10 kb, 1.5% for 200 bp to 3 kb and 2% for 50 bp to 
2 kb). Molten agarose was supplemented with either ethidium bromide (10 μg/ml) or 
more recently SYBR Safe DNA gel stain (Invitrogen) and allowed to set. 
Electrophoresis was performed with 1 x TAE buffer in a minigel electrophoresis unit 
(BioRad) at 80 volts for 30 min. A 1 kb DNA marker (Hyperladder V, Bioline) or 
TrackIt 50 (Invitrogen) was electrophesed alongside the samples. The DNA fragments 
were visualised with a UV transilluminator (UVP) and photographed using a gel-
documentation imager (Bio-Rad Chemi Doc). 
 
2.7.14 Purification of DNA by gel extraction 
 Resolved DNA fragments in agarose gel were excised by a scalpel blade under 
a long wave UV lamp (302 nm). The DNA was extracted from the agarose gel using a 
Qiaquick Gel Extraction Kit (Qiagen) following the manufacturer‟s instructions. 
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Table 2.3 Oligonucleotides used for cloning & sequencing in this study 
Restriction sites are underlined. Start and stop codons are bold. Biotin acceptor peptide (BAP), HA, and FLAG sequences are italic. Nucleotides inserted for correcting ORF 
are bracketed. FP, forward primer; RP, reverse primer  
Primer Sequence (5’ to’3) Remarks 
HisA40_F CATTCAATGGATCCTTAAAAGTTGTAGAACG A40RΔTM FP (BamHI) for pET-28a vector 
HisA40_Ft CATTCAATGGATCCGCATATATTAGAGAAGATTGTCC 
A40RΔTMΔSt FP (BamHI) for pET-28a 
vector 
HisA40_R CCTTAAGCTTTTATATAGTGTAACACGAATGCAGTTTGG A40R RP (HindIII) for pET-28a vector 
(N)Biotin_F TACGAAGCTT(G)CCGAATTCCGGATCACTGCATCATATTC BAP FP (HindIII) for pSecTag2 vector 
(N)BioA40R_F GGTGTGGAACCATCGTTTAAAAGTTGTAGAACGTAAATTAG BAP(A40RΔTM) RP (N) for pSecTag vector 
(N)BioA40R_R CTAATTTACGTTCTACAACTTTTAAACGATGGTTCCACACC BAP(A40RΔTM) FP (N) for pSecTag2 vector 
(N)BioA40R_Ft GGTGTGGAACCATCGTGCATATATTAGAGAAGATTGTCC 
(BAP)A40RΔTMΔSt FP (N) for pSecTag2 
vector 
(N)BioA40R_Rt GGACAATCTTCTCTAATATATGCACGATGGTTCCACACC 
(BAP)A40RΔTMΔSt RP (N) for pSecTag 
vector 
A40R_R CCTTGGATCCTTATATAGTGTAACACGAATGCAGTTTGGG 
A40R RP (BamHI) for pSecTag2 vector & 
pBac-2cp 
pSEL(N)Biotin_F TCCTCGAG(GG)ATGCCGAATTCCGGATCACTGC BAP FP (XhoI) for pSEL vector 
pSEL(N)BioA40R_F GAAAATGGTGTGGAACCATCGTATGAACAAACATAAGACAGATTATG (BAP)A40 (N) for pSEL vector 
pSEL(N)BioA40R_R CATAATCTGTCTTATGTTTGTTCATACGATGGTTCCACACCATTTTC BAP(A40) RP (N) for pSEL vector 
pSEL(N)BAPA40R_R CATCTAGATTATATAGTGTAACACGAATGC A40R RP (XbaI) for pSEL vector 
pSEL(C)A40RBAP_F TGCTCGAG(GG)ATGAACAAACATAAGACAGATTATGC A40R FP (XhoI) for pSEL vector 
pSEL (C) A40RBio_F CCCAAACTGCATTCGTGTTACACTATACCGAATTCCGGATCACTGC A40(BAP) FP for pSEL vector 
pSEL (C) A40RBio_R GCAGTGATCCGGAATTCGGTATAGTGTAACACGAATGCAGTTTGGG A40(BAP) RP for pSEL vector 
pSEL (C)A40RBAP_R CATCTAGATTAACGATGGTTCCACACCATTTTC BAP RP (XbaI) for pSEL vector 
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Table 2.3 continued. Oligonucleotides used for cloning & sequencing in this study 
Primer Sequence (5’ to 3’) Remarks 
IgκBAPA40_F CAGCCATGGAGACAGACACACTCC Igκ FP (NcoI) for pVOTE.1 vector 
IgκBAPA40_R GTGGTCGACTTATATAGTGTAACACG Igκ RP (SalI) for pVOTE.1 vector 
(N)FLAG_BAP_F ATTCCATGGATTACAAGGATGACGACG 
FLAG-BAP (N) FP (NcoI) for pVOTE 
vector  
(N)FLAG_BAP_R GCATAATCTGTCTTATGTTTGTTACGATGGTTCCACACCATTTTCTGC FLAG-BAP (N) RP for pVOTE vector 
(N)TAPA40_F GCAGAAAATGGTGTGGAACCATCGTAACAAACATAAGACAGATTATGC (TAP)A40 FP for pVOTE vector 
VOTE_A40_R AATGTCGACTTATATAGTGTAACACGAATGC A40 RP (SalI)for pVOTE vector 
Bac-2cp(N)Biotin_F TACGGGATCCGCCGAATTCCGGATCACTGC BAP FP (BamHI) for pBac-2cp vector 
Bac-2cpA40TM_F CATTCAATGGATCCGTTAAAAGTTGTAGAACG A40R FP for pBac-2cp vector 
Bac-2cpA40TMSt_F CATTCAATGGATCCGGCATATATTAGAGAAGATTGTCC A40R RP for pBac-2cp vector 
Y2H_A40R_F ATTAGCCGGGCCATTACGGCCATGAACAAACATAAGAC A40R FP for Dualmembrane vectors 
Y2H_A40R_R CGGCTAATGGCCGAGGCGGCCTTATATAGTGTAACACG A40R RP for Dualmembrane vectors 
T7F TAATACGACTCACTATAGG T7 sequencing FP 
T7R GCTAGTTATTGCTCAGCGG T7 sequencing RP 
pBT3-N_F CAGAAGGAGTCCACCTTAC pBT3-N sequencing FP 
pmb11 AGTCAGTCAGTCGCAATTATATAATGTA VOTE virus analysis FP 
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2.8 Protein expression, purification and analysis 
2.8.1 Production and purification of anti-BAP monoclonal antibody 
 The mouse hybridoma cell line LX035-9 was expanded to 1 L, containing ~ 1 x 
10
7
 cells. The cells were collected by centrifugation at 2,000 x g for 10 min and the 
supernatant was harvested. The cells were resuspended in 1 L of RPMI /SF and 
incubated with rotation for 7 days until maximum levels of mAb had been produced. 
The supernatant was centrifuged (1000 x g, 10 min) to remove cell debris, filtered 
through a 0.45 μM filter and applied to a protein G HiTrap column (GE Healthcare) 
using a peristaltic pump. The column was washed with PBS and the bound IgG was 
eluted with 100 mM glycine pH 2.8 on an AKTA purifier (Amersham Biosciences). 
The fractions were assessed for IgG content by SDS-PAGE and coomassie blue 
staining.  
 
2.8.2 Production of anti-BAP columns 
The IgG containing fractions were pooled, concentrated by using a Centriprep-
10 protein concentrator (Ambicon) and washed twice in Ab buffer (10 mM HEPES, pH 
7.5, 150 mM NaCl, 0.1% sodium azide). The IgG was coupled to cyanogen bromide 
(CNBr)-activated Sepharose beads (Pharmacia) following the manufacture‟s protocol. 
The beads were poured into Econo-Columns (BioRad) and washed with BAP affinity 
column buffer (25 mM Tris, 140 mM NaCl, 0.02% sodium azide [v/v], pH 7.4). The 
columns were stored at 4 °C until needed. 
 
2.8.3 Bacterial expression systems 
2.8.3.1 Bacterial protein expression for generation of anti-A40 antibody 
 Bacterial plasmids containing truncated A40 (pET-28a-HisA40ΔTM or pET-
28a-HisA40ΔTMΔSt, Section 2.7.5.) were expressed in E. coli by transformation into 
the E. coli strain Rosetta Gami 2 (Novagen), a strain that has trxB/gor mutations for 
disulphide bond formation and improved protein folding in vivo.  
 A single bacterial colony was used to inoculate 4 ml of LB containing 50 μg/ml 
kanamycin (Kan) at 37 °C with shaking. This culture was then used to inoculate 2 L LB 
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(plus antibiotic) and was incubated at 37 °C with shaking until reaching an OD595 
reading of 0.6. IPTG was added to a final concentration of 1 mM and the incubation 
was continued for 3 h. The cells were harvested by centrifugation at 3,000 rpm for 20 
min at 4 °C.  
 
2.8.3.2 Bacterial protein expression for crystallisation trials 
 E. coli strain Rosetta Gami 2 (DE3) was transformed with bacterial plasmids 
containing truncated A40 (pET-28a-HisA40ΔTM or pET-28a-HisA40ΔTMΔSt, section 
2.7.5.). A single bacterial colony was used to inoculate 10 ml of LB broth containing 
50μg/ml Kan and the culture was incubated at 37 °C with shaking. After overnight 
incubation, the culture was used to inoculate 2 L LB with Kan with shaking until 
reaching an OD595 reading of 0.6. IPTG was added to a final concentration of 1 mM 
and the incubation was continued at 37 °C for 3 h with shaking. The cells were 
harvested by centrifugation at 3,000 rpm for 20 min at 4 °C.  
 
2.8.3.3 Bacterial protein expression with Selenomethionine labelling for 
crystallisation studies 
 E. coli strain Rosetta Gami 2 (DE3) was transformed with bacterial plasmids 
containing truncated A40 as above. A single bacterial colony was used to inoculate 200 
ml of Selenomethionine (SeMet) base (190 ml SeMet O/N broth (AthenaES), 0.8 ml L-
methionine (10 mg/ml), 10 ml nutrient mix) containing 50 μg/ml Kan at 37 °C with 
shaking O/N. The culture was centrifuged at 3,000 rpm for 10 min and the cells were 
washed in 50 ml PBS, resuspended in 10 ml PBS and re-centrifuged as above and then 
resuspended in 8 ml PBS. This was added to 2 L of SeMet labelling broth (1.9 L SeMet 
base, 100 ml glucose free nutrient base, 8 ml selenomethionine (Merck chemicals). The 
bacteria were incubated with shaking at 37 °C until reaching an OD595 of 0.6. IPTG was 
added to a final concentration of 1 mM and the incubation was continued at 16 °C for 
16 h with shaking. The cells were harvested by centrifugation at 3,000 rpm for 30 min 
at 4 °C.  
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2.8.3.4 Small scale protein extraction to assess solubility of expressed 
recombinant A40 
 E. coli strains B834 (Invitrogen), BL21 (Invitrogen) or Rosetta Gami 2 were 
transformed with either pET-28aHisA40ΔTM or pET-28aHisA40ΔTMΔSt. A single 
colony of the strains was inoculated into 1 ml LB containing 50 μg/ml Kan and 
incubated at 37 °C with shaking. This culture was used to inoculate 100 ml LB with 
Kan and shaken at 37 °C until reaching an OD595 of 0.6. This culture was split into 5 ml 
cultures and incubated at either 16, 30 or 37 °C for various times with either 0.1, 0.5 or 
1 mM IPTG or induced by the Autoinduction system (Novagen). Before harvesting, the 
final OD560 of each culture was measured. Cell pellets from the induced 5 ml bacterial 
culture were frozen and thawed once. The cells were resuspended in 200 μl lysis buffer 
(50 mM Tris-HCl pH 8.0, 0.5 M NaCl, 2% [v/v] Triton X-100) per 1.0 OD560 of 
measured culture, vortexed rigorously and sonicated on ice for 15 s at 20% power 
output with 30 s incubation between each sonication for a total of 2 min. The cell 
lysates were centrifuged at 15,000 rpm for 15 min to separate soluble and insoluble 
proteins. The supernatants (soluble proteins) were collected and the insoluble proteins 
were suspended in an equal volume of lysis buffer. An equal volume of 2 x SDS buffer 
was added to the soluble and insoluble fractions and the samples were boiled at 95 °C 
for 7 min. The three fractions were analysed by SDS-PAGE (section 2.8.13). 
 
2.8.3.5 Purification of insoluble His-tagged proteins 
 Two litre cultures of induced cells were harvested and resuspended in 20 ml 
PBS. The cells were sonicated ten times on ice for 30 s at 20% power output with 30 s 
incubation between each sonication. The soluble fraction was harvested by 
centrifugation at 15,000 x g for 30 min and the supernatant was harvested. The 
fractions were analysed by SDS-PAGE and coomassie staining. 
 The pellet was suspended in inclusion body wash buffer (50 mM Tris pH 8.0, 
100 mM NaCl, 0.5% Triton X-100,) and re-collected by centrifugation at 15,000 x g for 
30 min. This wash step was repeated 4 times. The pellet was washed once in inclusion 
body wash buffer lacking Triton X-100 and the pellet was resuspended in denaturing 
buffer (100 mM Tris, 6 M guanidine, 2 mM DTT) and incubated at 4 °C overnight with 
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rotation. The lysate was then harvested by centrifugation at 15,000 x g for 30 min and 
the supernatant was decanted.  
 Protein refolding was performed using rapid dilution of denatured protein into 
refold buffer (50 mM Tris pH 8.0, 1 M L-arginine monohydrochloride, 3.7 mM 
cysteamine, 6.5 mM cystamine, 1 protease inhibitor complete cocktail tablet (Roche) 
per 50 ml) drop-wise with stirring at 4 °C and left to refold overnight. The refolded 
protein was concentrated to ~ 25 ml and dialysed against His binding buffer (0.5 M 
NaCl, 20 mM Tris; pH 8.0).  
 The refolded protein was applied to an equilibrated HisTrap HP column (GE 
Healthcare) and the column was washed in His binding buffer. The bound proteins 
were eluted with a 50 mM to 500 mM imidazole gradient. Fractions were tested for the 
presence of recombinant protein by SDS-PAGE followed by coomassie blue staining or 
immunoblotting for the His tag. Fractions containing the recombinant protein were 
combined and concentrated using a Centricon YM-10 to 2 ml. This was applied to a 
Superdex 75 10/300 column (GE Healthcare) in 0.5 ml aliquots and eluted 
subsequently in PBS. Fractions were assessed for protein by SDS-PAGE, coomassie 
blue staining or immunoblotting. Fractions containing the desired recombinant protein 
were combined.  
 
2.8.4 Transient transfection of COS-7 cells 
 FuGENE 6 Transfection Reagent (Roche) was used for transfection according 
to the manufacturer‟s instruction. Briefly, cells were seeded at 30-50% confluency. 
After 16-18 h, the culture medium was replaced by pre-warmed complete medium (1 
ml per well for a 6-well plate, 20 ml for a T175 flask). For 6-well plates, 4 μl of 
liposome was added to 100 μl serum-free DMEM for 5 min, and then 1 μg plasmid 
DNA was added into the mixture. The reagents were mixed gently, incubated for 20 
min at RT and added onto cells. 
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2.8.5 Mammalian expression system and in vitro biotinylation of BAP-fusion 
proteins with BirA enzyme 
 The procedure for biotinylating BAP-fusion proteins was adopted from (Brown 
et al., 1998). COS-7 cells were transfected with the psBAPA40ΔTM or 
psBAPA40ΔTMSt plasmids as described above. After transfection and overnight 
incubation, the supernatant was replaced by serum-free DMEM. After 3 days 
incubation, the supernatant containing the secreted recombinant protein was collected, 
centrifuged for 5 min at 2000 rpm at 4 ºC and filtered to remove cell debris. The 
supernatant was then concentrated 20-fold by centrifugation using a Centriprep-10 
protein concentrator (Ambicon). The concentrated proteins were diluted with 10 mM 
Tris pH 8.0 to the original volume and again concentrated 20-fold as above.  
 The concentrated recombinant BAP fusion proteins were purified over anti-
BAP affinity column (section 2.8.1). The concentrated supernatant was loaded onto the 
column, washed with 15 ml washing buffer (25 mM Tris; 140 mM NaCl; 0.02% azide; 
pH 7.4) and bound proteins were eluted by addition of 15 ml elution buffer (100 mM 
glycine pH 2.8). The eluant was concentrated 5-fold. Enzymatic biotinylation was 
performed using 1 μg (5000 U) of BirA enzyme (Avidity) overnight at RT as 
recommended by the manufacturer. Uncoupled biotin was removed by dialysis against 
PBS. 
 
2.8.6 Concentration of proteins in the supernatant from transfected COS-7 
cells by precipitation with trichloroacetic acid 
 One ml of harvested supernatant was mixed with 0.1 ml of trichloroacetic acid 
(TCA) and the samples were vortexed and left overnight at 4 °C. Samples were 
centrifuged for 15 min at 13,000 x g at 4 °C and the supernatant was discarded. Pellets 
were washed twice in ice-cold acetone, vortexed and then centrifuged for 5 min at 
13,000 x g at 4 °C. Pellets were air-dried, re-dissolved in 100 µl 2 x SDS protein 
loading buffer (100 mM Tris-HCl pH 6.5; 4% SDS; 10% glycerol; 0.2% bromophenol 
blue; 100 mM DTT) and boiled at 95 °C for 6 min.   
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2.8.7 Treatment of transfected COS-7 with tunicamycin 
 Cells were transfected as described above (section 2.8.4) with recombinant 
plasmids psBAPA40ΔTM, psBAPA40ΔTMΔSt, psHAA40ΔTM or psHAA40ΔTMΔSt 
in 6-well plates. The day after transfection, the medium was changed and the cells were 
incubated in the presence or absence of 1 μg/ml of tunicamycin 3 days. The supernatant 
was harvested, centrifuged at 2000 rpm to remove cell debris and then concentrated by 
TCA precipitation (section 2.8.6). Pellets were resuspended in 2 x loading buffer. Cells 
were harvested in lysis buffer 1 (LB1, 50 mM Tris HCl pH 7.4; 140 mM NaCl; 1 mM 
EDTA; 1 mM EGTA; 1% [v/v] Triton X-100; mini complete Protease tablet) for 30 
min at 4 °C and then 1/6 vol of 6 x SDS protein loading buffer (300 mM Tris HCl pH 
6.5; 12% SDS; 30% glycerol; 0.6% bromophenol blue; 100 mM DTT) was added and 
the samples were boiled at 95 °C for 6 min. Cell lysate and supernatant were analysed 
by immunoblotting with anti-HA or anti-BAP mAb.  
2.8.8 Treatment of proteins with endoglycosidases PNGase F and Endo H 
Proteins were incubated with 1 x denaturing buffer at 95°C for 10 min then the 
samples were made up to 20 µl with 1 x Reaction buffer (G7 for PNGase F, G5 for 
Endo H), 1% Nonidet P40 (NP-40) and 2 µl endoglycosidase. The samples were 
incubated at 37 °C for 6 h before4 µl 6 x SDS loading buffer was added, the samples 
boiled at 95 °C for 5 min and analysed by SDS-PAGE (section 2.8.13) and Coomassie 
blue (section 2.8.14) staining and by immunoblotting (section 2.8.15). RNase B was 
used as a control protein for deglycosylation. 
 
2.8.9 Protein expression from inducible recombinant vaccinia viruses 
 Confluent monolayers of BS-C-1 cells were infected with recombinant VACVs 
at 5 p.f.u./cell in DMEM/2.5%. After 90 min incubation at 37 °C, the inoculum was 
removed and replaced with DMEM with 190 mM NaCl and 1 mM IPTG. Cells were 
incubated for 24 h at 37 °C and then the supernatant was harvested and centrifuged at 
2,000 rpm for 10 min to remove cell debris. The supernatant was concentrated to 5 ml 
(per flask) using centrifugal concentrators with a molecular cut-off of 10 kDa 
(Centriprep YM-10). Virus infectivity was destroyed by the addition of psoralen and 
treatment with long-wave UV light for 10 min. 
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 The concentrated supernatant was then dialysed against 20 mM sodium 
phosphate buffer pH 7.0 and then applied to a Resource S column that had been pre-
equilibrated with 3 column volumes of 20 mM sodium phosphate buffer. Protein was 
eluted over a gradient of 0 – 1 M NaCl in 1 ml fractions. Twenty μl aliquots of each 
fraction were analysed by SDS-PAGE (section 2.8.13) and Coomassie blue (section 
2.8.14) staining and by immunoblotting (section 2.8.15). 
 
2.8.10 Trial expression of protein from insect cells 
 A 50 ml shaking culture of Sf9 cells were seeded at 5 x 10
5
 cells/ml and 
allowed to grow at 28 °C to 2 x 10
6
 cells/ml (2 days). The culture was infected at 5 
p.f.u./cell and 5 ml samples were collected at various times thereafter. Infected cells 
were collected by centrifugation and frozen at -20 °C. When needed the cells were 
lysed in 1 ml insect lysis buffer (ILB, 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% 
Triton X-100 and protease inhibitors) on ice for 45 min with occasional vortexing. The 
lysate was centrifuged for 30 min at 3000 rpm at 4 ºC and the supernatant was 
harvested in a 1.5 ml screw-cap tube. Two hundred μl 6 x SDS protein loading buffer 
was added to the lysate and the samples were analysed by SDS-PAGE (section 2.8.13) 
and Coomassie blue (section 2.8.14) staining and by immunoblotting (section 2.8.15) 
 
2.8.11 Large scale expression of protein from insect cells 
 Four 500 ml shaking cultures were seeded with Sf9 cells in log phase at 5 × 10
5
 
cells/ml and grown at 28 °C in an orbital shaker (150 rpm) to a density of 2 × 10
6
 
cells/ml. The culture was infected with recombinant baculovirus (section 2.5) at 5 
p.f.u./cell and incubated with shaking at 150 rpm at 28ºC. Cells were harvested at the 
time of maximal expression of the target protein (as determined previously in section 
2.8.10 above). Cells were collected by centrifugation for 30 min at 3000 rpm at 4 ºC, 
the supernatant was removed and the cells were lysed in ILB (section 2.8.10) on ice for 
45 min with occasional vortexing. The lysate was centrifuged for 30 min at 3000 rpm at 
4 ºC and the supernatant was harvested for protein purification by application to a His 
column. The column was washed in HisTrap binding buffer and the protein was eluted 
with a 50 mM to 500 mM imidazole gradient. Fractions were tested for the presence of 
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recombinant protein by SDS-PAGE followed by coomassie blue staining or 
immunoblotting for the His tag. 
 
2.8.12 Measurement of protein content 
 Samples were diluted in distilled water and mixed individually with Dye 
Reagent Concentrate (Bio-Rad) according to manufacturer‟s instructions. After adding 
the dye, the absorbance was measured at 595 nm and compared to a standard curve 
using either BSA or bovine gamma globulin. 
 
2.8.13 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 Protein samples were resolved by SDS-PAGE using the Tris/glycine 
discontinuous buffer system and a vertical electrophoresis unit Mini-PROTEAN III 
apparatus (Bio-Rad). For reducing gels, the samples were denatured by heating at 95 °C 
for 5 min in 1 x Laemmli loading buffer with 10 mM β-mercaptoethanol (β-ME). The 
samples were electrophoresed into the stacking gel (125 mM Tris, pH 6.8, 5% 
acrylamide, 0.1% ammonium persulphate and 0.1% N,N,N‟,N‟-
tetramethylethylenediamine, TEMED) at 60 V and resolved by the separating gel (375 
mM Tris, pH 8.8, 10 - 15% acrylamide, 0.1% SDS, 0.1% ammonium persulphate and 
0.04% TEMED v/v) at 180 V for 45 min in protein running buffer (25 mM Tris, pH8.3, 
250 mM glycine, 0.1% SDS). After electrophoresis, the gels were processed for 
coomassie blue staining or immunoblotting.  
 
2.8.14 Coomassie blue staining 
 Polyacrylamide gels were stained in coomassie blue stain solution (10% [v/v] 
acetic acid, 45% [v/v] methanol, 0.25% [w/v] coomassie brilliant blue (BDH)) for 1 h 
at RT, and then destained in destain buffer (10% [v/v] acetic acid, 45% [v/v] methanol). 
The destain buffer was exchanged until a suitable background was obtained. The gels 
were dried between 2 sheets of pre-wet cellophane membrane (Bio-Rad) in a hot-air gel 
dryer (GelAir drying system, Bio-Rad). 
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2.8.15 Immunoblot analysis of proteins 
 Polyacrylamide gels were equilibrated for 30 to 60 min in transfer buffer (190 
mM glycine, 25mM Tris, 0.1% SDS, 20% methanol) then transferred to Hyperbond 
ECL nitrocellulose membranes (GE Healthcare) at 18 V for 30 min. After transfer, the 
membranes were rinsed once in PBS and then blocked (5% milk, PBS) for 1 h at RT. 
The primary Ab (Table 2.1) was added in blocking solution and incubated overnight at 
4 °C. The membrane was washed 3 times in 0.1% Tween/PBS for 10 min, incubated 
with secondary Ab in blocking solution for 1 h at RT, washed 3 times in 0.1% 
Tween/PBS for 10 min and exposed with ECL Plus Western blotting detection reagent 
(GE Healthcare).  
 
2.8.16 Cell binding assay using microspheres coated with recombinant 
proteins 
 In a standard binding assay, 5 µl SPHERO
TM
 Avidin - coated fluorescent 
particles (0.4-0.6 µm, 0.1% w/v, Spherotech Inc) were washed in binding buffer (10 
mM HEPES, 140 mM NaCl, 10 mM CaCl2, 10 mM MgCl2, pH 7, 1% BSA). Saturating 
amounts of biotinylated recombinant protein (50 ng/µl beads) were incubated in 100 µl 
volume on ice for 1.5 h with occasional agitation. The beads were collected by 
centrifugation at 13,000 x g for 5 min, the supernatant was removed and the beads were 
washed with 500 µl binding buffer and recentrifuged. The beads were resuspended in 
100 µl binding buffer and sonicated by a cup-horn sonicator (20% power output, 3 x 20 
s).  
 Cells (2 x 10
5
) were added to beads in a 100 µl volume in binding buffer and 
incubated for 1 h on ice with occasional agitation. Samples were transferred to 5 ml 
Falcon tubes and topped up with 500 µl binding buffer and analysed by flow cytometry 
(FC, Calibre Becton Dickinson). The binding of the fluorescent beads was analysed 
(excitation 488 and emission at 538) in channel FL1 (FITC channel) with an argon 
laser. Compensation for non-specific binding was performed using a cell only sample 
after gating on forward and side scatter profiles.  
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2.8.17 Co-immunoprecipitation of proteins using microspheres coated with 
recombinant proteins 
 SPHERO
TM
 Avidin coated fluorescent particles (25 μl, 0.4-0.6 µm, 0.1% w/v, 
Spherotech Inc) were washed in binding buffer and prepared as above (section 3.6.13). 
Cells (2 x 10
6
) were lysed in 100 µl LB1 on ice for 30 min with agitation every 10 min. 
The lysate was centrifuged for 15 min at 15,000 x g to remove cell debris and the 
supernatant was collected.  
 The clarified lysate was added to the sonicated beads overnight at 4 °C with 
rotation. The cells were washed 4 times in LB1. The mixture was centrifuged at 3,000 x 
g for 1 min, the supernatant was removed and fresh buffer was added. The samples 
were rotated for 15 min at 4 °C and then recentrifuged as above. The final bead pellet 
was resuspended in 50 µl 2 x SDS loading buffer, boiled for 5 min at 95 °C and spun 
for 30 s. Samples were analysed by SDS-PAGE and coomassie blue staining.  
 
2.8.18 Immunoprecipitation of proteins using Protein G beads 
Cells (2 x10
7
) were lysed in LB1 on ice for 30 min, agitating the mix every 10 
min by vortexing. The lysate was centrifuged for 15 min at 15, 000 x g to remove cell 
debris and the supernatant was collected. Lysates were pre-cleared against 30 μl 
Protein-G Sepharose beads for 2 h on a rotor wheel at 4 ˚C. In parallel, 40 μl Protein G 
Sepharose beads per sample were washed in LB1 and spun for 1 min at 3000 x g. The 
supernatant was removed and the beads were incubated with a dilution 1:500 anti-BAP 
Ab for 2 h at 4 ˚C with rotation. The cell lysate:bead mix was centrifuged at 10000 x g 
and the supernatants of the cell lysates were harvested as pre-cleared cell lysate. The 
bead-Ab mix was centrifuged at 3000 x g for 3 min and the pellet was resuspended in 
the pre-cleared lysate and incubated for 4 h at 4 ˚C with rotation. The bead pellet was 
harvested by centrifugation at 3000 x g for 3 min and washed in LB1 four times. The 
beads were then resuspended in 2 x SDS loading buffer, centrifuged briefly and heated 
to 95 ºC for 5 min. The beads were then centrifuged prior to analyzing the supernatants 
by SDS-PAGE and immunoblotting. 
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2.8.19 Membrane protein extraction using ProteoExtract Native Membrane 
Protein Extraction (M-PEK) kit 
 A T175 flask of TK
-
143 cells was infected with vA40HA at 5 p.f.u/cell in 
DMEM/2.5% for 1 h at 37 °C or mock-infected, after which the cells were washed 
carefully in PBS and incubated in DMEM/10% for 8 h at 37 °C. The cells were washed 
in ice-cold PBS and membrane proteins were extracted using the ProteoExtract Native 
Membrane Protein Extraction Kit (Calbiochem) following the manufacturer‟s protocol. 
Each fraction was concentrated 10 x using a Centriprep Centrifugal YM-3 Filter. Each 
of the concentrated fractions were analysed by SDS-PAGE and immunoblotting 
(sections 2.8.13 & 2.8.15).  
 
2.8.20 Immunofluorescent analysis of the cellular localisation of A40  
 Cells used for fluorescent and confocal microscopy were grown on 22-mm 
sterilised glass coverslips (borosilicate glass, BDH) in 6-well plates. For infections, 
cells were seeded ~ 80% confluency overnight and infected with 10 p.f.u./cell. At 
various time-points, the cells were chilled on ice for 5 min in preparation for staining. 
For transfection/infections using pSEL, the cells were seeded at ~ 50% onto the 
coverslips overnight. The cells were transfected as described in section 2.8.4 ,and after 
4 h the medium was changed and the cells infected with 1 p.f.u./cell. At various time-
points the cells were chilled on ice for 5 min prior to staining. 
 For surface staining, the cells were washed once in ice-cold PBS and incubated 
with primary Ab diluted in DMEM/5% on ice for 1 h. Cells were washed three times in 
ice-cold PBS and then fixed in ice-cold 4%  paraformaldehyde (PFA, diluted in 0.5 M 
HEPES pH 7.4) for 10 min on ice. The supernatant was removed and replaced with 8% 
PFA and incubated for 20 min at RT.  Cells were washed three times (in PBS at RT), 
before being quenched for 10 min with 50 mM NH4Cl at RT. The cells were washed 
three times in 5% FBS/PBS then incubated for 30 min with Alexa488-conjugated 
secondary Ab (diluted in FBS/PBS) for 30 min at RT. The coverslips were washed 
three times in PBS followed by one wash in ddH2O. Then they were mounted in 
Mowiol-4‟, 6-diamidino-2-phenylindole (DAPI) mounting medium. 
 For intracellular staining, the cells were washed three times in ice-cold PBS, 
before being fixed with 4% PFA for 10 min on ice then with 8% PFA and quenched as 
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described above. After another three washes (in PBS at RT), cells were permeabilised 
and blocked in 0.2% (w/v) saponin/ 5% FBS in PBS for 1 h. The cells were then 
incubated for 1 h at RT with primary Ab diluted in the same blocking mixture. The 
cells were washed, incubated with secondary antibody and prepared for mounting as 
described for surface staining. Samples were examined with a Zeiss LSM5 Pascal 
confocal microscope using Zeiss LSM software and images were reconstructed and 
processed using Confocal Assistant and Adobe Photoshop software.  
 
2.9 Animal work 
2.9.1 Virulence Assays in murine models 
2.9.1.1 Intradermal infection model 
 Groups of female C57Bl/6 mice, between 6 and 8 weeks old, were anaesthetised 
and inoculated with sucrose-purified VACV in 10 μl of PBS into each ear pinna 
(Tscharke et al., 2002). Mice were examined daily and the diameter of lesions at the 
inoculation site was measured using a micrometer. Titres of inocula were confirmed by 
plaque assay.  
 
2.9.1.2 Vaccination and challenge model 
 Groups of female Balb/c mice, between 6 and 8 weeks old were anaesthetised 
and inoculated with sucrose-purified VACV in 10 μl of PBS in one ear pinna as above. 
Ears were monitored over the subsequent 7 days to establish “take”. Twenty-eight days 
later, mice were anaesthetised and inoculated i.n. with a lethal dose (1x 10
7 
p.f.u) of 
VACV WR in 20 μl PBS. Mice were weighed daily before and after infection. Signs of 
illness were also scored as above. Titres of inocula on both vaccination and challenge 
days were confirmed by plaque assay. 
 
2.9.2 Extraction of cells from infected ear tissues 
 Ear lobes from infected C57Bl/6 mice were collected, rinsed in 70% ethanol 
and allowed to dry. The central and dorsal dermal sheets were separated using fine 
forceps and transferred immediately to RPMI-10 containing 1 mg/ml collagenase 
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(Sigma-Aldrich, crude type XI) and 0.004% DNase I (Sigma-Aldrich) and incubated 
for 75 min at 37 ºC. The cells were passed through 0.45 μm cell strainers and 
centrifuged at 800 x g for 5 min. Cells were resuspended in erythrocyte lysis buffer for 
3 min before RPMI-10 was added and cells were centrifuged as before. Cells were 
enumerated using a haemocytometer and trypan blue exclusion. 
 
2.9.3 Virus analysis from infected tissues. 
 The titres of virus in tissues extracted as above were determined by plaque 
assay on duplicate monolayers of BSC-1 cells. 
 
2.9.4 Analysis of infiltrating cells at the site of infection 
Live cells were counted, washed with flow assisted cell sorting (FACS) buffer 
(0.1% BSA, 0.1% NaN3 in PBS), blocked with FACS blocking buffer containing 10% 
normal rat serum, and a 1:500 anti-CD16/CD32 Fc γ receptor in FACS buffer for 30 
min at 4 ºC. Cells were stained with appropriate combinations of FITC-, phycoerythrin 
(PE)-, allophycocyanin (APC) - or tricolour (TC)-labelled antibodies (Table 2.2) in 10 
μl FACS block solution per 2 x 105 cells. These were grouped into anti-CD3, anti-CD8 
and anti-CD4 for T lymphocytes, anti-NK1.1 for NK cells, anti-TCRγδ for TCR γδ 
cells, anti-Ly6G on neutrophils and anti-F480 on macrophages. Isotype controls for 
each fluorophore were obtained from BD biosciences as described (Jacobs et al., 2006), 
as well as single stains for each Ab to allow compensation between the different 
fluorophores to be judged accurately. These solutions were incubated with the cells for 
30 min at 4 ºC in the dark. Cells were washed three times in FACS buffer. The 
presence of cell-surface markers was
 
determined on a FACSCalibur flow cytometer 
with CellQUEST software
 
(BD Biosciences). A lymphocyte gate was used to analyse 
data
 
from at least 50000 events. 
 
2.9.5 Preparation of splenocytes 
 Spleens were placed into a Petri dish and 3 ml of RPMI containing 2.5% FBS 
was added. The end of a 5 ml syringe was used to mash each spleen until all visible 
clumps of cells had dispersed. Cells were then strained through a cell strainer (Falcon) 
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into fresh 10 ml centrifuge tubes and the volume of medium in each tube was made up 
to 10 ml. Cells were centrifuged (800 x g, 8 min) and the supernatant was aspirated. 
Red blood cells were depleted by a 5 min incubation with 2 ml lysis buffer (10 mM 
KHCO3, 150 mM NH4Cl, 0.1 mM EDTA pH 8.0) followed by the addition of 8 ml 
RPMI containing 2.5% FBS and another centrifugation (800 x g, 8 min). Cells were 
resuspended in 10 ml of RPMI containing 2.5% FBS and were counted using a 
Neubauer Haemocytometer with 20% trypan blue to visualise live cells.  
 Splenocytes were separated into enriched populations for cell binding assays as 
described for PBMCs in section 2.3.8. 
 
2.9.6 Preparation of mouse resident peritoneal macrophages 
 C57Bl/6 mice (4-6 week old) were euthanized and the abdomen were sterilised 
with 70% alcohol. A 30-cc syringe was attached to 19-G needle and was filled with 
harvest medium (RPMI/SF). With the bevelled end of needle facing up, the needle was 
inserted through the peritoneal wall and 10 ml harvest medium was injected into each 
mouse. Using the same syringe and needle, the needle was inserted bevelled end down 
into peritoneum and raised slightly to cause tenting of peritoneal wall and the peritoneal 
fluid was withdrawn slowly. A single 30-cc syringe was used to inject and collect fluid 
from three mice.  
 The pooled peritoneal fluid was transferred to a 50-ml polypropylene centrifuge 
tube on ice and the enumerated using a haemocytometer and trypan blue exclusion and 
0.2 ml was differentially stained (section 2.3.6). The peritoneal lavage fluid was 
centrifuged for 10 min at 800 x g at 4 °C, the supernatant discarded and the cell pellet 
resuspended in RPMI/10%. 
 
2.9.7 Isolation of mouse bone marrow cells 
 C57Bl/6 mice (4-6 week old) were euthanized and using aseptic technique, the 
skin was peeled from the top of each hind leg and down over the foot. The foot was cut 
off with the skin and discarded. The hind legs were cut off and placed in a dish 
containing sterile PBS. Excess muscle was removed from the legs by holding end of 
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bone with forceps and using sterile scissors to push the muscle downward away from 
forceps and the leg bones were severed between the joints. 
 A 25-cc syringe was attached to a 26-G needle and filled with sterile PBS. The 
needle was inserted into the bone marrow cavity of the femur or tibia and the cavity 
was flushed with 5 ml PBS, or until bone cavity appears white. The wash medium was 
allowed to collect in a sterile 50-ml conical centrifuge tube on ice and the cells were 
either used to prepare bone marrow derived macrophages or neutrophils (see below). 
 
2.9.8 Preparation of bone marrow derived macrophages 
 The cells collected in section 2.9.7 were centrifuged for 10 min at 1600 rpm at 
RT and the supernatant was discarded. The cell pellet was resuspended in 5 ml serum-
free Eagle‟s MEM (EMEM). Lymphocyte separation medium (5ml) was placed in a 
15-ml conical tube and overlaid with 5 ml of the bone marrow suspension. The 
separation medium was centrifuged for 20 min at 500 x g at RT with the brake off. The 
cells were gently removed at the interface with a Pasteur pipette by placing the pipette 
tip at the interface and slowly moving it over the interface while slowly drawing cells 
into the pipette. The cells were pooled and centrifuged for 10 min at 500 x g at 4 °C, 
resuspended in 10 ml EMEM/10 % FCS (EMEM/10) and cell numbers were counted. 
The remaining cells were centrifuged again for 10 min at 500 x g at 4 °C and 
resuspended in EMEM/10 to a final concentration of 5 × 10
6
 cells/ml. Cells were 
aliquoted at ~ 1–3 × 107 cells per 25-cm2 tissue culture flasks containing 10 ml 
EMEM/10 and IL-2 at 10 ng/ml and cells were incubated for 24 h at 37 °C. The non-
adherent cells were then transferred to a 75-cm
2
 tissue culture flask and 10 ml 
EMEM/10/IL-3 was added. The cells were incubated for a further 4 days after which a 
further 10 ml EMEM/10/IL-3 was added and the cells were incubated for another 3 
days. 
 The mature macrophages were then harvested by removing and discarding the 
culture supernatant. The remaining adherent cells were washed with 15 ml PBS. The 
PBS wash was discarded and 5 ml PBS/EDTA was added to the flask and incubated for 
5 min at 37 °C. The cells were loosened by banging the side of flask and EMEM/10 
was added to the flask and the detached cells were collected by centrifuging the cells 
for 10 min at 500 x g at 4 °C. The cells were resuspended in 5 ml of EMEM/10 and 
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using a haemocytometer and trypan blue exclusion and 2 x 10
4
 cells were taken for 
differential staining (section 2.3.6). 
 
2.9.9 Preparation of mouse bone marrow derived neutrophils 
 The cells collected in Section 2.9.7 were resuspend and cell clumps were 
disaggregated with a 19G needle and the cells collected by centrifugation at 112 x g for 
6 min at RT. The cell pellet was resuspended in 2 ml of DMEM/SF.  
 A Percoll gradient was made fresh each time using isotonic Percoll by adding 
one part 10 x PBS to nine parts Percoll. Percoll solutions of three different Percoll 
concentrations (52%, 64% and 72% [v/v] Percoll in PBS) were made and 2 ml of each 
concentration was added to a 15 ml centrifuge tube, starting with 72% on the bottom, 
then 64% and finally 52%. The 2 ml cell solution was layered onto the Percoll gradient 
and centrifuged for 30 min at 1060 x g at RT with the brakes off. The mature 
neutrophils were collected from between the 64% and the 72% layer using a Pasteur 
pipette and were washed twice in DMEM. Cells were enumerated using a 
haemocytometer and trypan blue exclusion and the purity was checked with differential 
staining (section 2.3.6). 
 
2.9.10 Cytotoxicity assay 
2.9.10.1 NK cytotoxicity assays using NK cells extracted from infected 
ears 
 Yac-1 target cells were centrifuged and resuspended at 10
6
 cells/ml. Cells were 
labelled with Na2
51
CrO4 (2 MBq in 1 x10
6
 cells) for 1 h at 37 °C and agitated every 15 
min. After labelling, cells were washed three times in RPMI/10 and resuspended at 1 x 
10
5
cells/ml. Labelled target cells were then aliquoted into the wells of v-bottomed 96-
well microtitre plates. The proportion of NK cells was assessed by flow cytometry so 
that the ratio of NK cells to labelled targets was standardised in each sample. In a 
separate plate, 100 µl doubling dilutions of effector cells were made, starting at a 
concentration of 10
6
 cells per well [to give a final effector:target (E:T) ratio of 100:1]. 
Samples were diluted in triplicate and then transferred into the corresponding wells of 
the plate containing the target cells (final volume of 200 µl). Minimum lysis was 
 120 
determined by incubating labelled targets in medium alone. For maximal lysis, an 
aliquot of each target population was incubated with RPMI containing 1% Triton X-
100. The plates were centrifuged at 1390 r.p.m. for 1 min and incubated at 37 °C. After 
4 h, plates were re-centrifuged and 50 µl supernatant from each well was transferred to 
the corresponding region on a Lumaplate-96 (Packard Instrument Company, Inc.) and 
counted. The percentage of specific 
51
Cr release was calculated as specific lysis = 
[(experimental release - spontaneous release)/(total detergent release – spontaneous 
release)] x100. The spontaneous-release values were always <5% of total lysis.  
 Statistical analysis. Student‟s t-test (two-tailed) was used to test the significance 
of the results (P<0.05). 
 
2.9.10.2 CTL cytotoxicity assay using CTL cells extracted from infected 
ears 
 EL-4 target cells were mock-infected or were infected with VACV WR at 10 
p.f.u./cell for 1 h at 37 ºC in 250 µl RPMI in the presence of Na2
51
CrO4. These cells 
were washed twice and counted. Serial dilutions of effector cells were incubated in 
duplicate cultures with either mock-infected or VACV-infected target cells in 96-well 
v-bottomed plates and incubated as described above for NK cytotoxicity assays. 
 
2.9.10.3 NK cytotoxicity assay using NK92MI cell line 
 Human NK92MI cells were mock-infected or infected at 1 p.f.u./cell for 16 h 
before labelling with 
51
Cr (section 2.9.10.1) and incubation with K562 targets cells 
mock-infected or infected at 1 p.f.u./ml for 16 h as described above. vTAPA40 
induction was performed in DMEM/10 with 2 mM IPTG and 190 mM NaCl.  
 
2.10 Production and purification of anti-A40 serum 
2.10.1 Production of rabbit anti-A40 polyclonal serum 
 Affinity-purified recombinant A40 protein was sent to Harlan Sera-Lab 
(Leicestershire, England) to generate a polyclonal rabbit serum. Pre-bleed serum 
samples were taken from two rabbits prior to immunisation and their serum was tested 
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for reactivity against VACV-infected cell lysates. Purified protein (100–200 µg with an 
estimated purity of 90%)
 was injected into New Zealand White rabbits with Freund‟s 
complete adjuvant full adjuvant to produce anti-A40
 
serum. Boosters of protein with 
Freund‟s incomplete adjuvant were injected at 14, 28, 42, 56 and 70 days after the 
primary immunisation. Test-bleeds were taken in 10 ml aliquots at 35, 49 and 63 days 
after the primary immunisation, and the terminal bleeds were taken 77 days after the 
initial immunisation. 
 
2.10.2 Purification of antiserum by pre-absorption on infected cells 
 To remove some of the non-specific binding of the antibody, the α-A40 (171) 
polyclonal antiserum was absorbed on RK13 cells that had been infected for 12 h with 5 
p.f.u/cell of vΔA40. Five T175 cm2 flasks of infected cells were scraped into the 
medium and collected by centrifugation at 2,000 rpm for 5 min at 4 °C. The cells were 
washed three times in ice-cold PBS and centrifuged between each wash. The washed 
cells were resuspended in 1ml PBS and were fixed by the addition of 1 ml 8% PFA and 
incubated on ice for 10 min. The fixed cells were recovered by centrifugation at 2000 
rpm for 5 min at 4 °C, the supernatant was removed and the cell pellet was resuspended 
in 2 ml 8% PFA and incubated on ice for 50 min. The fixed cells were washed twice in 
100 mM glycine in PBS followed by centrifugation at 2000 rpm for 5 min at 4 °C. The 
washed cells were permeabilised in 5ml 0.1% Triton X-100 in PBS for 5 min at RT. 
The permeabilised cells were resuspended in PBS and collected by centrifugation at 
2000 rpm for 5 min at 4 °C. These permeabilised cells were then blocked with 10% 
FBS in PBS for 1 h at RT. The FBS was removed from the cells by centrifugation for 5 
min at 2000 rpm at 4 °C. The pelleted cell material was resuspended in 2 ml α-A40 
antiserum and incubated at 4 °C for 12-14 h with rotation. Cells were removed by 
centrifugation at 15,000 rpm for 15 min at 4 °C (Heraeus Biofuge 15R). The 
supernatant was transferred to a fresh tube, sodium azide was added to a final 
concentration of 0.02% (w/v) to inhibit microbial growth and the pre-absorbed 
antiserum was aliquoted and stored at -20 °C. 
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2.10.3 Purification of IgG from antiserum 
 The IgG fraction of the antiserum was purified in an attempt to improve 
specificity and sensitivity of the antibody. The pre-absorbed α-A40 (171) antibody 
(section 2.10.2) was purified on a 1 ml Protein A Sepharose HiTrap affinity column 
(GE Healthcare) that was connected to an AKTApurifier 900 (GE Healthcare) for 
automated use. The column was equilibrated with 10 column volumes (CV) of 20 mM 
sodium phosphate buffer pH 7.0. The pre-absorbed α-A40 antibody was diluted 1:1 in 
20 mM sodium phosphate buffer and gradually introduced onto the column using a 
syringe fitted to the luer adaptor. The column was washed with 10 CV of 20 mM 
sodium phosphate pH 7.0 to remove unbound material and the bound IgG was eluted 
with 100 mM citric acid pH 3.0 in 1ml fractions into tubes containing 100 μl 1.5M 
Tris-HCl pH 8.8 to neutralise the acidity of the elution buffer and to preserve the 
activity of the acid-labile IgG. The IgG elution profile was monitored electronically by 
measuring absorbance at 280 nm and the fractions were assessed for IgG content by 
SDS-PAGE and coomassie staining. The IgG containing fractions were pooled, 
concentrated by using a Centriprep-10 protein concentrator (Ambicon) and dialysed 
against Ab buffer (10 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% sodium azide) using 
„Slide-A-Lyser‟ dialysis cassettes (Pierce) according to the manufacturer‟s instructions. 
This preparation of antibody is referred to as α-A40 IgG. 
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Chapter 3. Characterisation of the A40 protein from the VACV 
strain WR  
3.1 Introduction 
 Two laboratories have characterised the A40 protein previously (Duncan, 1992; 
Wilcock et al., 1999; Tscharke et al., 2002; Palacios et al., 2005) but these two groups 
have generated conflicting data. This project began by re-assessing the basic properties 
of the A40 protein from VACV WR and then sought to understand the function of A40 
by investigating its contribution in vivo and by seeking to identify its binding partners.  
 
3.2 Previous characterisation 
3.2.1 VACV WR A40 characterisation by the Smith lab 
 The VACV strain WR A40R open reading frame (ORF) (YP_233047.1) is 480 
bp long and is located in the right-hand region of the VACV genome (Smith et al., 
1991). Computational analysis predicted that A40R encodes an 18,152 Dalton protein 
of 159 aa with a pI of 8.4. The protein was predicted to have a type II membrane 
topology with a hydrophobic N terminus, which may act as a TM signal and anchor 
sequence. The TM domain is followed by a short alpha-helical region and finally a C-
type lectin-like domain (Duncan, 1992; Duncan & Smith, 1992) that would be exposed 
on the outside of the cell or the lumen of an intracellular vesicle. Three potential sites 
for N-linked glycosylation and three for O-linked glycosylation were identified. 
 An experimental characterisation of the A40 protein was undertaken by 
Wilcock et al. (1999). A rabbit polyclonal Ab (anti-A40R1) was raised against A40 aa 
77-159 (corresponding to most of the C-type lectin-like domain) that had been 
expressed in E. coli. This Ab was used to identify the A40R gene products in infected 
cells (by immunoblotting) as four proteins (18, 28, 35 and 38 kDa) that were present in 
lysates from VACV-infected cells but were absent from cells infected by a deletion 
mutant lacking the A40R gene (Wilcock et al., 1999).In the presence of tunicamycin, an 
inhibitor of N glycosylation, only the 18-kDa protein was found indicating that A40 
contains N-linked carbohydrate. Furthermore, in cell lysates prepared without β-
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mercaptoethanol, one additional band at 70-76 kDa was identified and it was suggested 
that this might represent homodimers of the glycosylated A40.  
Analysis of transcriptional regulatory signals indicated that A40 is expressed 
early in infection, with the presence of the sequence (ACA3TGA7T) at the 5‟ end of the 
ORF, which closely resembles the early promoter consensus (A5TGA8) but no late 
transcriptional initiation consensus at its 5‟ end. Northern blotting and S1 nuclease 
protection analysis of RNA extracted from VACV-infected cells revealed an early 
transcript of ~ 600 nucleotides and an early initiation site 12 bases upstream of the ORF 
but no late initiation site was identified (Wilcock et al., 1999). Analysis of proteins 
made at different times during infection and in the presence of the inhibitor of DNA 
replication, cytosine arabinoside (AraC), when only early genes are able to be 
transcribed, indicated that the A40 proteins were made early during infection, 
consistent with the promoter region of the A40R gene. The isolation of the virus 
deletion mutant (vΔA40) showed that the A40R gene was non-essential for virus 
replication, which is consistent with the ORF not being conserved in all OPVs and its 
loss did not affect either virus plaque size or replication kinetics (Wilcock et al., 1999). 
The A40 protein, was not incorporated into virions, unlike the A34 C-type lectin-like 
protein that is in the EEV outer membrane (Duncan & Smith, 1992).  
 Wilcock et al. (1999) also reported that the A40 protein partitioned to the 
membrane fraction when infected cells were treated with Triton X-114. In vitro 
transcription analysis of the A40R gene and translation of the mRNA in vitro in the 
presence or absence of micosomes, confirmed that the A40 protein was glycosylated 
and that it was membrane associated with its lectin-like domain present within the 
lumen of the vesicle (type II membrane topology).  
 Bioinformatic analysis showed that the highest FASTA score (198) with a non-
poxvirus protein was against the human natural killer cell G2-A protein (accession no. 
P26715). The predicted CRD domain of A40 contains 5/14 invariant and 17/32 
conserved residues of the CRD consensus sequence (Duncan & Smith, 1992; Wilcock 
et al., 1999). However, it lacks one of the cysteine residues predicted to form 
intradomain disulphide bonds and residues equivalent to loop 2 and β sheet 5. Some C-
type lectins lacking several conserved residues and containing a deletion in the loop 
regions still may bind carbohydrate.  
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 An investigation into the virulence of the virus deletion mutant compared to 
WT and Rev controls showed that the deletion mutant remained virulent in an 
intranasal infection model (Wilcock et al., 1999), whilst a subsequent study showed 
that in an intradermal model the deletion mutant induced smaller lesions that were 
cleared faster compared to the control viruses (Tscharke et al., 2002). 
 
3.2.2 Opposing data by Palacios et al. 
 In contrast to the conclusions of Wilcox et al., (1999), Palacios et al., (2005) 
reported that A40 was modified by sumoylation  rather than glycosylation and was an 
intracellular protein that was not associated with membranes (Palacios et al., 2005). To 
reach these conclusions, they raised a peptide antibody against 71 -86 aa of the A40 
protein which they tested against cells infected with VACV strain WR. They did not 
use a deletion mutant to control for the specificity of the serum and indeed suggested 
that the A40R gene was essential because they had been unable to isolate a deletion 
mutant. This suggestion ignored the facts i) a well characterised deletion mutant had 
already been reported and ii) some other orthopoxviruses, such as VARV have the 
A40R ORF disrupted into small fragments by mutation (Aguado et al., 1992).  
 A number of proteins, mainly located in the nucleus, are sumoylated (Yeh et al., 
2000; Muller et al., 2001; Seeler & Dejean, 2003). Sumoylation is a pathway similar to 
ubiquitination that modifies proteins reversibly and post-translationally and can alter a 
protein‟s intracellular location, activity, stability and interactions. Palacios et al., (2005) 
proposed that sumoylation of A40 prevented it forming polymers and a small amount 
of unsumoylated A40 could aid bringing ER membranes together before they fuse to 
generate an ER-derived envelope that is proposed to surround the virus factory (Sodeik 
& Krijnse-Locker, 2002).  
 The differences between the conclusions of Palacios et al., (2005) and those 
reported by Wilcock et al., (1999) were proposed by Palacios et al., (2005) to be due to 
a lack of specificity of the Ab used by Wilcock et al. However, controls had been 
provided and the Ab reacted with proteins in cells infected with WT and Rev viruses 
but not a virus mutant lacking the A40R gene (Wilcock et al., 1999). In comparison, 
Palacios et al., 2005 did not show controls for the specificity of the peptide Ab. 
Palacios et al., also claimed that the A40 protein was not glycosylated, but showed no 
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data supporting this claim. If the peptide Ab used by Palacios et al., is binding A40, the 
presence of A40 in the ER may reflect its normal transport through the host cell‟s 
secretory pathway. 
 
(A) 
 
 
(B) 
 
(C) 
 
Fig. 3.1. VACV strain WR A40 protein.  
(Accession no. YP_233047.1) The predicted transmembrane region (TM), the stalk (St) region and the 
carbohydrate recognition domain (CRD) is in red, green and purple, respectively. (A) Amino acid 
sequence of A40 protein. Conserved CRD amino acids are underlined. Predicted N-glycosylation sites 
are in blue and underlined. (B) Kyte & Doolittle hydropathy plot of A40. (C) Schematic of A40‟s 
predicted structure. 
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Fig. 3.2 Amino acid alignment of VACV WR A40 and comparable proteins in other OPVs 
Proteins, identified using BLASTP and the PBR centre, were aligned using GeneDoc. When several strains have identical sequences, only one name is listed in the alignment 
and the remaining proteins in this group are listed below. VACV-WR (VACV WR protein A40, YP-233047), VACV-Lister (VACV strain Lister protein 211, 
VBRC_gene_id 46242), CXPV-GER (cowpox virus strain Germany 91-3 protein C-type lectin-like type-II membrane protein, ABD97512), VACV_ CXPV_BR (cowpox 
virus strain Brighton Red protein 177,NP_851590), CXPV_GRI-90 (cowpox virus strain GRI-90 protein A42, CAD90709), HSPV_MNR-76 (horsepox virus strain MNR-76 
protein 162, ABH08271), VACV_MVA (VACV strain modified vaccinia virus Ankara protein 152, AAB96533), VACV_Copenhagen (VACV strain Copenhagen protein 
A40, AAA48171), VACV_Acam2000 (VACV strain Acambis 2000 protein 176, AAR18008), VACV_3737 (VACV strain 3737 protein 159, ABD57694), 
VARV_Garcia(Variola minor virus strain Garcia-1966 protein A48), VARV_India (Variola virus strain India 1967 protein A42). 1) Proteins with identical sequences to 
VACV-Lister. VACV-CVA (VACV strain CVA protein 173, CAM58337), VACV-TianTan (VACV Tian Tan protein 51R, AA089444), RXPV_Utrecht (rabbitpox virus 
strain Utrecht protein 148, AAS49861), VACV_LC16m8 (VACV strain LC16m8 protein m8221, AAW23600), VACV_LC16m0 (VACV strain LC16m0 protein m0221, 
AAW23882), VACV_Lister (VACV Strain Lister 107 protein 157, ABD52656). 2) Proteins with identical sequences to VACV-MVA. VACV_MVAI721 (VACV strain 
MVA I721 protein 154, VBRC_genome), (VACV strain Acambis 3000 Modified Virus Ankara protein 154, AAT10550). 3) Proteins with identical sequences to VACV-
3737. VACV_Acambis 3 (VACV strain Acambis 3 protein 176, AAQ93262), VACV_Duke (VACV strain Duke protein 173, ABD98635). Shading shows conserved amino 
acid identities. Black = 100 %, dark grey = 80 %, light grey = 60 % of aligned sequences have the same amino acid at that position. Consensus sequence shown below 
aligned sequences. 
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Table 3.1 Amino acid identity of proteins compared to VACV WR A40 
Protein Organism 
% amino acid 
ID (1-159) 
% ID to CRD 
(40 – 159) 
Accession 
Number 
Non-viral proteins: 
Clr-b 
Rattus  
norvegicus 
21 24 Q0H8B9 
CD94 Homo sapiens 20 22 AAH28009 
NKG2-C Homo sapiens 18 18 NP_002251 
KLRG1 Homo sapiens 17 19 AAH12621 
NKG2-A Homo sapiens 17 28 NP_998823 
NKG2-B Homo sapiens 16 27 NP_998822 
NKG2-D Homo sapiens 16 22 AAH39836 
NKG2-H Homo sapiens 16 21 AAD46108 
NKG2-A Saimiri sciureus 13 26 ABW03002 
NKG2-E Homo sapiens 12 20 NP_002252 
KLRG1 
Rattus 
norvegicus 
11 6 NP_113837 
KLRG1 Mus musculus 10 12 NP_058666 
L-SIGN Homo sapiens 10 21 NP_999841 
DC-SIGN Mus musculus 10 13 AAL13234 
DC-SIGN Homo sapiens 9 19 AAK20997 
L-SIGN Mus musculus 8 16 NP_081248 
CD23 Homo sapiens 8 17 AAH62591 
Viral proteins: 
RCMV RCTL 
Rat 
cytomegalovirus 
25 28 AAG40235 
VACV  
WR A34 
Vaccinia virus 
strain WR 
19 13 YP_233039 
DpV83 
Mule deer (DPV) 
poxvirus  
W-848-83 
11 15 YP_227519 
fp9.008 
Fowlpox virus 
(FWPV) strain 
HP1-438 Munich 
10 13 CAE52554 
FPV253 
FWPV strain 
Iowa 
10 13 NP_039216 
FPV008 
FWPV strain 
Iowa 
10 13 NP_038971 
fp9.003 
FWPV strain 
HP1-438 Munich 
9 12 CAE52549 
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Fig. 3.3 Amino acid alignment of CRD domain of A40 with distal poxvirus proteins and non-viral proteins  
Residues 56-159 of VACV WR A40 were aligned with related proteins from other poxviruses and non-viral proteins (identified by BLASTP). The alignment was generated 
using GeneDoc. VACVWRA40 (VACV strain WR protein A40), VACVWRA34 (VACV strain WR protein A34, YP_233039), Clr-b (Rat Clr-b, Q0H8B9), RCTL (RCMV 
RCTL protein, AAG40235), CD94 (human protein CD94, AAH28009) NKG2A (human protein NKG2-A, NP_998823), KLRG1 (human protein KLRG1, AAH12621), 
LSIGN (human protein L-SIGN (CD209L), NP_999841), DCSIGN (human protein DC-SIGN (CD209), AAK20997), CD23 (human protein CD23, AAH62591), DpV83 
(Mule deer poxvirus strain W-848-83 protein 144, YP_227519), fp9008 (FWPV strain HP1-438 protein 008, CAE52554), fp9003 (FWPV strain HP1-438 protein 003, 
CAE52549). Shading shows conserved amino acid identities. Black = 100%, grey = 60% conserved. The consensus sequence is shown below aligned sequences. 
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3.3 Bioinformatic analysis of VACV WR A40 
3.3.1 Amino acid sequence alignment with VACV WR A40 compared to: 
3.3.1.1 Other orthopoxvirus proteins 
 Proteins from cells and poxviruses that are related to A40 (YP_233047.1) were 
found by a comparison of the A40 aa sequence (Fig. 3.1 A) with the European 
Molecular Biology Laboratory (EMBL) database using BLASTP 2.2.19+ (Altschul et 
al., 1997) and the Poxvirus bioinformatics resource (PBR) centre (www.poxvirus.org) 
(Fig. 3.2 and Fig. 3.3). 
 The full-length A40 protein is found in 2 out of the 7 species of orthopoxviruses 
(VACV and CPXV) and is conserved in many VACV strains including CVA, Tian Tan 
(TA51R), Lister (Lister 221) and its derivative LC16m8 (211R) (Morikawa & Ueda, 
1993), and RPXV Utrecht (RPXV148). In other VACV strains there are three different 
types of modification to the sequence of the A40 protein; i) single aa substitutions, ii) 
internal changes in length and iii) C-terminal frameshift mutations near the C-terminus. 
 Horsepox virus (HSPV) strain MNR-76 protein 162 (HSPV162) (Tulman et al., 
2006) and CXPV strain GRI-90 protein A42 both share 94.5% identity to WR A40 but 
have an insertion of 6 aa at position 145, and 4 independent substitutions each. 
However, they each contain the same C-terminal residues as A40 WR. CXPV strain 
Brighton Red protein 177 (CPXV177) has 8 aa changes compared with A40 WR 
including a single insertion at residue 41, but overall keeps the same C-terminal 
sequence as WR. 
 In VACV strain Copenhagen, a frameshift mutation replaced the C-terminal 22 
residues present in other VACV strains with 31 unrelated residues. VACV strains 
Acambis 2000 (protein 176), 3737 (protein 159), Duke (protein 173) and Acambis 3 
(protein 176) have the Copenhagen C terminal modification except for one aa 
substitution compared to Copenhagen, as well as 4 independent aa substitutions relative 
to WR. VACV MVA protein 152 and VACV strain MVA I721 protein 154 are 
identical to A40 WR from aa residue 1 to 154, but the last five residues are replaced 
with 14 unrelated residues (Fig. 3.2). 
 The VACV International Health Department (IHD)-J strain does not express 
A40 (Duncan & Smith, 1992; Wilcock et al., 1999) and in all sequenced VARV strains, 
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such as Harvey 1947, India 1967 and Bangladesh 1975 the gene is disrupted. This is in 
contrast to VACV protein A34, another a C-type lectin-like protein, which is highly 
conserved between the viruses listed above, and is incorporated into the EEV (Duncan 
& Smith, 1992). This alignment suggests that the WR strain sequence is the 
predominant sequence and this was why the WR strain sequence was chosen to be 
studied.  
 The A34 protein from VACV WR has 19% aa identity to A40. A40 and A34 
have the same type II membrane topology with a C-type lectin-like domain in the C-
terminal region.  
 
3.3.1.2 FWPV genes 
When A40 was compared to proteins from other chordopoxviruses such as 
avipoxviruses, several proteins are found in both fowlpox virus (FWPV) strains Iowa 
and Munich. For instance, FPV253 and FPV008, from FWPV Munich have 10% 
identity to A40 over the whole protein, rising to 13% if only the CRD is compared 
(Table 3.1 and Fig. 3.3).  
 
3.3.1.3 RMCV RCTL 
 The RCMV RCTL protein has previously been aligned with VACV A40 Cop 
(Voigt et al., 2001). When aligned to VACV A40 WR, there is 26% aa identity and 
38% aa similarity along the whole of the proteins. When only the CRD domain is 
considered, RCMV RCTL and VACV A40 WR share 28% aa identity (Table 3.1 and 
Fig. 3.3). 
 
3.3.1.4 Non-viral proteins 
 While OPV A40 proteins are very closely related, non-viral protein matches are 
very distant (~ 20% aa identity) and are various C-type lectin-like proteins. The closest 
match along the whole protein is with the rat Clr-b protein then human CD94 protein 
(Fig. 3.3 and Table 3.1), and the highest identity within the CRD domain (aa 40 – 159) 
are with the rat Clr-b, the NKG2 proteins, CD94 and murine and human DC SIGN. Clr-
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b is a ligand of the NKR-P1B inhibitory receptor. CD94 is expressed as disulphide-
linked heterodimer with members of NKG2 family, including NKG2A, which 
transduces inhibitory signals and NKG2C which transduces activatory signals. The 
extracellular portion of CD94 has been shown by X-ray crystallography to have a 
unique variation on the classical C-type lectin fold. The CRD is altered significantly 
and the calcium binding site appears non-functional (Borrego et al., 2002). 
 
3.3.2 A40 is a glycoprotein with type II membrane topology 
 In agreement with previous bioinformatic analysis of A40R, the WR 165 ORF 
of 480 bp is predicted to encode a type II membrane protein 
(https://www.expasy.ch/tools). A hydrophobicity plot predicts that A40 is likely to be a 
membrane-integrated protein and has no putative cleavage sites 
(http://www.cbs.dtu.dk/services/SignalP/). A short seven aa tail at the N terminus 
resides in the cytoplasm, followed by ~ twenty hydrophobic residues comprising a 
transmembrane spanning region (8 – 29, coloured red, Fig. 3.1C). Adjacent to this 
region ~ twenty residues (30-55, green, Fig. 3.1C) are predicted to form an alpha 
helical region designated the „stalk‟. Residues 56 – 159 are predicted to encode a 
carbohydrate recognition domain (CRD) or C-type lectin-like domain (CLECT). 
Within this CRD there are three predicted N-linked glycosylation sites (aa 121-123, 
132-134 & 136-138, http://www.cbs.dtu.dk/services/NetNGlyc/). 
 Several motif prediction programmes (http://ca.expasy.org/tools/) did not 
predict any likely conserved motifs such as phosphorylation sites within the small 
cytoplasmic tail that would point to a way in which A40 could function.  
 The analysis of A40 protein sequence by several secondary structure prediction 
programmes (Protein Homology/analogY Recognition Engine (PHYRE), a profile – 
profile matching algorithm, Fugue, an aa-dependent algorithm and GenTHREADER, a 
protein fold recognition program) suggested A40 may have a similar tertiary structure, 
within the CRD, to a snake coagglutinin beta chain from the Habu snake (Trimeresurus 
flavoviridis), part of the heterodimeric coagulation factors IX/X-binding protein (IX/X-
BP) (Mizuno et al., 1997) and CD69 (Natarajan et al., 2000). Although the aa sequence 
showed a low percentage identity (14%) it is possible that there is reasonable structural 
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similarity. The newly resolved X-ray crystal structures of such CRD domains could 
provide a basis to model A40 upon. 
 
3.4 Expression of A40 in VACV-infected cells 
 Although the data provided by Wilcock et al., 1999 are more convincing than 
those from Palacios et al., 2005, at the outset of this thesis it was important to confirm 
the properties and location of the protein before designing and undertaking an 
experimental strategy to seek A40 binding partners and understand the mechanism of 
action. To do this, I started by preparing a new and improved anti-A40 polyclonal 
antiserum, as the one described by Wilcock et al., (1999) did not work well in 
immunofluorescence. The new Ab was raised against aa 30 – 159 of WR A40 
expressed in E. coli (section 5.3. & 2.10). This was used in immunoblot analysis to 
determine when the protein is expressed, its size, localisation and expression in a range 
of OPVs. 
 
3.4.1 VACV WR A40 is expressed early in infected cells 
 To investigate the time of expression of A40, BS-C-1 cells were infected with a 
WT VACV strain WR called vWt (Wilcock et al., 1999) in the presence or absence of 
cytosine arabinoside (AraC), an inhibitor of DNA replication and therefore 
intermediate and late protein expression. Infected cells were harvested at various times 
p.i. and cell lysates were immunoblotted with anti-A40 Ab. The cell lysates were also 
blotted for a late VACV protein, D8, to confirm that these infections and time-points 
are characteristic of published analysis (Fig. 3.4 A). A40 was detected 2 h after 
infection, increased up to 8 h, and was still present at 24 h. Multiple bands ranging 
from ~25 – 50 kDa were detected at all time-points from virus infected cells and absent 
from mock infected cells. In the presence of AraC, A40 was still produced, supporting 
the previous conclusion that A40 is an early protein. In contrast, D8 was detected only 
after 6 h, increasing at 8 h and is still present at 24 h. In the presence of AraC, no D8 
protein is detected, showing that the inhibition of late protein expression was complete. 
This agrees with expression data from Wilcock et al., (1999) and also kinetic analysis 
for the temporal transcription profile of VACV WR published by Assarsson et al., 
(2008).  
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(B) 
(i) (ii) 
 
(C) 
 
Fig. 3.4 Characterisation of A40 in VACV-infected cells  
(A)Time course of A40 expression. BS-C-1 cells were infected with WT at 5 p.f.u./cell in the presence or 
absence of 1 μg/ml AraC. Cells were harvested at 0, 2, 4,6, 8, 12 and 24 h p.i and expression of A40 was 
analysed in lysates by SDS-PAGE (15% gel) followed by immunoblotting with the α-A40 Ab, 171 or 
D8. (B) Post-translational modification of A40 (i) BS-C-1 cells were infected with vA40HA or vB14HA 
(Chen et al., 2006) at 1 p.f.u./cell for 24 h in the presence/absence of tunicamycin (1 μg/ml). Cells were 
lysed and lysates were analysed by SDS-PAGE (15% gel) followed by immunoblotting with the HA 
mAb. (ii) BSC-1 cells were infected with WT at 5 p.f.u./ml for 24 h. Cells were lysed and lysates were 
treated with/out the endoglycosidase PNGase F for 16 h at 37 °C then analysed by SDS-PAGE (15% gel) 
followed by immunoblotting with the Ab 171. (C) Oligomerisation of A40. BS-C-1 cells were infected 
with WT at 5 p.f.u/cell for 24 h. Cells were lysed and lysates were resuspended in 2x Laemmli buffer 
with or without β-mercaptoethanol then analysed SDS-PAGE (15% gel) followed by immunoblotting 
with the Ab 171. Bound antibodies were detected with HRP-conjugated goat anti-rabbit IgG antibody 
(Sigma-Aldrich) (A40 171) or HRP-conjugated goat anti-mouse IgG antibody (Sigma-Aldrich) (D8 or 
HA) both diluted 1:2000 and ECL reagents (Amersham). Positions of molecular mass markers are shown 
on the left with sizes in kDa. 
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Fig. 3.5 Localisation of A40HA within VACV-infected cells 
(A) TK
-
143 cells were infected at 1 p.f.u/cell for 18 h. Proteins were extracted using the M-PEK kit 
(Pierce) and were analysed by SDS-PAGE and immunoblotted for (i) HA & (ii) B5 (mAb 19C2) and K7. 
M and S represent membrane; and soluble fractions respectively. Bound antibodies were detected with 
HRP-conjugated goat anti-rabbit IgG antibody (Sigma-Aldrich) (A40), HRP-conjugated goat anti-mouse 
IgG antibody (Sigma-Aldrich) (B5) or HRP-conjugated goat anti-rat IgG antibody (Sigma-Aldrich) 
diluted 1:2000 and ECL reagents (Amersham). Positions of molecular mass markers are shown on the 
left with sizes in kDa. (B) BS-C-1 cells were transfected with either pSEL (mock), pSEL(N)BAPA40 or 
pSEL(C)A40BAP (Section 5.4.4) and incubated overnight. Cells were then infected with vDelA40 at 1 
p.f.u./cell for 6 h. For surface staining, cells were incubated with an anti-BAP Ab at a 1:400 dilution for 
1 h on ice. The cell were then fixed and incubated with an anti-mouse Alexa488-conjugated secondary 
Ab. For internal staining, the cells were fixed in PFA, permeabilised in saponin (0.2 % w/v) for 1 h and 
then incubated with an anti-BAP Ab followed by an anti-mouse Alexa488-conjugated secondary Ab.  
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3.4.2 VACV WR A40 is post-translationally modified by glycosylation  
 BS-C-1 cells were infected with vA40HA (with or without tunicamycin and cell 
extracts were analysed by immunoblotting (Fig. 3.4Bi). In the absence of tunicamycin, 
several proteins were detected ranging from ~24 to ~ 40 kDa corresponding with data 
from (Wilcock et al., 1999). Furthermore, in the presence of tunicamycin, these 
proteins were replaced by a single protein of ~18 kDa confirming the higher molecular 
weight forms are glycosylated. VACV B14 was used as a control. B14 is a 15 kDa 
protein that is not N-glycosylated and therefore, no shift in mobility is seen.  
 As an alternative method to demonstrate that A40 is glycosylated, VACV WR 
cell lysates were treated with endoglycosidases. Peptide: N-Glycosidase F ((PNGase 
F), cleaves between the innermost N-Acetylglucosamine (GlcNAc) and asparagine 
residues of high mannose, hybrid, and complex oligosaccharides from N-linked 
glycoproteins). Endoglycosidase H ((Endo H) cleaves within the chitobiose core of 
high mannose and some hybrid oligosaccharides from N-linked glycoproteins). These 
lysates were then analysed by immunoblotting (Fig. 3.4Bii). In the absence of PNGase 
F treatment, several protein bands were detected ranging from ~ 25 to ~38 kDa, again 
corresponding to data from Wilcock et al. With PNGase F treatment, these bands are 
replaced by a single band ~ 18 kDa.  
 These BS-C-1 cell lysates were also used to determine if A40 forms oligomers. 
The lysates were dissolved in Laemmli buffer in the presence or absence of β-ME and 
then immunoblotted with the α-A40 Ab (Fig. 3.4C). In the absence of β-ME several 
higher bands are seen ranging from ~ 50 – 75 kDa which are not present when the 
samples are treated with β-ME, suggesting that A40 forms oligomers within an infected 
cell.  
 
3.4.3 VACV WR A40 localises to the infected cell surface membrane 
 The subcellular localisation of A40 was investigated by immunoblotting and 
immunofluorescence. Cells were either mock-infected or infected with vA40HA and 
proteins were extracted using the ProteoExtract Native Membrane Protein Extraction 
Kit (Section 2.8.19) and analysed by immunoblotting (Fig. 3.5A). A40HA was detected 
only in the membrane fraction but not in the soluble fraction. As a control the samples 
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were also blotted for B5, a known VACV membrane protein and K7 as a cytosolic 
protein (Fig. 3.5Aii). As expected, B5 was only found in the membrane fraction, 
whereas K7 was detected only within the cytosol.  
 To assess the localisation of A40 within an infected cell by an independent 
method, A40 was tagged with either a C- or N-terminal BAP tag (Section 5.2 & 5.4.4). 
These genes were inserted downstream of the early/late promoter in vector pSEL 
(Ahmad, 2003). HeLa cells were transfected with either plasmid, incubated overnight 
and then infected with vΔA40 (Wilcock et al., 1999) for 8 h (section 2.8.20). Cells 
were either stained live on ice (left panel, Fig. 3.5B) or fixed, permeabilised and then 
stained (right panel, Fig. 3.5B).  
 In the live stained cells, BAP-tagged A40 was detected with the C-terminally 
tagged A40 but not the N-terminally tagged protein and no protein was detected in the 
mock transfected/infected cells (left panel, Fig. 3.5B). In the permeabilised cells (right 
panel, Fig. 3.5B), BAP-tagged A40 was detected in both the cells transfected with N- 
and C-terminally tagged A40 but not in the mock-transfected cells. In this system, A40 
is localised to the surface membrane of the infected cells and because the C-terminally 
tagged A40 was detected without membrane permeabilisation (left panel), these data 
show that A40 is a type II membrane protein with the C-terminal domain exposed 
outside the cell.  
 
3.4.4 A40 is expressed by several VACV strains 
 Whilst the bioinformatic analysis (Fig. 3.1 - 3 and section 3.3.1) indicated that 
A40 orthologues were found in 2 of the 7 different sequenced OPV species, a 
comparison by immunoblotting for expression of A40 confirmed that A40 is expressed 
by different VACV strains, some of which have been sequenced, and whose similarity 
to WR A40 was discussed above. 
 RK13 cells were infected with 17 different VACV strains and CPXV strain BR 
and the A40 deletion mutant vΔA40. The cell lysates were analysed by immunoblotting 
for A40, F13 (a late viral protein (35 kDa) to check for viral infection) and tubulin (to 
check for consistent loading). 
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 As previously described, WR A40 is present as multiple bands ~ 25-38 kDa and 
these are glycosylated. In Fig. 3.6, the A40 Ab detected similar multiple bands from 
lysates of cells infected with VACV strains Lister, Tian Tan and RPXV (as expected 
from their sequences). Two of the sequenced CPXV strains (CPXV BR and Germany 
91-3 (Ger)), have a single aa insertion at position 39 (Fig. 3.2) which may alter the 
protein, but for CPXV BR, a band is seen ~ 37 kDa whilst for elephantpox-2 (EL-2), 
the A40 Ab did not detect anything above the non-specific bands present in all the 
lanes. VACV Copenhagen A40 has a predicted molecular mass of 19.3 kDa but is 
detected faintly with the A40 Ab with bands present ~ 28 kDa and 35 kDa. As 
mentioned in section 3.3.1.1, the sequence of the VACV Copenhagen A40 protein 
varies from VACV WR A40 in the last 22 residues. The replacement of these residues 
with 31 unrelated residues accounts for the difference in size and may explain be why 
the α-A40 Ab is not as efficient at detecting VACV Copenhagen compared to VACV 
WR A40. No A40 protein was detected in lysates of cells infected with VACV MVA 
suggesting either the Ab cannot detect this variant of A40 or that the substitution of the 
terminal five aa with 14 unrelated aa relative to WR makes the MVA protein unstable. 
 The A40 protein from VACV strain buffalopox was detected strongly with the 
same size bands as WR, but with a stronger signal at each size. For VACV strains 
Evans, Patwadangar and USSR the multiple band pattern of WR A40 is seen. In 
contrast, VACV Dairen, King‟s Institute, Tashkent and Wyeth do not express 
detectable A40 detected by this anti-A40 Ab. These VACV strains have not been 
sequenced, and so it is probable that the A40 protein in Evans, Patwadangar and USSR 
are very similar to VACV WR by sequence, like Lister and Tian Tan. VACV strains 
Dairen, King‟s Institute and Tashkent may have insertion and/or mutations as seen with 
the different strains of CPXV, VACV Copenhagen and MVA. 
 
3.5 Summary 
3.5.1 Reaffirmation of A40 characteristics 
 The expression and localisation of A40 has been confirmed independently as a 
glycoprotein that is expressed early in infection and is present on the cell surface with 
type II membrane topology. 
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 As predicted by their known sequences, VACV strains Lister, Tian Tan and 
rabbitpox express A40 and A40 is also expressed by VACV strains buffalopox, Evans, 
Patwadangar and USSR. 
 
3.5.2 Possible protein-protein interaction searches 
 The localisation, topology and predicted domain structure of A40, will 
influence its function and are important when considering strategies to identify its 
interacting partners. Fig. 3.7 summarises four possible ways in which A40 could 
associate with ligands. The first is that A40 could interact with a molecule(s) expressed 
on the surface membrane of immune cells (Fig. 3.7A).This association would most 
likely be mediated by the predicted C-terminal CRD domain of A40. 
 A second possibility is that A40 could interact with a protein expressed at the 
surface of the VACV-infected cell (Fig. 3.7B). Through this interaction A40 could 
disrupt or alter the interacting partner‟s function. This interaction could be mediated by 
the C-terminal CRD domain, the cytoplasmic tail or the interceding stalk region and 
transmembrane domain, or a combination of all of them. 
 A third possibility is that A40 could interact in the extracellular matrix with a 
soluble protein that has been secreted by the host cells (Fig. 3.7C). Lastly, A40 could 
interact with an intracellular protein expressed with the infected cell via the A40 short 
N-terminal region (Fig. 3.7D). Unlike proteins such as NKG2, A40 has no predicted 
protein-protein interaction domains such as ITIM or ITAM, and the cytoplasmic 
sequence is also very short (7 amino residues) suggesting that this possibility is less 
likely than the others. 
 In consideration of these possible associations, a cloning and experimental 
strategy was devised to explore each of these options and clarify the function of A40 
and its proposed role in modulating the host immune system during infection.  
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Fig. 3.6 Expression of the A40 protein by VACV strains 
RK13 cells were infected at 5 p.f.u./cell for 24 h. The cells were washed in PBS then lysed in LB1 on ice (section 2.8.7) and analysed by SDS-PAGE (15% gel) and 
immunoblotting with the anti-α-tubulin mouse Ab (1:5000), the anti-F13 mouse Ab (1:1000) or the anti-A40 rabbit (1:1000). Bound antibodies were detected with HRP-
conjugated goat anti-rabbit IgG antibody (Sigma-Aldrich) (A40) or HRP-conjugated goat anti-mouse IgG antibody (Sigma-Aldrich) (tubulin and F13) both diluted 1:2000 
and ECL reagents (Amersham). Positions of molecular mass markers are shown on the left with sizes in kDa.  
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Fig. 3.7 Summary of possible A40 interactions 
(1) Cell – cell interaction. The A40 extracellular domains may interact with membrane protein(s) (ligand 
A) on another cell. This neighbouring cell might be part of the immune system. (2) A40 could interact 
with other membrane proteins (ligand B) on the same cell. This could occur via any of the A40 domains. 
(3) A40 could interact with soluble protein(s) (ligand C) within the extracellular matrix. This interaction 
could be mediated through the A40 extracellular domain. (4) A40 could interact with intracellular 
protein(s) (ligand D) expressed in the VACV-infected cell.  
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Chapter 4. A40 affects the outcome of infection in the murine 
intradermal infection model 
4.1 Introduction 
 Although deletion of A40 has no effect on in vitro growth properties of the 
VACV (Wilcock et al., 1999) there are many examples of VACV proteins (particularly 
immunomodulatory proteins) that do not alter virus replication in tissue culture, but 
have a significant effect on the outcome of in vivo infections. Examples include 
secreted proteins such as the VACV vIL-1βR (encoded by the WR gene B15R) (Alcamí 
& Smith, 1992; Spriggs et al., 1992a), as well as intracellular proteins such as N1 
(Bartlett et al., 2002; Cooray et al., 2007) all of which down-regulate the functioning of 
a component of the host immune system. 
 Two mouse models have been used to study the contribution of specific genes 
in VACV virulence in our laboratory; the intranasal (i.n.) model (Turner, 1967) and the 
intradermal (i.d.) model (Tscharke & Smith, 1999; Tscharke et al., 2002). In the i.n. 
model, there is virus replication in the lungs, dissemination to other organs including 
the brain and induction of a systemic infection the outcome of which is dependent on 
the virus dose administered (Williamson et al., 1990). In severe infections, death is 
attributed to pneumonia since a marked consolidation of the lungs can be observed 
(Turner, 1967; Taylor et al., 1991; Law et al., 2005). The severity of infection in this 
model is measured by monitoring weight loss and grading signs of illness (Alcamí & 
Smith, 1992). Mice are sacrificed if they reach humane endpoints defined by weight 
loss and signs of severe disease to comply with animal welfare legislation. 
 In contrast, the i.d. model mimics a dermal vaccination (Tscharke et al., 2002) 
causing a highly localised infection with a local skin lesion in the infected ear and little 
if any virus spread to other sites (Tscharke & Smith, 1999). In the i.d. model, virulence 
is measured by the size of the lesion. Virus titres present at various times p.i. can be 
determined by tissue extraction and plaque assay, and the inflammatory infiltration can 
be determined by cell extraction and flow cytometry (Jacobs et al., 2006). Within our 
lab, both models are used to assess the virulence of different VACV strains and VACV 
mutants engineered to lack specific genes. A specific deletion mutant may show a 
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phenotype in one model but not the other, both models, or neither model (Tscharke et 
al., 2002). Also gene deletion may either increase or decrease virulence. 
 A comparison of the recombinant VACV stain WR vΔA40, in which the A40R 
gene is disrupted and partially deleted, with the wild-type (WT) parent virus and a 
revertant (Rev), in which A40R is restored to its natural locus within the deletion 
mutant, showed that the removal of A40 from VACV does not produce a phenotype in 
the i.n. model (Wilcock et al., 1999)but does in the i.d. model (Tscharke et al., 2002). 
In the i.d. model, vΔA40R induced a 30% reduction in lesion size compared to WT and 
Rev viruses in both Balb/c and C57B1/6 mice (Tscharke et al., 2002). This would 
suggest that A40 interacts with one or more cellular ligands within the dermis and in 
doing so, modulates the way in which VACV interacts with its host. Within the i.d. 
model, it is possible to characterise the leukocytes infiltrating into the infected lesion 
and this was done with WT VACV WR previously (Jacobs et al., 2006). Here the 
consequence of deleting A40 on leukocyte infiltration was assessed at different times 
after infection. 
 
4.2 Intradermal infection with vΔA40 
4.2.1 Effect of A40 on the infiltration of leukocytes into VACV-infected lesions 
 To examine if loss of A40 affected virus virulence in the i.d. model, C57Bl/6 
mice were infected i.d. (section 2.9.1) as described previously (Tscharke & Smith, 
1999; Tscharke et al., 2002). The titre of each virus inoculum used for infection was 
checked by titration of diluted virus samples on BSC-1 cells and the infectious doses 
administered were titrated and found to be within 0.2 p.f.u./ml for all the different 
viruses. The migratory cells in the infected ears were collected by collagenase-based 
extraction (Jacobs et al., 2006) and section 2.9.2) and analysed by flow cytometry 
(section 2.9.4) at days 2, 4, 7, 10 and 17 p.i. 
 To begin with, the total number of cells recruited to the ear dermis of mice 
infected with the three different viruses was assessed by trypan blue staining and 
enumeration using a haemocytometer (Fig. 4.1). At day 2 p.i., the total number of cells 
per ear was higher in the ears of mice infected with the virus lacking A40 but this 
difference was not significant. The number of cells in vΔA40 infected ears was 
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significantly higher at days 4 and 7 p.i., but this significance was lost at day 10 p.i. 
compared to the cell numbers recruited by WT and Rev infections. At day 17 p.i., the 
number of cells within vΔA40 infected ears was significantly less than the cell numbers 
within WT and Rev infected ears.  
 
 
 
 
Fig. 4.1 Leukocyte infiltration in the intradermal mouse model 
Mice (n=4) were infected in both ears with 1 x 10
4
 p.f.u. of vΔA40 and control viruses and at the 
indicated times p.i. cells that migrated into each ear of each infected mouse were pooled. The total 
number of viable cells was determined by trypan blue exclusion. Data are expressed as means +/- SD of 
cell counts. P-values were calculated using the Student T-test, ¥ = 0.064, *= 0.05, $ = 0.02, ** = 0.01, 
*** = 0.005.  
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 The type of leukocytes infiltrating the site of infection was investigated further 
by flow cytometry. The number of CD3
+
 T lymphocytes was significantly greater at 
days 2 and 7 p.i., equivalent at day 10 p.i. and significantly less at day 17 p.i with 
vΔA40 compared to WT and Rev (Fig. 4.2A.). The infiltration of F4/80+ macrophages 
after infection with vΔA40 was equivalent at day 2 p.i. but increased to be significantly 
greater than controls at day 4 p.i. (Fig. 4.2B). Thereafter, the numbers were equivalent 
for all three viruses. 
 The T lymphocyte population was examined further by looking at the separate 
CD4
+ 
and CD8
+
 subpopulations and TCRγδ+ cells. The number of CD8+ T cells was 
equivalent between the mice infected with the different viruses at days 2, 4 and 10 p.i.  
However, infection by vΔA40 induced a greater infiltration at day 7 p.i., and a smaller 
infiltration at day 17 p.i. compared to controls (Fig. 4.2C). For CD4
+
 T cells (Fig. 
4.2D), there is a significantly higher number at day 2 and day 7 p.i. with no difference 
between the three viruses at day 10 p.i and then significantly less cells at day 17 p.i. 
The TCRγδ T cells in vΔA40-infected mice were significantly higher in number than 
the controls at day 2 p.i. with a trend to be higher at day 7 p.i. but at this time-point this 
difference was not statistically significant. At day 10 p.i. there was a significantly 
higher number after infection with vΔA40 but this was not apparent at day 17 p.i. (Fig. 
4.2E)  
 There was no significant difference in either NK1.1
+
 NK cells (Fig. 4.2F) or 
Ly6G positive granulocytes (Fig. 4.2G) after infection with the different viruses. 
Although there were no significant changes, there was a trend for more NK cells at day 
7 p.i. in the absence of A40. 
The expression of MHC class II on cells within the lesions was also analysed 
and a significantly higher number of cells expressing MHC class II was seen at days 2 
and 7 p.i. and a significantly lower expression seen at day 17 p.i. (Fig. 4.2H) relative to 
WT and Rev cell numbers. 
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Fig. 4.2 Analysis of infiltrating cells in the intradermal infection model  
Mice (n=5) were infected in both ears with 1 x 10
4
 p.f.u. of vΔA40 and control viruses and at the 
indicated times p.i. cells that migrated into each ear of each infected mouse were pooled. The total 
number of viable cells was determined by trypan blue exclusion. Data are expressed as means +/- SD of 
cells counts. In this cell population the (A) CD3
+
 cells, (B) macrophages, (C) CD8
+
 T cells, (D) CD4
+
 T 
cells, (E) TCRγδ T cells, (F) NK cells, (G) granulocytes and (H) MHC class II+ cells were identified by 
appropriate surface markers as described in Section 2.9.4. The means +/-SD of data from 4 infected mice 
were analysed by cell staining and flow cytometry at the days indicated. P-values were calculated using 
the Student T-test, ¥ = 0.064, *= 0.05, $ = 0.02, ** = 0.01, *** = 0.005. 
 147 
4.2.2 Natural killer activity of extracted Natural killer cells 
Given that the number of NK cells was increased slightly from the deletion 
mutant infected dermal tissue, although this difference was not statistically significant, 
the NK cells from infected ears (days 4 –7 p.i.) were assessed for their NK killing 
activity by chromium release assays using Yac-1 target cells (Section 2.9.10.1). The 
release of 
51
Cr was assessed and the percentage of cytotoxicity calculated (Fig. 4.3).  
 There was no significant difference in NK killing activity by NK cells from ears 
infected with the different viruses at any of time-points assessed.  
 
 
Fig. 4.3 Natural killer cell activity 
Chromium release assay of cells isolated from infected ears against NK-sensitive Yac-1 cells. Mice 
(n=3) were infected in both ears with 1 x 10
4
 p.f.u. of vΔA40 and control viruses and at the indicated 
times p.i. cells that migrated into each ear of each infected mouse were pooled. The total number of 
viable cells was determined by trypan blue exclusion. The ratio of effector: target cells was calculated 
with the absolute number of NK cells as determined by FACS. Data shown are means ± SEM of two 
experiments. Test was measured in triplicate.  
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4.3 Cytotoxic T-lymphocyte activity of extracted T lymphocytes 
The cytolytic T cell activity of extracted T lymphocytes was also assessed 
(Section 2.9.10.2). The targets in these 
51
Cr
 
release assays were EL4 cells (specific 
for T cells from C57Bl/6 mice). If the effector cells were incubated with mock-
infected EL4 cells (dashed lines), there was no significant difference between the 
viruses at day 6 or 7 p.i. (Fig. 4.4). 
If the EL4 cells were infected prior to incubation with the effector cells (solid 
lines) all three viruses increased cytolytic of the extracted cells but no difference was 
seen between the three viruses (Fig. 4.4).  
 
 
 
 
Fig. 4.4 Cytolytic T lymphocyte activity of extracted T lymphocytes from infected dermal samples 
Chromium release assay of cells isolated from infected ears against cytotoxic T cell-sensitive EL4 cells. 
Mice (n=3) were infected in both ears with 1 x 10
4 p.f.u. of vΔA40 and control viruses and at the 
indicated times p.i. cells that migrated into each ear of each infected mouse were pooled. The total 
number of viable cells was determined by trypan blue exclusion. Mock EL4 targets (- -), EL4 infected 
targets (̶ ). Ratio of Effector: Target cells was calculated with the absolute number of CD8 T cells as 
determined by FACS. Data shown are means ± SEM of two experiments. Test was measured in 
triplicate.   
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4.4 Immunisation challenge study  
The ability of the vΔA40 virus to protect mice against a lethal challenge with 
WT virus was assessed relative the control viruses (Fig. 4.5). Mice were infected with 
10
4
 p.f.u./ml virus i.d. and assessed for „take‟ of the virus for 7 days. After 28 days, the 
mice were challenged i.n. with a lethal dose of WT virus (10
7
 p.f.u.). The weight loss of 
the challenged mice was assessed every day post-challenge.  By day 3 p.i., all the 
challenged mice had lost ~ 15 % of their body weight. By day 4, the mice inoculated 
with vΔA40 showed significantly less weight loss compared to the control mice, with 
the weight loss levelling off whilst the control mice still lost weight at day 4 compared 
with day 3. By day 5, all the challenged mice began to gain weight and the mice 
inoculated with vΔA40 still had a significant difference in weight at day 7 p.i. 
compared to the WT and Rev mice. 
 
 
Fig. 4.5 Vaccination and challenge model 
All mice were vaccinated i.d. with 10
4
 p.f.u. of the indicated virus. Mice were challenged i.n. 28 days p.i. 
with 1 x 10
7
 p.f.u. of WT virus and weights were measured daily. The data are presented as the indicated 
mean +/- SEM. P-values were calculated using the Student T-test.  
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4.5 The effect of A40 on natural killer activity in vitro 
4.5.1 Effect of infection of NK cells on NK killing activity 
The role of A40 in NK recognition of infected cells was also assessed in vitro 
(section 2.9.10.3). Human NK92MI cells were infected prior to incubation with 
51
Cr-
labelled WR infected K562 target cells. Infection of NK cells with all three viruses 
increased their cytotoxic activity relative to mock infected NK cells but no significant 
difference in cytotoxicity between the vΔA40 virus infected NK cells and those 
infected with the control viruses was observed (Fig. 4.6A). 
 The infection of the NK92MI cells was assessed by immunoblotting for A40 
and tubulin (Fig. 4.6Ci).  
 
4.5.2 Effect of infection of target cells on NK killing activity 
 If the K562 cells were infected prior to 
51
Cr labelling (Section 2.9.10.3) and 
incubation with uninfected NK cells, the absence of A40 from the infected target cells 
seems to increase cytotoxicity relative to the controls (Fig. 4.6Bi). At E:T ratios 1:6 and 
1:12, the cytotoxicity of NK cells to target cells infected with virus lacking A40 is 
significantly increased compared to cytotoxicity to target cells infected with Wt or Rev 
virus.  
 Conversely, if A40 was over-expressed from an IPTG inducible virus 
(vTAPA40) there is less cytotoxicity to these target cells relative to the control infected 
cells (Fig. 4.6Bii). At the lowest (1:3) and highest (1:100) E:T ratios, the cytotoxicity of 
NK cells to target cells over-expressing A40 were significantly lower compared to 
cytotoxicity towards target cells infected with Wt and Rev viruses. When the E:T ratios 
are increased, the Wt and ΔA40 lines converge whilst vTAPA40 diverges from the 
controls suggesting what as the amount of A40 increases, its inhibitory effect on the 
cytotoxicity of the effector NK cells increases. All the cytotoxicity assays for this 
section were performed at the same time but have been separated into two graphs for 
ease of assessment. 
 The expression of A40 was assessed by SDS-PAGE and immunoblotting for 
A40 and tubulin (Fig. 4.6Cii). 
 151 
(A) 
 
(B) 
(i)           (ii) 
 
(C) 
(i) (ii) 
        
Fig. 4.6 Natural killer activity in vitro  
Chromium release assay of NK92MI cells against NK-sensitive K562 cells. (A) NK92MI cells were 
infected with vΔA40 and control viruses at 1 p.f.u./cell 16 h prior to incubation with labelled target cells. 
(B) (i) K562 cells were infected with vΔA40 and control viruses at 1 p.f.u./cell. l for 16 h prior to 
labelling and incubation with uninfected effector cells. (ii) K562 cells were infected with vTAPA40 and 
control viruses at 1 p.f.u./cell and induced for 16 h prior to labelling and incubation with uninfected 
effector cells. The total number of viable cells was determined by trypan blue exclusion. Ratio of 
effector: target cells was calculated with the absolute number of NK cells. Data shown are means ± SEM 
of two experiments. Test was measured in triplicate. (C) (i) NK and (ii) K562 cells were analysed for 
infection by SDS-PAGE (15%) and immunoblotting for A40 and tubulin as a loading control. Positions 
of molecular mass markers are shown on the left with sizes in kDa. P-values were calculated using the 
Student T-test, ¥ = 0.064, *= 0.05, $ = 0.02, ** = 0.01, *** = 0.005. 
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4.6 Summary 
 The deletion of A40 from the VACV WR genome causes attenuation of 
leukocyte infiltration to the site of VACV infection in the murine i.d. model. The 
absence of A40 from an infection results in an increase in the number of cells recruited 
to the site of infection and this difference is seen from day 4 p.i. A difference in cell 
number is also seen at day 17 p.i. correlating with the earlier clearance of A40 from an 
infected animal and the smaller lesion size of vΔA40 previously observed (Tscharke et 
al., 2002).  
 These changes were analysed and an increase in macrophages, CD3
+
 T cells and 
TCRγδ T cells was seen in mice infected with vΔA40 compared to the control viruses 
whilst no significant difference was seen in NK cell infiltration. When the CD3
+
 T cell 
populations were analysed, a significant increase in CD4
+
 T cells was seen at day 2 p.i. 
followed by an increase in CD8
+
 T cells at day 7 p.i.  
 The increase in MHC class II
+
 cells correlates with the increase in macrophage 
cell number. It may also represent an increase in other types of APCs which were not 
present in a significant enough number to be analysed with the total cell population, 
which could increase in the vΔA40 infected ears relative to WT and Rev, but their 
contribution to the immune response may be masked by the relative abundance of the 
other leukocyte cell populations. 
 The cytotoxic killing activity of NK and CTL T cells from infected ears was not 
affected by the absence of A40 at the times assessed.  
 The ability of the vΔA40 virus was to protect mice against a lethal challenge of 
WT virus was better than mice vaccinated with WT and Rev viruses. 
 In vitro, infection of NK cells prior to chromium release assays increased the 
cytotoxicity of human NK92MI cells but the absence of A40 does not affect this 
killing. This increase in ability to kill target cells does not correlate with observations 
by Chisholm et al., (2006) that infection of NK cells by VACV inhibits their ability to 
sense target cells. The increase in cytotoxicity could be due to VACV activating the 
NK cells or due to the NK cells co-infecting the target cells during the incubation 
period. 
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 When the target cells were infected prior to incubation with NK92MI cells, 
there is an increase in cytotoxicity with all three viruses relative to the cytotoxicity 
towards the mock target cells. When A40 is absent from infected target cells, there is an 
increase in NK killing activity but there is no significant difference relative to the 
cytotoxicity directed towards WT and Rev infected target cells. If A40 is over-
expressed in target cells, this seems to provide some protection from NK killing as the 
percentage cytotoxicity to these cells is reduced relative to the percentage cytotoxicity 
of target cells infected with WT or Rev. Collectively, these data indicate that A40 may 
regulate NK recognition/killing of infected cells to the advantage of the virus 
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Chapter 5. Protein production & characterisation 
5.1 Introduction 
 Having fully established the localisation of WR A40 within the cell and its 
characteristics such as time of expression in infection and how it is post-translationally 
modified in mammalian cells, a series of protein mutants were designed to help 
elucidate A40‟s role in viral infection and to search for its potential binding partners. 
 
5.2 Cloning strategy 
 Six DNA plasmid vectors, pSecTag2C (Invitrogen), pSEL (Vasta et al., 2004), 
pCI (Promega), pET-28a (Novagen), pVOTE.1 (Ward et al., 1995) and pBac-2cp 
(Novagen) were used to generate recombinant protein. 
 Two truncated versions of A40 were developed. In A40ΔTM, the short N-
terminal region (aa 1-6) and transmembrane region (aa 7-29) of A40 were removed to 
aid expression in bacteria and to enable fusion with a signal peptide for secretion of 
soluble protein from mammalian cells. In A40ΔTMΔSt, in addition to the two regions 
mentioned above, the hypothesised “stalk” region (aa 30-49) between the 
transmembrane region and C-type lectin-like domain was also removed. This was to 
determine whether this region influenced the ability of A40 to bind either to itself or to 
any possible interacting partners. 
 pET-28a was utilised to create 2 different versions of A40 in bacteria. Both 
lacked the transmembrane domain and one also lacked the stalk region. In each case 
A40 was fused with an N-terminal His6 tag and utilised the natural A40 termination 
codon This bacterial expression vector had the extracellular domains (Fig. 5. 1 and Fig. 
5.2B, C). The A40 protein produced from E. coli was used for binding studies and also 
for X-ray crystallisation trials. 
 pSecTag2C was used for expression in mammalian cells of truncated A40 fused 
with a biotin acceptor protein (BAP) (PNSGSLHHILDAQKMVWNHR) (Schatz, 
1993) at the N terminus (Fig. 5.1 and Fig. 5.2D & E). The BAP peptide enables the 
recombinant proteins to be labelled in vitro at the lysine residue within the fusion 
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protein with biotin using the bacterial enzyme BirA (Schatz, 1993; O'Callaghan C et 
al., 1999). Furthermore, the BAP can be fused at either the N or C terminus allowing 
maintenance of the correct orientation of the recombinant proteins for binding studies. 
 The domains of A40 and BAP were amplified by PCR from pSAD3 (Fig. 5.3A) 
(Duncan, 1992) and pEMR-Bio (Law, 2001) respectively (Fig. 5.3B). The A40 and 
BAP sequences were fused together by splicing by overlap extension (Horton et al., 
1989) using the PCR products from the first reaction as templates (Fig.5.3C) and were 
inserted into the expression vector pSecTag2C. BAP-A40ΔTM, and BAP-
A40ΔTMΔSt, were digested with restriction enzymes (RE) HindIII and BamHI and 
inserted into the multiple cloning site (MCS) of pSecTag2C to generate the 
recombinant clones psBAP-A40ΔTM and psBAP-A40ΔTMΔSt. The fusion products 
were inserted between the human CMV (HCMV) immediate early promoter (Boshart et 
al., 1985) and bovine growth hormone polyadenylation sequence for high levels of 
protein expression in eukaryotic cells (Goodwin & Rottman, 1992). All the fusion 
products were inserted in frame and downstream of the Igκ-chain leader sequence 
allowing secretion of the recombinant proteins. BAP-tagged products relied on the 
translation start site within the vector. 
 pSEL was used to express BAP-tagged (Fig. 5.1 and Fig. 5.2F and G) full-
length A40 in VACV-infected cells. The BAP was fused to either the N or C terminus. 
pSEL was generated by insertion of the VACV early/late promoter (Davison & Moss, 
1990) into the pBluescript SK (+) plasmid (Stratagene) (Ahmad, 2003). The same 
cloning strategy for pSecTag was used to insert full-length A40 into the vector under 
the control of the VACV early/late promoter (E/L). BAP-A40 and A40-BAP were 
digested with restriction enzymes BamHI and HindIII to insert into the MCS of pSEL. 
Clones pSEL(N)BAPA40 and pSEL(C)A40BAP were generated using this method. 
These plasmids were used to study the localisation of A40 (section 3.4.3) and seek its 
interacting partners (section 6.2).  
 pCI was used to express BAP-tagged full-length A40 (Fig. 5.1 and Fig. 5.2F 
and G) in mammalian cells. The constructs from pSEL were re-cloned into pCI under 
the control of the CMV enhancer/promoter. 
 The pVOTE1 plasmid was used to construct recombinant VACVs derived from 
vT7lacOI (Ward et al., 1995) that expressed A40 in an IPTG-inducible manner (section 
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5.5). BAPA40ΔTM and BAPA40ΔTMΔSt from the pSecTag2 vectors including their 
Igκ secretion sequence (METDTLLLWVLLLWVPGSTGDAAQPARRAVRSL) were 
amplified using the primers (N)IgκBAPA40_F & (N)IgκBAPA40_R. The PCR 
products were digested with NcoI and SalI and ligated into pVOTE.1. The resulting 
plasmids pVOTE-BAP40ΔTM & pVOTE-BAPA40ΔTMΔSt were used to produce 
recombinant viruses that produce secreted truncated A40 with an N terminal BAP tag 
upon addition of IPTG. A full-length A40 tagged with both a FLAG and a BAP tag at 
the N terminus was also produced. The dual tagged A40 was named TAPA40. The 
FLAG tag was incorporated into the forward primer (N)FLAG_BAP_F and fused to the 
BAPA40 from pSEL by overlapping extension to produce (N)FLAGBAPA40. This 
was then digested with NcoI and SalI and cloned into pVOTE1. This plasmid (pVOTE-
TAPA40) was then used to construct a recombinant VACV (Section 2.5.). 
 pBac-2cp was used to generate recombinant baculoviruses expressing proteins 
in insect cells. This protein was designed as an alternative source of protein for cell 
binding studies and to study if post-translation modifications, such as glycosylation, are 
important for binding. BAP-A40ΔTM and BAP-A40ΔTMΔSt were re-amplified using 
the alleles within pSecTag2, digested with the restriction enzymes BamHI and HindIII 
and inserted into pBac-2cp in frame downstream of the His tag sequence. Flanking 
baculovirus sequences are present to permit the generation of recombinant 
baculoviruses. In this way, the clones pBacHisBAPA40ΔTM and 
pBacHisBAPA40ΔTMΔSt were constructed and used to regenerate recombinant 
baculoviruses expressing HisBAPA40ΔTM (Fig. 5.1 and Fig.5.2 I) and 
HisBAPΔTMΔSt (J). 
 For all vectors, the clones were verified by restriction digestions and DNA 
sequencing. The calculated molecular mass of the recombinant proteins are displayed 
in Table 5.1. 
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Table 5.1 Predicted properties of the recombinant proteins expressed in mammalian, bacterial and 
viral expression systems 
Protein Predicted size (aa) Molecular mass (kDa) pI 
A40 159 18.16 9.18 
His-A40ΔTM 164 18.61 9.53 
His-A40ΔTMΔSt 144 16.30 9.42 
BAP-A40ΔTM 150 17.38 9.43 
BAP-A40ΔTMΔSt 130 15.08 9.29 
BAP-A40 180 20.62 9.26 
A40-BAP 179 20.49 9.26 
FLAG-BAP-A40 189 21.63 8.94 
His-BAP-A40ΔTM 206 23.27 9.15 
His-BAPA40ΔTMΔSt 186 20.97 8.94 
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(A)  A40: 159 aa 
1 MNKHKTDYAG YACCVICGLI VGIIFTATLL KVVERKLVHT PSIDKTIKDA YIREDCPTDW 
61 ISYNNKCIHL STDRKTWEEG RNACKALNPN SDLIKIETPN ELSFLRSIRR GYWVGESEIL 
121 NQTTPYNFIA KNATKNGTKK RKYICSTTNT PKLHSCYTI 
 
(B)  His-A40ΔTM: 164 aa 
1 MGSSHHHHHH SSGLVPRGSH MASMTGGQQM GRGSLKVVER KLVHTPSIDK TIKDAYIRED 
61 CPTDWISYNN KCIHLSTDRK TWEEGRNACK ALNPNSDLIK IETPNELSFL RSIRRGYWVG 
121 ESEILNQTTP YNFIAKNATK NGTKKRKYIC STTNTPKLHS CYTI  
 
(C)  His-A40ΔTMΔSt: 144 aa 
1 MGSSHHHHHH SSGLVPRGSH MASMTGGQQM GRGSAYIRED CPTDWISYNN KCIHLSTDRK 
61 TWEEGRNACK ALNPNSDLIK IETPNELSFL RSIRRGYWVG ESEILNQTTP YNFIAKNATK 
121 NGTKKRKYIC STTNTPKLHS CYTI  
 
(D)  BAP-A40ΔTM: 150 aa 
1 PNSGLSHHIL DAQKMVWNHR LKVVERKLVH TPSIDKTIKD AYIREDCPTD WISYNNKCIH 
61 LSTDRKTWEE GRNACKALNP NSDLIKIETP NELSFLRSIR RGYWVGESEI LNQTTPYNFI 
121 AKNATKNGTK KRKYICSTTN TPKLHSCYTI 
 
(E)  BAP-A40ΔTMΔSt: 130 aa 
1 PNSGLSHHIL DAQKMVWNHR AYIREDCPTD WISYNNKCIH LSTDRKTWEE GRNACKALNP 
61 NSDLIKIETP NELSFLRSIR RGYWVGESEI LNQTTPYNFI AKNATKNGTK KRKYICSTTN 
121 TPKLHSCYTI 
 
(F)  BAP-A40: 180 aa 
1 MPNSGSLHHI LDAQKMVWNH RMNKHKTDYA GYACCVICGL IVGIIFTATL LKVVERKLVH 
61 TPSIDKTIKD AYIREDCPTD WISYNNKCIH LSTDRKTWEE GRNACKALNP NSDLIKIETP 
121 NELSFLRSIR RGYWVGESEI LNQTTPYNFI AKNATKNGTK KRKYICSTTN TPKLHSCYTI 
 
(G)  A40-BAP: 179 aa 
1 MNKHKTDYAG YACCVICGLI VGIIFTATLL KVVERKLVHT PSIDKTIKDA YIREDCPTDW 
61 ISYNNKCIHL STDRKTWEEG RNACKALNPN SDLIKIETPN ELSFLRSIRR GYWVGESEIL 
121 NQTTPYNFIA KNATKNGTKK RKYICSTTNT PKLHSCYTIP NSGSLHHILD AQKMVWNHR 
 
(H)  FLAG-BAP-A40: 189 aa 
1 MDYKDDDDKS GPNSGSLHHI LDAQKMVWNH RNKHKTDYAG YACCVICGLI VGIIFTATLL 
61 KVVERKLVHT PSIDKTIKDA YIREDCPTDW ISYNNKCIHL STDRKTWEEG RNACKALNPN 
121 SDLIKIETPN ELSFLRSIRR GYWVGESEIL NQTTPYNFIA KNATKNGTKK RKYICSTTNT 
181 PKLHSCYTI 
 
(I)  His-BAP-A40ΔTM: 206 aa 
1 MPMVHHHHHH SAGLVPRGSG KETAAAKFER QHMDSASGGG DDDDKSPGFS SKGLDPPNSG 
61 SLHHILDAQK MVWNHRLKVV ERKLVHTPSI DKTIKDAYIR EDCPTDWISY NNKCIHLSTD 
121  RKTWEEGRNA CKALNPNSDL IKIETPNELS FLRSIRRGYW VGESEILNQT TPYNFIAKNA 
181 TKNGTKKRKY ICSTTNTPKL HSCYTI 
  
(J)  His-BAP-A40ΔTMΔSt: 186 aa 
1 MPMVHHHHHH SAGLVPRGSG KETAAAKFER QHMDSASGGG DDDDKSPGFS SKGLDPPNSG 
51 SLHHILDAQK MVWNHRAYIR EDCPTDWISY NNKCIHLSTD RKTWEEGRNA CKALNPNSDL 
121 IKIETPNELS FLRSIRRGYW VGESEILNQT TPYNFIAKNA TKNGTKKRKY ICSTTNTPKL 
181 HSCYTI 
 
Fig. 5.1 Amino acid sequences of A40 and recombinant A40 proteins 
A40, BAP-A40, A40-BAP, FLAG-BAP-A40 BAP-A40ΔTM, BAP-A40ΔTMΔSt, His-A40ΔTM, His-
A40ΔTMΔSt, His-BAP-A40ΔTM & His-BAP-A40ΔTMΔSt. The transmembrane region is italicised. 
Asparagine (N)-linked glycosylation sites are underlined and bold. BAP, His or FLAG tag sequences are 
underlined.  
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Fig. 5.2 Schematic of A40 recombinant proteins 
(A) Full length A40. (B) Truncated A40 with the transmembrane region removed and a His tag fused to 
the N terminus. (C) Truncated A40 with the transmembrane region and stalk region removed and a His 
tag fused to the N terminus. (D) Truncated A40 with the transmembrane region removed (ΔTM) and a 
BAP tag fused to the N terminus. (E) Truncated A40 with the transmembrane region and stalk region 
removed (ΔTMΔSt) and a BAP tag fused to the N terminus. (F) Full-length A40 with a BAP tag fused to 
the N terminus. (G) Full-length A40 with a FLAG & a BAP tag fused to the N terminus. (H) Full-length 
A40 with FLAG and BAP tags fused to the C terminus. (I) Truncated A40 with the transmembrane 
region removed and a His tag and a BAP tag fused to the N terminus. (J) Truncated A40 with the 
transmembrane region and stalk region removed and a His tag and a BAP tag fused to the N terminus.  
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Fig. 5.3 Generation of recombinant BAP fusion proteins by overlapping extension PCR (OEP) 
(A) The complete A40R ORF or the region encoding the extracellular domains of A40 were amplified 
from pSAD3 by PCR. BAP sequences were linked at the 5‟ -end of the forward primers (N)BioA40R_R, 
(N)BioA40R_Rt, pSEL(N)BioA40R_F and the reverse primer pSEL(C)A40RBio_R. (B) BAP sequences 
were amplified from pEMR-Bio plasmid DNA by PCR using primers (N)Biotin_F, (N)BioA40R_R and 
(N)BioA40R_Rt for the fusion with A40RΔTM and A40RΔTMΔSt respectively and pSEL(N)Biotin_F 
and pSEL(N)BAPA40R_R for the fusion with A40R. In the case of A40RΔTM, A40RΔTMΔSt & 
(N)A40R sequences were linked with the BAP sequence in the 5‟-end of the reverse primers 
(N)BioA40R_R, (N)BioA40R_Rt and pSEL(N)BioA40R_R respectively. The (C)A40R sequence was 
linked with the BAP sequence in the 5‟-end of the forward primer pSEL(C)A40RBio_F. (C) OEP. The 
PCR products from (A) & (B) were purified and used as templates for the generation of BAP-fusion 
sequences by OEP. As overlapping sequences were introduced into the ends of the PCR products, the 
PCR fragments can be joined together by OEP to form BAP-A40ΔTM, BAP-A40ΔTMΔSt, BAPA40 and 
A40BAP. “ATG” and “STOP” represent the translation initiation and stop codons, respectively.  
ATG                                                             3’(BAP)  
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STOP
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5’(BAP)
STOP
ΔTMΔSt
5’(BAP)
STOP
pSAD3
(A)
BAP + A40R
A40R + BAP
BAP + A40RΔTM
BAP + A40RΔTMΔSt
BAP -A40R
A40R -BAP
BAP -A40RΔTM
BAP -A40RΔTMΔSt
STOP
STOP
STOP
STOP
ATG
(C)
(B)
3’(A40R)
3’(A40RΔTM)
pEMR-Bio
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5.3 Production of recombinant His –tagged A40 from E.coli 
5.3.1 Generation of rabbit anti-A40 polyclonal serum 
 To produce an antibody to A40, recombinant truncated A40 was expressed from 
pET-28a in E. coli. Small scale cultures were used to determine conditions giving the 
most soluble protein (Table 5.2). In all conditions tested the recombinant HisA40ΔTM 
and HisA40ΔTMΔSt produced were completely insoluble. Rosetta gami 2 (DE3) pLys 
cells induced with 1 mM IPTG for 3 h were chosen as these conditions gave the best 
level of expression and scaled up to 1 L cultures (Fig. 5.4). This recombinant protein 
was harvested, denatured and purified by on-column refolding on a HisTrap column 
(section 2.8.3.1). Protein derived from denatured inclusion bodies (IB) was applied to a 
HisTrap column pre-equilibrated with denaturing His-binding buffer containing 8 M 
Urea. The column was washed in binding buffer and the His-tagged protein refolded 
using buffer exchange with a linear gradient, gradually reducing the concentration of 
urea to zero (Fig. 5.5A). The protein was eluted in 500 mM imidazole (Fig. 5.5B) and 
the fractions were assessed for HisA40ΔTM by SDS-PAGE and coomassie staining 
(Fig. 5.5C). A band was present in the elution fractions 19 -22 at the predicted size of 
HisA40ΔTM (~18 kDa, Table 5.1). These fractions were pooled together, concentrated 
to 0.5 ml and applied to a pre-equilibrated Superdex 75 column (Fig. 5.6A) and the 
eluted fractions were analysed by SDS-PAGE, coomassie staining (Fig. 5.6B) and 
immunoblotting (Fig. 5.6 C) for the His tag. Fractions 17 - 22 were pooled and the 
concentration determined (using the NanoDrop) to be 1.2 mg/ml. This purified protein 
was sent to Harlan to inoculate two rabbits per recombinant protein (section 2.10.1). 
 
5.3.2 Purification of antiserum by pre-absorption on infected cells 
 The final bleeds were tested against recombinant A40 to analyse the antiserum. 
When tested by immunoblotting against cell lysate from VACV infected cells, the anti-
serum showed specific bands characteristic of A40 and these were absent from cells 
infected with the vΔA40 virus and from mock-infected cells. However, non-specific 
bands were seen in all of lysates (Fig. 5.7Bi). 
 To remove these bands, anti-A40 antiserum was absorbed against vΔA40 cell 
lysates. Five flasks of confluent RK13 cells were infected with vΔA40 at 5 p.f.u/cell for 
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18 h. The cells were washed, harvested and fixed in PFA (section 2.10.2). The cells 
were then permeabilised and incubated with 1 ml of antiserum overnight at 4 ºC. The 
unbound antiserum was collected, centrifuged at 15,000 rpm for 15 min at 4 ºC 
(Heraeus Biofuge 15R) to remove cell debris. 
 To purify the antibody further, the IgG fraction was isolated by affinity 
chromatography on a HiTrap Protein G column connected to the Akta (section 2.10.3). 
The elution of the antibody was monitored by absorbance at 280 nm and the pH of the 
eluant was neutralised by pre-aliquoting 1 M Tris pH 8.8 in the collection tubes. As 
seen in Fig. 5.7A most of the bound protein eluted in fractions 2 & 3. These fractions 
were combined together, dialysed against 2x antibody buffer (section 2.10.3), diluted 
1:1 with sterile glycerol,  aliquoted and stored at 4 ºC for immediate use and at -20 ºC 
for long term storage. 
 The purified IgG was compared with the original and pre-cleared antiserum by 
using comparable dilutions in immunoblots to detect the A40 protein from virus-
infected cell lysates (Fig. 5.7B). The purified antibody gave a much better signal and 
lowered the background significantly (Fig. 5.7Bii) compared to the original antiserum 
(Fig. 5.7Bi). This purified antibody was subsequently used for immunoblotting and 
immunofluorescence to analyse the A40 protein. 
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Fig. 5.4 Production of recombinant His-tagged A40 proteins in bacterial cells 
HisA40ΔTM and HisA40ΔTMΔSt were transformed into Rosetta Gami 2 (DE3) pLys and scaled up to 1 
L of LB medium with 50 μg/ml kanamycin. Expression was induced for 3 h with 1 mM IPTG. The cells 
were harvested and lysed by sonication in lysis buffer on ice (section 3.6.4). A small aliquot was taken 
(Total) and 1/5 vol of 6 x SDS loading buffer was added. The lysate was centrifuged at 13,000 x g for 30 
min and separated into soluble protein fraction (supernatant) and insoluble fraction (pellet). The 
insoluble fraction was resuspended in an equal volume of lysis buffer. Each fraction was analysed for the 
presence of His-tagged A40 protein by SDS-PAGE (15% gel). (A) Coomassie staining of small-scale 
production from pET-28a recombinant plasmids. (B) Immunoblot for (N) terminal His tag. (T) Total, (S) 
Soluble, (I) Insoluble. Positions of molecular mass markers are shown on the left with sizes in kDa.  
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Fig. 5.5 Purification of recombinant His-tagged protein from E. coli using a HisTrap column 
HisA40ΔTM was produced in E. coli, the insoluble protein fraction was harvested and the inclusion 
bodies were washed and then denatured (section 2.8.3.5). The denatured protein was applied to a HisTrap 
column. (A) Binding, washing and on column refolding of HisA40ΔTM. The column was washed in 
buffer containing 8 M urea, then the protein was refolded using buffer exchange with a linear gradient of 
8 – 0 M urea. (B) Elution of HisA40ΔTM using a step gradient of imidazole. The refolded protein was 
washed with 5 mM imidazole, then 300 mM imidazole and finally was eluted in 500 mM imidazole. (C) 
Fractions were tested for HisA40ΔTM by SDS-PAGE and coomassie staining. Positions of molecular 
mass markers are shown on the left with sizes in kDa.   
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Fig. 5.6. Purification of HisA40ΔTM by gel filtration.  
HisA40ΔTM from on-column refolding fractions 18-24 were pooled and concentrated to 0.5 ml and 
applied to a Superdex 75 column pre-equilibrated in PBS. (A) Chromatogram of HisA40ΔTM elution 
from Superdex in PBS. Eluted fraction 18 – 25 were analysed for presence and purity of HisA40ΔTM by 
SDS-PAGE and (B) coomassie staining or (C) immunoblotting for His tag. Positions of molecular mass 
markers are shown on the left with sizes in kDa.  
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Fig. 5.7 Purification of the anti-A40 antiserum and isolation of IgG fraction 
Anti-serum raised against HisA40ΔTM was pre-cleared against vΔA40-infected cells to remove cell non-
A40 background bands (section 2.10.2). The pre-cleared serum was diluted 1:2 in PBS and applied to a 
pre-equilibrated Protein A column (A). The column was washed in PBS and the IgG eluted with 100 mM 
Citric acid pH 3. The fractions were neutralised with 1.5 M Tris pH 8.8 and fractions 2 and 3 pooled and 
dialysed against 2 x Ab buffer. (B) BS-C-1 cells were mock-infected or infected with either WT ΔA40 or 
Rev virus at 15 p.f.u./ml for 16 h. Cells were lysed in LB1 (Section 2.8.7) and the proteins separated by 
SDS-PAGE and analysed by immunoblotting with (i) anti-A40 Rb 171 anti-serum, (ii) purified IgG 
fraction of pre-cleared anti-A40 (α-A40 IgG). Positions of molecular mass markers are shown on the left 
with sizes in kDa. 
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5.3.3 Crystallisation trials 
 To improve the chances of obtaining material suitable for crystallisation trials, 
the conditions of expression of recombinant A40 expressed from pET-28a in E. coli 
were varied to try to improve the protein solubility. Three different strains of E. coli 
commonly used within our lab were tried. In addition, the temperature, IPTG 
concentration and length of induction and the presence of 1% glucose within the 
induction medium were all tested. 
 In all the conditions tested, the test cultures were harvested, the final OD595 
tested and the pellets were resuspended in lysis buffer with added protease inhibitors, 
sonicated and the solubility of expression with each set of conditions analysed by SDS-
PAGE (section 2.8.3.4.). Whilst all the conditions tested did not increase the amount of 
soluble A40 protein, the Rosetta Gami 2 cells gave the highest expression overall and it 
was decided that the best way to obtain recombinant A40 was to harvest the insoluble 
protein within cleaned inclusion bodies and denature, refold and affinity purify this 
material (section 2.8.3.2). 
 A two L culture of RG2 cells transformed with pET28a-HisA40ΔTM and 
induced for 3 h with 1 mM IPTG at 37 ºC with shaking was harvested by centrifugation 
and the pellet analysed for expression. To process the cells, the pellet was resuspended 
in PBS containing protease inhibitors on ice. After the samples were sonicated, they 
were centrifuged and the soluble fraction removed. The insoluble pellet was then 
resuspended in inclusion body wash buffer and the inclusion bodies were washed four 
times in this buffer to remove as much contaminating protein as possible. This IB 
preparation was then denatured using 8 M guanidine overnight. The denatured samples 
were harvested by centrifugation to remove any remaining insoluble material and 
transferred to a fresh tube. The protein concentration was determined and the denatured 
proteins were diluted into refold buffer with stirring. This refolded material was then 
concentrated and dialysed against His binding buffer to remove the L-arginine within 
the refold buffer. This is needed within the refold buffer to stabilise the protein as it 
refolds, but is detrimental to the HisTrap column. As the refolded protein was 
concentrated, some material did aggregate and this probably represented either 
misfolded protein or refolded protein aggregating as it became more concentrated. 
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 The concentrated, dialysed material was applied to a pre-equilibrated HisTrap 
column, washed in His binding buffer and then eluted in a gradient of imidazole. The 
elution was assessed by absorbance at 280 nm (Fig. 5.8) and the fractions were 
assessed by SDS-PAGE followed by Coomassie staining (Fig. 5.8B). 
 The fractions containing His-tagged A40 were combined, re-concentrated and 
dialysed against PBS and applied to a pre-equilibrated gel filtration column. The 
elution profile of the A40 protein was again assessed by absorbance at 280 nm (Fig. 
5.9A) and fractions were assessed by SDS-PAGE and coomassie staining (Fig. 5.9B). 
Samples of the fractions were prepared for SDS-PAGE in SDS loading buffer with or 
without β-ME. In the fractions containing HisA40ΔTM, in the absence of β-ME the 
protein runs as a doublet ~ 38 kDa whilst in the presence of β-ME, HisA40ΔTM is 
present as a band ~ 18 kDa. 
 The pooled purified protein was further assessed by SDS-PAGE and 
immunoblotting for the His-tag (Fig. 5.10A). His-tagged N1 (Cooray et al., 2007) was 
used as a control and runs at ~ 15 kDa as predicted, whilst HisA40ΔTM is present ~ 18 
kDa. The samples were also assessed in a native gel, and immunoblotted for His (Fig. 
5.10B) or A40 (Fig. 5.10C). N1 (detected by the His tag) runs lower than A40.  
 Fractions 50 -58 from the gel filtration column were combined and concentrated 
to 0.8 mg/ml and sent to our collaborators at the Division of Structural Biology, Oxford 
for crystallisation trials. Of the different conditions trialled for A40, crystals were 
obtained when diffused against 0.1 M HEPES ph 7.5, 0.5 M lithium acetate, 18% w/v 
PEG 4000 (Fig. 5.11A) or 0.1 M MES pH 6.0, 0.4 M potassium acetate, 18% PEG 
4000 using free-interface diffusion at RT and these were taken to the ESRF synchrotron 
in Geneva. The diffraction pattern obtained from these crystals was only to 8 Å (Fig. 
5.11B). The protein was also analysed by dynamic light scattering (DSL) and dye-
binding shift (thermofluor) experiments to assess the stability and that the protein is 
folded properly (data not shown). The protein was monomeric by DSL and shown to be 
natively folded by the refolding experiments. The protein was not made more stable by 
the addition of Ca
2+
 to the thermofluor experiments. When assessed by MALDI mass 
spectrometry, HisA40ΔTM was shown to have a mass of 19.1 kDa, which is 500 Da 
more than predicted but when digested with trypsin and sequenced, the protein was 
shown to be A40. The reason for this small difference remains unknown.   
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Fig. 5.8. Affinity purification of refolded HisA40ΔTM 
(A) Refolded and concentrated HisA40 from E. coli inclusion bodies was applied to a pre-equilibrated 
HisTrap column. The column was washed in native His binding buffer and His tagged A40ΔTM was 
eluted using a linear gradient of 20 – 500 mM imidazole. (B) Fractions were tested for HisA40ΔTM by 
SDS-PAGE and coomassie staining. Positions of molecular mass markers are shown on the left with 
sizes in kDa. 
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Fig. 5.9. Purification of HisA40ΔTM by gel filtration. 
Refolded HisA40ΔTM fractions from HisTrap column were applied to a Superdex 75 10/300 column for 
gel filtration. Half ml aliquots were applied to the column and were eluted in PBS. The fractions (0.5 ml) 
were analysed for the presence of His-tagged recombinant protein by SDS-PAGE. (A) Separation of 
HisA40ΔTM using gel filtration. (B) Coomassie staining of eluted fractions prepared with or without β-
mercaptoethanol in the SDS loading buffer. Positions of molecular mass markers are shown on the left 
with sizes in kDa. 
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Fig. 5.10. Analysis of refolded HisA40ΔTM for crystallization trials 
Fractions 48-58 from gel filtration were pooled and analysed by SDS-PAGE and on native gels to assess 
oligomeric properties of purified HisA40ΔTM. HisA40ΔTM and purified N1 protein were analysed by 
(A) SDS-PAGE (15 %) and (B) native gel (10 %). The recombinant proteins were detected by 
immunoblotting with α-His Ab. (C) The native membrane was stripped and re-blotted using α-A40 IgG. 
Positions of molecular mass markers are shown on the left with sizes in kDa for (A).   
 172 
(A) 
 
(B) 
 
Fig. 5.11 Crystallisation of HisA40ΔTM and diffraction pattern obtained. 
Purified HisA40ΔTM was sent to Prof. D Stuart‟s group, Division of Structural Biology, Oxford for 
crystallisation trials. The purified protein was dialysed in TBS and concentrated to 3.4 mg/ml and used to 
set up 96-well microfluidics crystallisation experiments. (A) Crystals were obtained from two conditions. 
HisA40ΔTM in one condition (0.1 M HEPES pH 7.5, 0.5 M lithium acetate, 18% w/v polyethylene 
glycol 4000) is shown. (B) Diffraction pattern obtained from crystals. Resolution obtained was 8 Å.  
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Table 5.2 Conditions used for expressing recombinant His tagged A40 in E. coli. 
 Cell Induction system Temp 
(°C) 
Time 
(h) 
Glucose 
(%) 
1 B834 IPTG 0.1 mM 37 3 - 
2 B834 IPTG 0.5 mM 37 3 - 
3 B834 IPTG 1 mM 37 3 - 
4 B834 IPTG 0.1 mM 37 3 1 
5 B834 IPTG 0.5 mM 37 3 1 
6 B834 IPTG 1 mM 37 3 1 
7 BL21 IPTG 0.1 mM  37 3 - 
8 BL21 IPTG 0.5 mM  37 3 - 
9 BL21 IPTG 1 mM  37 3 - 
10 BL21 IPTG 0.1 mM  37 3 1 
11 BL21 IPTG 0.5 mM  37 3 1 
12 BL21 IPTG 1 mM  37 3 1 
13 RG2 IPTG 0.1 mM  37 3 - 
14 RG2 IPTG 0.5 mM  37 3 - 
15 RG2 IPTG 1 mM  37 3 - 
16 RG2 IPTG 1 mM  37 6 - 
17 RG2 IPTG 1 mM  20 20 - 
18 RG2 IPTG 1 mM 37 3 1 
19 RG2 AI 37 16 - 
20 RG2 AI 20 16 - 
21 RG2 AI 20 32 - 
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5.3.4 Selenomethionine labelling of recombinant A40 
 A40 shares only around 20% aa identity with proteins that have had their crystal 
structure determined, and therefore it was likely that selenomethionine-labelled A40 
crystal would be necessary to overcome the phase problem and the obtain a high 
resolution crystal structure. The E. coli strain B834 are specifically adapted for in 
selenomethionine labelling studies because they are methionine auxotrophs. However 
in these cells, no detectable HisA40 was seen in any of the conditions used. Rosetta 
cells have been used as an alternative source of selenomethionine labelled protein by 
using the biosynthesis poisoning pathway method in conjunction with 
selenomethionine containing culture medium (Graham et al., 2007). However the 
conditions used to induce unlabelled HisA40ΔTM in RG2 cells did not produce any 
detectable protein, so the conditions were varied again and some insoluble protein was 
detected when the culture was induced at ~ OD560 0.6 with 1 mM IPTG and left 32 h.  
 A trial affinity purification using Ni NTA beads using guanidine to denature the 
IBs and binding the denatured insoluble material to the beads in denaturing conditions 
with urea showed that the denatured protein could be bound to the nickel beads. 
 A trial purification of the selenomethionine labelled refolded protein from IBs 
was unsuccessful as most of the protein aggregated with the concentration step before 
application to the HisTrap column. Whether the protein produced is labelled, correctly 
folded or could be successfully purified was beyond the time limits of this project and 
will have to be continued in any future project. 
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Fig. 5.12. Expression & characterisation of recombinant A40 protein in mammalian cells 
(A) COS-7 cells were transfected with pSecTag2, psBAPA40ΔTM or psBAPA40ΔTMΔSt. After 
overnight incubation, the medium was replaced and cells were incubated in absence (-) or presence (+) of 
tunicamycin (1 μg/ml). Four days after transfection, the cells and supernatant were harvested and the 
samples were analysed by SDS-PAGE and immunoblotting for presence of BAP tag using α-BAP Ab. 
(B) RNase B (control protein) (i) or purified BAP-tagged A40 proteins (ii & iii) were treated with either 
endoglycosidase PNGase F (P), Endo H (E) or mock treated (-) for 6 h @ 37 °C and analysed by SDS-
PAGE (15%) and coomassie staining or immunoblotting for BAP tag using α-BAP Ab. Positions of 
molecular mass markers are shown on the left with sizes in kDa. 
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5.4 Production of recombinant fusion proteins using a mammalian 
expression system 
 To generate soluble glycosylated recombinant protein for cell binding studies, 
truncated versions of A40 were expressed by transient transfection of COS-7 cells with 
plasmids psBAP-A40ΔTM or psBAP-A40ΔTMΔSt (section 2.3.7.). Small-scale 
transfections were performed in 6-well plates. The tissue culture supernatants were 
collected 3 days after transfection and concentrated by TCA precipitation (Section 
2.8.6). 
To characterise the fusion proteins produced, psBAP-A40ΔTM and psBAP-
A40ΔTMΔSt were transfected into 6-well plates of COS-7 cells, and incubated with or 
without tunicamycin to inhibit the addition of N-linked glycans. The supernatant was 
harvested and the cells were lysed (section 2.8.7). Both samples were analysed by 
immunoblotting against their fusion tag. In psBAP-A40ΔTM transfected samples, in 
the absence of tunicamycin, several proteins of apparent molecular mass ranging from 
~30 - 45 kDa were seen in the supernatant (Fig. 5.12A). Similarly, for psBAP-
A40ΔTMΔSt proteins of ~ 27 - 42 kDa (Fig. 5.12A) were observed in the supernatant 
fraction. No bands were observed in the cell lysates for either form of A40, showing 
that the great majority of protein is secreted. However, in the presence of tunicamycin, 
a single band of ~ 17 and 15 kDa for BAP-A40ΔTM and BAP-A40ΔTMΔSt, 
respectively, was present only in the cell extracts and not in the culture medium, 
indicating that glycosylation is needed for protein secretion (Fig. 5.12A). These smaller 
proteins are the expected size of BAP-A40ΔTM and BAP-A40ΔTMΔSt (Fig. 5.12A) 
 The presence of multiple bands in the supernatants of the transfected cells and 
the observation that tunicamycin reduced the size of these bands to a single intracellular 
protein, indicates that the proteins are both secreted and glycosylated and suitable for 
purification under non-denaturing conditions. 
 Once expression had been verified, the production of A40 was scaled up to 5 x 
T175 flasks. The supernatants were collected, concentrated and buffer-exchanged at 
day 3 post-transfection. This concentrated supernatant was purified by application to a 
BAP affinity column and eluted at pH 2.8 (section 2.8.5). The α-BAP columns were 
generated by coupling α-BAP mAb, grown in culture and purified on a protein G 
column, to CNBr-activated Sepharose beads and the coupled beads were poured in 
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Eco-columns. The column fractions were analysed by SDS-PAGE and immunoblotting 
against mAb BAP (Fig. 5.13). Fractions 2 - 5 were pooled and concentrated and the 
recombinant BAP-fused proteins were biotinylated with BirA enzyme (Fig. 5.14). After 
dialysis against PBS, the concentration of each protein was calculated by spectrometry 
at OD280 and each protein‟s coextinction coefficient 
(http://www.expasy.ch/tools/protparam.html). The yields of proteins were 1.5 µg/10
7
 
cells of BAP-A40ΔTM and 3 µg/107 cells of BAP-A40ΔTMΔSt. 
 To verify that the recombinant BAP-A40 proteins are modified by 
glycosylation, the purified BAP-A40ΔTM and BAP-A40ΔTMΔSt were treated with 
either PNGase F or Endo H. RNase B is a high mannose glycoprotein and was used as 
a positive control for the endoglycosidases. RNase B has a single N-linked 
glycosylation site, which makes it ideal for SDS-PAGE gel shift assays. 
When RNase B was treated with PNGase F or Endo H, a reduction in size was seen 
(Fig. 5.12B). Similarly, when the BAP-tagged A40 proteins were treated with PNGase, 
the multiple higher bands seen in the mock treated proteins are replaced with a single 
band ~ 15 kDa for BAPA40ΔTMΔSt and ~ 17 kDa for BAPA40ΔTM representing the 
unmodified protein. When the proteins were treated with Endo H, this shift was not 
seen suggesting that the N-linked glycans have not been cleaved indicating that the N-
glycosylation on A40 is not of a high mannose form. 
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(A) 
 
(B) 
 
Fig. 5.13 Purification of secreted BAP-tagged A40 proteins from COS-7 cells 
Five T175 flasks of COS-7 cells were transfected with psBAP-A40ΔTM or psBAP-A40ΔTMΔSt. Four 
days after transfection the supernatant was harvested, concentrated using a Centricon YM-10 to 10 ml, 
re-diluted in Tris buffer and re-concentrated. This concentrated supernatant was applied to a pre-
equilibrated BAP affinity column. The column was washed in PBS until absorbance returned to base 
level. Bound BAP-tagged proteins were eluted in 100 mM glycine, pH 2.8. To each eluted fraction a 1/10 
volume 1 M Tris pH 8.0 was added. Each fraction was analysed for the presence of BAP-tagged protein 
by SDS-PAGE and immunoblotting using mAb BAP with mAb BAP run as a control. M, Marker, St, 
Starting material, FT, Flow through, W, Wash, E, Elution, Ab, BAP mAb control (A) BAPA40ΔTM 
recombinant protein (B) BAPA40ΔTMΔSt recombinant protein. Positions of molecular mass markers are 
shown on the left with sizes in kDa. 
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Fig. 5.14 Biotinylation of purified BAP-tagged proteins 
Purified BAP-tagged proteins were biotinylated using BirA and dialysed against PBS. Samples were 
analysed for successful biotinylation by SDS-PAGE (15%) and immunoblotting using extravidin Ab. 
Positions of molecular mass markers are shown on the left with sizes in kDa. 
 
5.4.1 Generation of stable cell lines expressing secreted recombinant A40 
 To reduce the need to repeatedly transfect COS-7 cells to generate A40 protein, 
stably transfected cell lines expressing the two secreted forms of truncated BAP-tagged 
A40 were produced. 
 The pSecTag2 plasmid includes a zeocin resistance gene that can be used to 
select for cells that harbour the required plasmid. A killing curve was performed on 
COS-7 cells to determine the concentration of zeocin at which non-transfected cells 
would die off but stably transfected cells would be allowed to grow and form colonies.  
 Cells were seeded overnight and then transfected with either of the two 
plasmids expressing the BAP-tagged A40 protein. The cells were left for 3 days in 
DMEM/2% to reach confluency and the supernatant was harvested and analysed by 
immunoblotting for A40 protein to check that the transfection has been successful. The 
cells were then seeded at various ratios to give low confluency and the medium 
changed to include 0.2% zeocin. The cells were left to expand and the medium changed 
every 2-3 days for 3 weeks. At this point, the plates containing the mock transfected 
samples were devoid of cells, whilst, in contrast, both psBAPA40ΔTM and 
psBAPA40ΔTMΔSt-transfected cell plates had distinct colonies. 
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 Several of these colonies were picked for each transfection and used to seed a 
T25 flask and this in turn was expanded to a T175 flask in the presence of zeocin. Once 
the cells had expanded enough, they were tested for the level of A40 protein expression 
by immunoblotting (section 2.8.15, Fig. 5.15) and others were harvested for 
cryopreservation (section 2.3.4).  
 Cell lines from both transfections expressed secreted A40 with the characteristic 
multiple bands (Fig. 5.15).  These cell lines will aid future studies of A40, in the same 
way that previous BAP-tagged VACV protein expressing cell lines have aided the 
study of the Ab response to VACV vaccination (Law et al., 2005; Putz et al., 2006). 
(A) 
 
(B) 
 
Fig. 5.15 Generation of stable cell lines expressing secreted recombinant truncated A40 
COS-7 cells adapted to 2% serum were transfected with either (A) psBAPA40ΔTM.8 or (B) 
psBAPA40ΔTMΔSt.1 and left for 3 days. The cells were split and selective pressure for stable 
transfection applied (0.2% zeocin [v/v] in DMEM/2%). After 3 weeks, individual colonies were picked 
and expanded. To test for expression of the secreted recombinant proteins, individual cell lines were 
seeded in a well of a 6-well plate and left for 3 days in 1 ml of serum free medium. The supernatant was 
harvested, cell debris removed by centrifugation and proteins in the resultant medium TCA precipitated 
and analysed by SDS-PAGE (15% gel), and immunoblotting with α-BAP mAb. Positions of molecular 
mass markers are shown on the left with sizes in kDa. M = mock. 
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5.4.2 Expression of BAP-tagged control proteins from COS-7 cells 
 To validate the cell binding assay data (section 6.2) three BAP-tagged protein 
constructs were obtained from Prof. Neil Barclay, Oxford. These were rat CD4 
(domains 3 & 4, pEF-BIOS-rCD4d3d4), rat CD200 (pEF-BIOS-CD200) or mouse 
SIRPα (pEF-BIOS-mSIRPα) with an N-terminal BAP tag and have been used 
previously to study the interactions of CD200 (Hoek et al., 2000; Hatherley & Barclay, 
2004; Hatherley et al., 2005) and SIRPα (Vernon-Wilson et al., 2000; Barclay et al., 
2002) with other immune proteins and cell types. 
 Plasmids encoding these three proteins were transfected into COS-7 cells in the 
same way as the A40 constructs (sections 2.3.7, 2.8.4 & 1.1). Three days after 
transfection, the supernatant from a small-scale transfection was analysed for the 
presence of the BAP-tagged proteins by TCA precipitation, SDS-PAGE and 
immunoblotting with the anti-BAP mAb. Transfection of COS-7 cells with pEF-BIOS-
rCD4d3d4 resulted in a secreted BAP-tagged protein of ~25 kDa, whilst pEF-BIOS-
CD200 resulted in a secreted protein of ~45 kDa and pEF-BIOS-mSIRPα expressed a 
secreted protein ~ 50 kDa. Therefore, larger amounts of protein were produced and 
purified by anti-BAP affinity columns. The purified proteins were then biotinylated and 
dialysed as described for the BAP-tagged A40 proteins (sections 2.8.5 & 1.1). 
 The concentrations of the proteins were assessed using a Nanodrop 
spectrometer (section 2.8.12) and the proteins were then aliquoted and frozen until 
needed.  
 
Fig. 5.16 Expression of control BAP-tagged proteins from COS-7 cells 
COS-7 cells were transfected with either pEF-BIOS- rCD4d3d4, pEF-BIOS-CD200 or pEF-BIOS-
mSIRPα. After 3 days the supernatants were harvested and 1ml was tested for the presence of BAP-
tagged protein by TCA precipitation of proteins, followed by SDS-PAGE (10% gel) and immunoblotting 
with α-BAP mAb. Positions of molecular mass markers are shown on the left with sizes in kDa. 
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5.4.3 Transient transfection of mammalian cells with pCI expressing A40 
 To study the effect of A40 in the absence of any other VACV proteins, full-
length A40R ORF with either a BAP or HA tag at the N or C terminus were generated 
using OEP and cloned into the pCI vector under the HCMV immediate-early 
enhancer/promoter region. The resulting plasmids pCI-(N)HAA40, pCI(C)A40HA, 
pCI-(N)BAPA40 (Fig. 5.1F and Fig. 5.2F) and pCI-(C)A40BAP (Fig. 5.1G and Fig 
5.2G)were transfected into several cell types to test for expression, using 
pCI(C)B14HA (Chen et al., 2006) as a positive control. After 48 h the supernatant was 
removed, the cells were washed in ice-cold PBS and lysed with ice-cold LB1 buffer. 
After removing the nuclear debris, the lysates were analysed by SDS-PAGE and 
immunoblotting with the anti-HA mAb and the anti-A40 Ab (Fig. 5.17).  
 Using the HA Ab, the HA tagged B14 protein is seen ~ 15 kDa but neither of 
the HA-tagged A40 constructs are detected (Fig. 5.17). When using the A40 Ab, only 
the N-terminally BAP-tagged A40 is detected (Fig. 5.17). Due to the poor expression of 
A40 from these vectors, further analysis using these plasmids was not pursued.  
 
5.4.4 Expression of BAP tagged A40 from pSEL 
 At the same time as cloning the full-length BAP-tagged A40 alleles into pCI 
(section5.4.3), the PCR products generated by OEP were also cloned into the pSEL 
plasmid under the VACV early/late promoter. The resultant plasmids pSEL-
(N)BAPA40 and pSEL(C)BAPA40 were transfected into HeLa cells and after 4 h the 
cells were infected with vΔA40 at 1 p.f.u./cell and incubated for 16 h. The cells were 
harvested and lysed in LB1 and the clarified lysates were analysed by SDS-PAGE and 
immunoblotted for the presence BAP-tagged recombinant A40 (Fig. 5.18). Both 
plasmids expressed A40 within the cell that was detected by the anti-A40 Ab with 
bands ~ 26 – 38 kDa and no bands were detected with either Ab in the mock lanes 
where the cells were transfected with pCI and infected with vΔA40.  
 These plasmids were then used to transfect HeLa cells seeded on coverslips that 
had been infected with vΔA40R. These cells were analysed by immunofluorescent 
staining to study the localization of A40 within an infected cell as described in section 
3.4.3 and Fig. 3.5. 
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Fig. 5.17 A40 expression using pCI 
HeLa cells were transfected with pCI, pCI-(N)BAPA40, pCI-(C)A40 or pCI(C)B14HA. Cells were 
harvested 48 h after transfection and analysed by SDS-PAGE (15%) and immunoblotting with α-A40, α-
HA Ab (A) and α-tubulin Ab as a loading control. Positions of molecular mass markers are shown on the 
left with sizes in kDa. 
 
 
Fig. 5.18 A40 expression using pSEL and vΔA40 
HeLa cells were transfected with pSEL, pSEL-(N)BAPA40 or pSEL-(C)A40. Cells were infected with v 
ΔA40 at 1 p.f.u./ml for 24 h. Cells were harvested and analysed for the presence of A40 by SDS-PAGE 
(15%) and immunoblotting with α-A40 and  D8 as virus infection control and α-Tubulin Ab as a loading 
control. Positions of molecular mass markers are shown on the left with sizes in kDa.   
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(A) 
 
(B) 
 
Fig. 5.19 The VOTE system 
(A) Regulation of A40 expression in the presence (blue) and absence (red) of inducer (IPTG). The lac 
repressor is transcribed under the control of the VACV early/late (PEL) promoter. In the absence of 
inducer, the repressor binds to the lac O site (LO), preventing transcription of the T7 RNA polymerase 
(T7 gene 1) and also to the modified lac O (SLO) preventing transcription of the target gene should leaky 
synthesis of the T7 RNA polymerase occur. When IPTG is added, the repressor dissociates from the 
operator and transcription of the T7 RNA polymerase ORF occurs. After translation T7 RNA polymerase 
binds to the T7 promoter and transcribes the target gene. Transcription is terminated at the transcriptional 
terminators (TT) and the stability and translation of A40 transcripts is improved by the 
encephalomyocarditis virus internal ribosome entry site. (IRES) (B) i) The pVOTE plasmid. HA (A56R) 
fragments for insertion into the VACV genome and position of the MCS. Illustration adapted from 
(Ward et al., 1995). (ii) A40R inserted at the HA locus. Primers for PCR amplification to validate that 
recombinant A40 has recombined into the HA locus are shown. 
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5.5 The VOTE system 
 The VOTE system (Vaccinia-lac Operon-T7-Encephalomyocarditis virus 
upstream translational enhancer element) (Ward et al., 1995) is constructed using 
vT7lacOI, a VACV WR virus with the lac I and T7 gene 1 inserted into the tk locus as 
shown in Fig. 5.19A. The virus contains an intact HA gene, into which the target gene 
and control elements are inserted using the pVOTE plasmid (Fig. 5.19Bi). The pVOTE 
plasmid contains the Ecogpt selectable marker so that viruses containing the pVOTE 
DNA can be selected in the presence of MPA. Recombination occurs between the 
fragments of the HA gene in pVOTE and the HA gene in the virus. This inserts the 
gene of interest between the HAL and HAR fragments of the VACV genome. 
 The two pVOTE plasmids available (Ward et al., 1995) pVOTE.1 and 
pVOTE.2 differ in the restriction endonuclease site for the insertion of the 5‟ end of the 
target gene (NcoI in pVOTE.1 and NdeI in pVOTE.2). Although each plasmid contains 
7 restriction endonuclease sites at which the 3‟ end of the target gene can be inserted, 
the position of the 5‟ end of the target gene cannot be varied, as this affects 
translational efficiency of T7 RNA polymerase transcripts. Since A40R does not 
contain either of the 5‟ restriction endonuclease sites, either plasmid was suitable and 
pVOTE.1 was selected. 
 
5.5.1 Expression of recombinant A40 from VOTEA40 viruses 
5.5.1.1 Secreted BAP-tagged truncated A40 viruses 
 DNA encoding truncated A40 tagged with BAP was cloned from 
psBAPA40ΔTM & psBAPA40ΔTMΔSt including the Igκ leader sequence into 
pVOTE.1 plasmid and the resultant plasmids (pVOTE-BAPA40ΔTM & pVOTE-
BAPA40ΔTMΔSt) were transfected into RK13 cells that had been infected with the 
vT7lacOI virus at 0.05 p.f.u./cell. The virus population, obtained two days later were 
then plaque purified on BS-C-1 cells three times in the presence of MPA to select 
recombinant viruses. The presence of the inserted gene was checked by PCR (section 
2.7.11 - 2.7.12 & Table 2.3). The vT7lacOI virus contains an A40R gene at its natural 
locus in addition to that being inserted within the A56R gene locus. Therefore it is 
possible for the transfected plasmid to recombine within the genome at this point 
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instead of at the HA locus. To check that integration had occurred at the A56R gene, the 
HA locus was amplified using a primer specific to the A56R gene (A56R_R) and a 
primer for A40R (A40_R). A PCR product of the expected size was seen for the newly 
isolated VOTE-BAPA40ΔTM and VOTE-BAPA40ΔTMΔSt viruses. A positive isolate 
for each virus was then used to seed a master, submaster and working stock. 
 These viruses were then used to infect cells to check for expression of the 
required protein. Different parameters were checked to maximise protein expression. 
These included various cell types (RK13, BS-C-1 and HEK 293T cells), different m.o.i. 
(0.1 – 10), differing NaCl concentration in the culture medium (150-250 mM) and 
different concentrations of IPTG (0.1 – 5 mM). Cells were infected for 90 min in 
medium containing 2.5% FBS. The medium was changed to induction medium (serum 
free) containing varying concentrations of IPTG and NaCl and harvested after 16 h. 
The medium was harvested, cell debris were removed by centrifugation and proteins in 
the clarified supernatant were concentrated by TCA precipitation overnight (section 
2.8.6). Proteins were dissolved and analysed by SDS-PAGE and immunoblotting for 
the presence of BAP-tagged A40.It was found that an infection at 5 p.f.u/ml in HEK 
293T cells for 16 h in medium containing 190 mM NaCl and 2 mM IPTG gave the best 
production of secreted BAP-tagged A40. These conditions were used to express 
truncated A40 for the use in cell binding studies (section 6.2).  
For large-scale A40 expression, 5 x T175 flasks were infected per virus and the 
secreted proteins were harvested at 16 h p.i., concentrated approximately 10-fold to 5 
ml and buffered against 10 mM Tris pH 8.0. The concentrated supernatant was treated 
with psoralen and then placed under long-wave UV to inactivate virus infectivity. To 
purify the secreted protein, the psoralen/UV treated supernatant was purified using anti-
BAP affinity columns and biotinylated as described for the COS-7 expressed proteins. 
The concentration of the proteins was calculated using the Nanodrop and each protein‟s 
coextinction coefficient. Yields were approximately 6.6 µg/10
7
 cells for 
vBAPA40ΔTM and 9.8 µg/107 cells for vBAP-A40ΔTMΔSt. 
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5.5.1.2 Full-length A40 from VOTEA40 virus 
 Using the plasmid pVOTE-TAPA40, the virus vVOTE-TAPA40 was generated 
in the same way as described above for VOTE-BAPΔTM and VOTE-
BAPA40ΔTMΔSt. The presence of the inserted A40R gene was checked by PCR and a 
product of the expected size was obtained.  
 The same range of conditions was used to test the expression of this full-length 
recombinant A40 within cells. Instead of harvesting the supernatant, infected cells were 
harvested 16 h after induction with LB1 (section 2.8.7) and analysed by SDS-PAGE 
and immunoblotting for BAP-tagged A40 within the cell lysates (Fig. 5.20C). This 
showed that VOTE-TAPA40 expressed BAP-tagged A40 within infected cells as 
multiple bands (~ 30- 40 kDa) are detected with both the α-A40 Ab (and α-BAP mAb, 
data not shown). 
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(A) 
 
 
(B)        (C) 
            
Fig. 5.20 Generation of recombinant VACVs, expressing recombinant A40 proteins inducibly 
(A) Primers A56_R and A40R_R gave a PCR product of approximately 1.6 kbp from viruses where 
pVOTE-BAPA40ΔTM had recombined into the HA locus. A PCR product of 1.5 kbp was obtained from 
viruses where pVOTE-BAPA40ΔTMΔSt had recombined successfully and a PCR product of 2.2 kbp 
was obtained from viruses generated using pVOTE-TAPA40. (B) Anti-A40 immunoblot of supernatants 
taken 24 h p.i. from uninfected cells, VOTE-BAPA40ΔTM or VOTE-BAPA40ΔTMΔSt infected cells 
with or without 2 mM IPTG. (C) Cells were either mock infected or infected with VOTE-TAPA40 at 5 
p.f.u./cell and incubated for 24 h with or without 2 mM IPTG added to the medium. Cell were harvested 
and lysed in LB1 and analysed for the presence of TAPA40 by SDS-PAGE (15%) and immunoblotting 
with anti-A40 Ab. Positions of molecular mass markers are shown on the left with sizes in kDa.  
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5.6 Generation of recombinant baculoviruses expressing A40 
 To generate an alternative source of unglycosylated, recombinant A40 protein, 
recombinant baculoviruses were constructed using pBac-2cp. The truncated BAP-
tagged A40R alleles from pSecTag2 were inserted into pBac-2cp inframe with the N-
terminal His tag. The plasmids pBacHisBAPA40ΔTM and pBacHisBAPA40ΔTM were 
used to co-transfect Sf9 cells (section 2.6) along with BacVector Triple Cut Virus DNA 
to generate bvHisBAPA40ΔTM and bvHisBAPA40ΔTMΔSt. The recombinant viruses 
were then plaque purified on Sf9 cells twice and the presence of the inserted gene was 
checked by PCR using viral DNA from infected cells as template (section 2.7.11 and 
Fig. 5.21A). A positive isolate for each virus was used to seed master stocks and these 
were used to generate high titre stocks from shaking cultures of infected Sf9 cells. 
 The recombinant baculoviruses were then checked for expression of BAP-
tagged A40. Shaking cultures of Sf9 cells were either infected with 
bvHisBAPA40ΔTM or bvHisBAPA40ΔTMΔSt at 5 p.f.u./cell and samples were 
removed from the shaking culture at several time-points p.i. The cells were harvested 
by centrifugation, the supernatant was removed and the pellets were freeze/thawed 
before being lysed in ILB (section 2.8.10). The lysate was analysed for the expression 
of His-tagged recombinant A40 using SDS-PAGE and immunoblotting using an α-His 
Ab (Fig. 5.21B).  
 A single band at the predicted size of 23 kDa was detected using the α-His Ab 
on lysates from bvHisBAPA40ΔTM infected Sf9 cells (Fig. 5.21Bi)and a single band at 
~ 20 kDa is seen in bvHisBAPA40ΔTMΔSt infected cells(Fig. 5.21Bii). For both 
infections, the proteins are expressed from 24 h p.i., and are detectable at 72 h p.i. but 
seem to be degraded thereafter (Fig. 5.21B).  
 Having verified that the recombinant viruses express the truncated A40 
proteins, a large scale shaking culture was infected with either of the viruses at 5 
p.f.u./cell and the cells harvested 72 h p.i. The pellets were lysed and the recombinant 
A40 applied to a HisTrap column for affinity purification. For both proteins, the 
HisTrap was not successful and no protein was eluted with imidazole and the 
recombinant A40 may have precipitated out of solution as the cell lysate supernatant 
was applied to the column. Due to time constraints, this method of producing 
recombinant A40 was not further pursued.  
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(B) 
(i)        (ii) 
 
     
 
Fig. 5.21 Generation of recombinant baculovirsuses expressing His-tagged truncated proteins 
(A) Primers (N)Biotin_F and A40R_R gave a PCR product of approximately 450 bp in viruses where 
pBacHisBAPA40ΔTM had combined with Baculo DNA to produce bacHisA40ΔTM. A PCR product of 
390 bp was obtained in viruses where pBacHisBAPA40ΔTMΔSt had recombined successfully. (B) Sf9 
cells were infected with (i) bacHisBAPA40ΔTMt or (ii) bacHisBAPA40ΔTMΔSt at 5 p.f.u./ml and 
samples were taken every 24 h. The cells were lysed and analysed for the presence of His-tagged protein 
by SDS-PAGE and immunoblotting using α-His Ab. Positions of molecular mass markers are shown on 
the left with sizes in kDa. 
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5.7 Summary 
 Recombinant A40 has been expressed from several systems in an attempt to 
produce sufficient quantities of protein to aid in the search for a ligand for A40 and 
help analyse how A40 acts within an infected cell and ultimately its role in an infected 
host system. 
 A40 expressed from E. coli was used to i) generate a new anti-A40 Ab to help 
characterise A40 and ii) crystallisation trials in Oxford for structure determination. 
Whilst A40 was successfully crystallised using this protein, to increase the resolution 
and solve the structure, a selenomethionine labelled form of the protein will need to be 
produced and crystallised. 
 Secreted recombinant forms of A40 were produced in mammalian cells which 
were glycosylated and similar to A40 expressed by VACV. This protein was then used 
in cell binding assays (Chapter 6) to find an interacting partner for A40. Stable cell 
lines expressing these BAP-tagged A40 proteins were produced. BAP-tagged control 
proteins were also produced and purified to help validate the results of the cell binding 
assay.  
 As an alternative source of glycosylated recombinant A40, recombinant VACV 
were generated that express the secreted forms of BAP-tagged A40 under an IPTG-
inducible promoter. These proteins were purified and used in conjunction with the 
proteins produced from pSecTag to validate cell binding results. A VACV-expressing a 
full-length FLAG-BAP-tagged A40 virus was also generated and characterised.  
 Recombinant baculoviruses were also generated expressing His-BAP tagged 
truncated A40, which did express the recombinant proteins but due to time constraints 
their purification was not followed up.  
 These recombinant proteins are a valuable source of reagents for use in further 
characterising the role of A40 in infection.  
 192 
Chapter 6. Identifying potential binding partners of A40 
6.1 Introduction 
 To search for potential binding partners of A40, soluble A40 was added to a 
variety of different cells and binding was measured by flow cytometry. 
 The recombinant A40 protein expressed from mammalian cells by either 
pSecTag or the IPTG-inducible VACVs, was characterised and found to be similar to 
the native A40 made during virus infection. In both cases A40 was modified by N-
linked glycosylation and was either transported to the cell surface or secreted (if the N-
terminal transmembrane domain was absent). The two different proteins BAP-
A40ΔTM and BAP-A40ΔTMΔSt were added to different types of cells. Both proteins 
were included to assess the importance of the alpha helical region or „stalk‟ region in 
the interactions of A40 with potential ligands. 
 Previously, a similar binding assay has been used to assess the binding of 
VACV proteins B5, A33, A56 and A34 (Law, 2001) and for other low-affinity binding 
molecules such as CD48 (Brown et al., 1998). The recombinant proteins were labelled 
with BirA at a highly specific residue in the BAP sequence. As the interaction between 
biotin and avidin has a very high affinity (Kd = 10
-14
 M) and avidin is tetrameric, this 
system provides a rapid method for multimerising proteins to increase the affinity in 
binding studies whilst keeping the orientation of the protein with the C-type lectin-like 
domain exposed externally. 
 The biotinylated forms of A40 were coupled to fluorescent polystyrene beads 
covered with avidin and the binding of these proteins to various cells was investigated 
by fluorescent activated cell sorting (FACS). In addition to the two forms of 
recombinant A40, three biotinylated proteins were used as controls. There were 
biotinylated CD4d3d4 (recombinant IgG domains 3 and 4 of rat CD4, (Brown et al., 
1998)), mouse CD200 (CD4d3d4-mCD200) and mouse SIRPα (CD4d3d4-mSIRPα) 
and all contained the BAP sequence preceding the CD4d3d4 domain and were kindly 
provided by Dr N Barclay (University of Oxford).  
 The conditions used by M Law (Section 2.8.16,) were selected to trial A40 
binding. The binding was performed in binding buffer with 1% BSA, pH 7 and 
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incubated at 4 °C to try to reduce non-specific phagocytosis of the protein-coated 
beads. The amount of each recombinant protein was determined by Nanospectrometry 
and 250 ng of recombinant protein, diluted in binding buffer was added to the washed 
beaded per assay. The biotinylated-A40 protein coated beads were incubated with the 
target cells for 1 h before binding was assessed by FACS. 
 
6.2 Binding of recombinant A40 proteins to cells 
 The fluorescent polystyrene beads covered with either form of A40 did not bind 
to 293T cells (Fig. 6.1A), BS-C-1 cells (Fig. 6.1B) or HeLa cells (Fig. 6.1C). In 
contrast, binding to RAW 264.7 cells (Fig. 6.3A) B3Z cells (Fig. 6.3B), SP3 cells (Fig. 
6.3C), AK31 cells (Fig. 6.2C) and NK92MI cells (Fig. 6.4A) was observed. The same 
molar amount of the recombinant proteins was used in each assay (250 ng), suggesting 
that BAPA40ΔTM binds to NK92MI cells at the highest level, followed by B3Z cells, 
SP3 cells and RAW 264.7 cells (Fig. 6.9). When the binding of BAP-fusion protein 
coated beads to different cell types was expressed as a percentage of the difference in 
mean fluorescence between the control (cells and beads only) and BAP-fusion coated 
beads, there was an increase in mean fluorescence (Fig. 6.9) for Jurkat E6.1 cells 
(4.81% & 3.7%), RAW cells (BAP-A40ΔTM 63.87% & BAPA40ΔTMΔSt 62.72%), 
AK31 cells (4.77% & 100.92%), SP3 cells (49.66% & 67.70%), B3Z cells (34.23% & 
75.16%) and NK92MI cells (143.30% & 74.42%). For 293T cells, BS-C-1 cells and 
HeLa cells there was on average a slight decrease (0.02% & -1.14%), (-3.05% & -
0.38%), and (-5.03% & -12.86%) respectively. This suggested a non-specific binding 
of the avidin-coated beads to these cells in the absence of A40. This non-specific 
binding was eliminated when the beads were incubated with the BAP-fusion 
recombinant proteins prior to incubation with cells. This non-specific binding seems to 
be especially strong on incubation with BS-C-1 cells. For DG75 cells there was a slight 
increase for BAPA40ΔTM (2.87%) but not for BAPA40ΔTMΔSt (-1.6%) (Fig. 6.2B). 
Overall, recombinant A40 binds to NK cells, macrophages and some T cell lines but 
does not bind to epithelial cells. 
 To investigate the nature of the putative surface molecule interacting with A40, 
NK92MI cells were treated with trypsin to remove surface proteins. The cells were 
harvested in the same way as untreated NK92MI cells except for being incubated in 
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0.05% Trypsin/EDTA for 10 min at RT before washing once in FBS containing 
medium and twice in PBS (-Mg
2+
, -Ca
2+
). This treatment inhibited binding of both the 
recombinant A40 proteins to NK92MI cells (Fig. 6.4B, 29.62% & 7.85%). Therefore, 
the ligand(s) bound by A40 were either proteins or were molecules bound to proteins. 
 Having found some cell lines that recombinant A40 could bind to, the binding 
to primary cells from human PBMCs and mouse bone marrow derived cells and 
splenocytes was analysed by the same assay. Human PBMCs were harvested from 
volunteers‟ blood samples by Lymphoprep separation and cryo-preserved until 
required. Once revived, the cells were incubated with human IL-2 overnight and the 
adherent cells allowed to attach to the culture flask. The non-adherent cells were 
harvested in the culture medium and analysed separately to the adherent cells (Fig. 6.5). 
The recombinant A40 proteins did not bind to the non-adherent cells (Fig. 6.5A, 
BAPA40ΔTM (4.80%) and BAPA40ΔTMΔSt (8.12%)) which represent the 
lymphocyte populations of PBMCs (Fig. 6.8 A) but did bind to the adherent cell 
population (Fig. 6.5B) with an increase in mean fluorescence upon incubation with 
BAPA40ΔTM of 266.63% and of 317.85% for BAPA40ΔTMΔSt. The adherent cell 
portion of PBMCs is enriched in monocytes, macrophages and IL-2 induced adherent 
natural killer cells (Fig. 6.5B). The recombinant A40 protein binds to one or more of 
these cells in the PBMCs but unfortunately, exactly which cell type(s) were binding 
A40was not successfully determined in the time available. 
 When primary mouse cells were analysed, peritoneal macrophages (Fig. 6.6A) 
gave an increase in fluorescence with BAPA40ΔTM (49.52%) and slightly less with 
BAPA40ΔTMΔSt (22.83%) whilst with mouse splenocytes there was no strong binding 
with either the adherent cell population (Fig. 6.6C, 9.88% & 4.01%) or non-adherent 
cells (Fig. 6.6B, 4.81% & 5.79%). 
 When the difference in average increase in mean fluorescence for each cell type 
was analysed, there was no significant difference between the binding capacity of 
BAPA40ΔTM and BAPA40ΔTMΔSt except for AK31 cells where BAPA40ΔTMΔSt 
bound to the cells whilst BAP40ΔTM does not (P = 0.007). With B3Z cells, both forms 
of A40 bound but binding was increased significantly with the form lacking the stalk 
(P=0.001). Conversely, for NK92MI and the mouse peritoneal macrophages, binding 
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was statistically significantly increased when A40 has the stalk (P = 0.005 & 0.03, 
respectively). 
 To verify that the binding seen with A40 and the cell types was specific, BAP-
tagged control proteins were expressed and purified in the same way as the 
recombinant A40 proteins. Examples of the binding seen with different cell types are 
shown in Fig. 6.7. As expected CD4d3d4, which is a negative control, did not bind to 
any of the cell types tested with A40, suggesting that the increase seen in the binding 
assays with recombinant A40 is specific. CD200, which binds to its ligand CD200R on 
macrophages from many tissues, shows higher binding to RAW 264.7 cells than seen 
with the A40 proteins (Fig. 6.7B). This higher affinity for RAW 264.7 cells is also seen 
with SIRPα, which binds to CD47 on all cells. 
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Fig. 6.1 Does recombinant biotinylated BAPA40ΔTM or BAPA40ΔTMΔSt bind to epithelial cells?  
The biotinylated recombinant A40 proteins were coupled to avidin-coated yellow fluorescent polystyrene beads at a ratio of 50 ng per µl of beads. The beads were washed, 
re-suspended in binding buffer and sonicated before being adding cells (2 x 10
5
 cells per 5 µl beads). After incubation, the samples were analysed by FACS on a FACS-
Calibre (Becton Dickinson, BD). The binding of the fluorescent beads to cells was examined by the filter sets (excitation at 488 nm and emission at 538 nm) and the data 
were analysed using Cellquest software (BD) and WinMDI. The background fluorescence of the cells without any beads (cells only) is shown as well as cells and beads 
control. Chromatographs are representative of one average binding assay. The assays were repeated at least 3 times. (A) HEK 293T cells, (B) BS-C-1 cells and (C) HeLa 
cells.  
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Fig. 6.2 Binding of recombinant biotinylated A40 proteins onto immune cells 
The biotinylated recombinant A40 proteins were coupled to avidin-coated yellow fluorescent polystyrene beads at a ratio of 50 ng per µl of beads. The beads were washed, 
re-suspended in binding buffer and sonicated before being added to cells (2 x 10
5
 cells per 5 µl beads). After incubation, the samples were analysed by FACS on a FACS-
Calibre (Becton Dickinson, BD). The binding of the fluorescent beads to cells was examined by the filter sets (excitation at 488 nm and emission at 538 nm) and the data 
were analysed using Cellquest software (BD) and WinMDI. The background fluorescence of the cells without any beads (cells only) is shown as well as cells and beads 
control. (A) Jurkat E6.1 T cells, (B) DG75 B cells and (C) AK31 B cells.  
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Fig. 6.3 Binding of recombinant biotinylated A40 proteins onto immune cells 
The biotinylated recombinant A40 proteins were coupled to avidin-coated yellow fluorescent polystyrene beads at a ratio of 50 ng per µl of beads. The beads were washed, 
re-suspended in binding buffer and sonicated before being added to cells (2 x 10
5
 cells per 5 µl beads). After incubation, the samples were analysed by FACS on a FACS-
Calibre (Becton Dickinson, BD). The binding of the fluorescent beads to cells was examined by the filter sets (excitation at 488 nm and emission at 538 nm) and the data 
were analysed using Cellquest software (BD) and WinMDI. The background fluorescence of the cells without any beads (cells only) is shown as well as cells and beads 
control. (A) Raw 264.7 cells, (B) B3Z hybridoma T cells and (C) SP3 T cells.  
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Fig. 6.4 Binding of recombinant biotinylated A40 proteins onto NK92MI cells 
The biotinylated recombinant A40 proteins were coupled to avidin-coated yellow fluorescent polystyrene beads at a ratio of 50 ng per µl of beads. The beads were washed, 
re-suspended in binding buffer and sonicated before being added to cells (2 x 10
5
 cells per 5 µl beads). For trypsin treated cells (B), NK92MI cells were treated with 0.5% 
Trypsin for 5 min, washed in PBS/EDTA and re-suspended in binding buffer prior to incubation with sonicated protein coated beads. After incubation, the samples were 
analysed by FACS on a FACS-Calibre (Becton Dickinson, BD). The binding of the fluorescent beads to cells was examined by the filter sets (excitation at 488 nm and 
emission at 538 nm) and the data was analysed using CellQuest software (BD) and WinMDI. The background fluorescence of the cells without any beads (cells only) is 
shown as well as cells and beads control.   
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Fig. 6.5 Binding of recombinant biotinylated A40 proteins onto peripheral blood mononuclear cells 
The biotinylated recombinant A40 proteins were coupled to avidin-coated yellow fluorescent polystyrene beads at a ratio of 50 ng per µl of beads. The beads were washed, 
re-suspended in binding buffer and sonicated before adding cells (5 x 10
5
 cells per 5 µl beads). PBMCs were split into monocyte enriched (Adherent) and lymphocyte 
enriched (non-adherent) populations by incubation in tissue culture flasks overnight (section 2.3.8). After incubation, the samples were analysed by FACS on a FACS-Calibre 
(Becton Dickinson, BD). The binding of the fluorescent beads to cells was examined by the filter sets (excitation at 488 nm and emission at 538 nm) and the data were 
analysed using CellQuest software (BD) and WinMDI. The background fluorescence of the cells without any beads (cells only) is shown as well as cells and beads control. 
(A) Non-adherent cell population of human PBMCs, (B) adherent cell population of human PBMCs.   
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Fig. 6.6 Binding of recombinant biotinylated A40 proteins onto mouse macrophages and splenocytes 
The biotinylated recombinant A40 proteins were coupled to avidin-coated yellow fluorescent polystyrene beads at a ratio of 50 ng per µl of beads. The beads were washed, 
re-suspended in binding buffer and sonicated before adding cells (5 x 10
5
 cells per 5 µl beads). Splenocytes were split into monocyte-enriched (adherent) and lymphocyte 
enriched (non-adherent) populations by incubation in tissue culture flasks overnight (sections 2.3.8 &2.9.5) prior to incubation with protein coated beads. After incubation, 
the samples were analysed by FACS on a FACS-Calibre (Becton Dickinson, BD). The binding of the fluorescent beads to cells was examined by the filter sets (excitation at 
488 nm and emission at 538 nm) and the data were analysed using CellQuest software (BD) and WinMDI. The background fluorescence of the cells without any beads (cells 
only) is shown as well as cells & beads control. (A) Mouse peritoneal macrophages, (B) non-adherent cell population of mouse splenocytes, (C) adherent cell population of 
mouse splenocytes.   
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Fig. 6.7 Binding of recombinant biotinylated control proteins to validate cell binding data 
The biotinylated recombinant A40 proteins or control BAP-tagged proteins were coupled to avidin-coated yellow fluorescent polystyrene beads at a ratio of 50 ng per µl of 
beads. The beads were washed, re-suspended in binding buffer and sonicated before adding cells (5 x 10
5
 cells per 5 µl beads). Human PBMCs were split into monocyte 
enriched (adherent) and lymphocyte enriched (non-adherent) populations by incubation in tissue culture flasks overnight (sections 2.3.9 &2.9.5) prior to incubation with 
protein coated beads. After incubation, the samples were analysed by FACS on a FACS-Calibre (Becton Dickinson, BD). The binding of the fluorescent beads to cells was 
examined by the filter sets (excitation at 488 nm and emission at 538 nm) and the data were analysed using CellQuest software (BD) and WinMDI. The background 
fluorescence of the cells without any beads (cells only) is shown as well as cells and beads control. (A) HEK 293T cells, (B) mouse RAW 264.7 macrophage cells,  
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(A) Non-adherent cells 
(i) (ii) 
 
 
(iii) (iv) 
  
 
(B) Adherent cells 
(i) (ii) 
  
(iii) (iv) 
  
Fig. 6.8 Cell populations in enriched fractions of human peripheral blood mononuclear cells 
Human PBMCs were revived from frozen overnight, in medium containing IL-2. The cells were 
harvested in adherent and non-adherent fractions (section 2.9.5), re-suspended in FACS buffer and 
stained for characteristic antigen markers to determine which cell types are within each fraction (i) CD3, 
(ii) CD20, (iii) CD56, (iv) CD14. (A) non-adherent PBMCs, (B) adherent PBMCs. 
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Fig. 6.9 Cell binding assessed by increase in mean fluorescence 
Increase in mean fluorescence upon incubation of cells pre-coated with either BAPA40ΔTM or BAPA40ΔTMΔSt. n=3 independent experiments. These data are presented as 
the indicated mean +/- SEM. P MØ = peritoneal macrophage cells, PBMC N = non-adherent PBMCs, PBMC A = adherent PBMCs, Spleen N = non-adherent splenocytes, 
spleen A = adherent splenocytes. Clear bars = cell binding to BAPA40ΔTM, filled bars = cell binding to BAPA40ΔTMΔSt.  
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6.3 Immunoprecipitations of A40 
 To be able to identify a ligand for A40, the ability to precipitate A40 from either 
infected or transfected cells needed to be demonstrated. BS-C-1 cells were infected 
with vTAPA40 and induced to express A40 with IPTG for 16 h. The cells were washed 
and then harvested in lysis buffer. The lysate was divided in half and incubated with 
either α-A40 Ab pre-bound to protein A sepharose beads or α-BAP Ab bound to 
protein G sepharose beads. The beads were washed and then re-suspended in SDS 
loading buffer and any protein precipitated by the Ab-bound beads was analysed by 
SDS-PAGE and immunoblotting for the presence of A40 protein. 
 In the lysate incubated with α-A40 Ab, no A40 protein was detected even with 
overnight exposure of the membrane (Fig. 6.10A) and this might be due to the fact that 
this polyclonal Ab was raised against antigen derived from expression in E. coli. 
However, using the α-BAP mAb, BAP-tagged A40 was detected in the 
immunoprecipitated lysate (Fig. 6.10B). 
 
6.3.1 Co-immunoprecipitations using vTAPA40 
 Having been able to immunoprecipitate A40 from infected cells using an α-
BAP Ab, this method was used in co-immunoprecipitations using cells or membrane 
preparations from cells that bound recombinant A40 in the cell binding assays (section 
6.2) including NK92MI, RAW 246.7 and human PBMCs. The co-
immunoprecipitations were also performed with cross-linking reagents such as bis 
(Sulfosuccinimidyl) suberate (BS3) and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) but due to time constraints, this section of work was 
unable to be completed.  
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Fig. 6.10 Immunoprecipitation of A40 
BS-C-1 cells were infected at 1 p.f.u./ml of vTAPA40 and induced with 2 mM IPTG for 16 h. The cells 
were harvested (Section 2.8.18) and the lysates were incubated with (A) α-A40 Ab:protein A beads or 
(B) α-BAP mAb:protein G beads. The immunoprecipitated proteins were analysed by SDS-PAGE (12% 
gel) followed by immunoblotting with α-A40 Ab. Positions of molecular mass markers are shown on the 
left with sizes in kDa. 
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6.4 Summary 
 As a first step towards understanding the mechanism by which A40 affects the 
infiltration of leukocytes to the site of infection, the binding of biotinylated A40 to a 
variety of cell types was investigated. Recombinant A40 was found not to bind to the 
epithelial cells tested but did bind to various immune cells including NK cells, 
macrophages and T cells. 
 In view of these data, binding of A40 to primary human PBMCs was 
investigated and it was found thatA40 bound preferentially to monocyte enriched 
populations compared to lymphocyte-enriched populations. BAP-tagged A40 protein 
produced by transient expression in uninfected mammalian cells and also from 
recombinant-VACV infected cells gave comparable results. Both forms of recombinant 
A40 (with or without the stalk) behave in a similar manner in the binding assays (with 
minor exceptions). 
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Chapter 7. Discussion & Future work 
7.1 Introduction 
 After the eradication of smallpox, research with VACV continued particularly 
in two areas. The first focused on increasing our understanding of VACV interactions 
with the host cell and immune system. Not only has this brought advancement in our 
understanding of how VACV subverts numerous pathways for its own benefit, but it 
has also increased our understanding of the host immune system and cell signalling 
pathways. The second area of research with VACV focuses on the development of 
vaccine vectors. The large size of the VACV genome, the ease of its genetic 
manipulation and the broad host cell range, as well as the improved safety profile have 
maintained VACV at the forefront of vaccine research in many disease models. 
 The two areas converge when considering the numerous VACV proteins that 
interfere with the host immune response. Identifying these proteins and characterising 
how they function not only allow better understanding of viral-host interactions, but 
also enables improvement of VACV immunogenicity. VACV immunomodulatory 
proteins characterised hitherto can be loosely divided into two groups. VACV proteins 
that are secreted from the infected cells and bind to inflammatory cytokines, 
chemokines or IFNs include B18, B8, B15, C12 and CrmE. These bind IFN-α/β, IFN-γ, 
IL-1β, IL-18 and TNF-α respectively, and thereby prevent the activation of the 
inflammatory cascades initiated by these cytokines, and impede the host immune 
response to infection. The second group act within the cell upon intracellular signalling 
pathways that orchestrate anti-viral responses. This group include A46, A52, B14, K1, 
K7, and M2 which inhibit the intracellular TLR/IL-1 receptor pathway and NF-κB 
activation, while F1 and N1 inhibit pathways leading to apoptosis. 
 While these proteins have been identified and their functions in infection 
defined, at least in part, there are many VACV proteins that are still ill-defined. At the 
outset of this project, VACV WR A40 was among these. It was noted that A40 bears 
sequence similarity to C-type lectins and had a type II membrane topology. 
Characterisation of VACV WR A40R (Wilcock et al., 1999) showed that the gene was 
transcribed early during infection and the gene product was glycosylated and present on 
the surface of infected cell but not incorporated into virions. While the absence of the 
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A40 protein did not affect the outcome of VACV infection in the mouse i.n. model 
(Wilcock et al., 1999), it resulted in attenuation in the i.d. model (Tscharke et al., 
2002). This suggested A40 might act as an immunomodulator. Unlike the two groups 
of VACV immunomodulators described above, A40 is present on the cell surface and 
so might act via altering cell-to-cell contacts. In contrast to the work of Wilcock et al., 
(1999) another group reported that the A40 protein was modified by sumoylation, 
allowing it to localise to the viral factories where it was postulated to have a role in the 
fusion of ER cisternae to enclose the VACV replication sites.  
 The goals of this project were to re-define the properties of the VACV WR A40 
protein including its temporal expression, localisation and post-translational 
modifications, and to understand where, when and how A40 might exert its function. 
The mechanisms by which A40 affects the host immune response were investigated 
focusing on its role in the in vivo intradermal model of infection. To understand the 
mechanism of action of A40, binding partners for A40 were sought by the production 
of recombinant A40 that was tagged with a biotin acceptor peptide. 
 
7.2 VACV WR A40R gene and protein product 
 VACV WR A40R is located in the right-hand region of the virus genome, a 
region rich in immunomodulatory proteins. For instance, gene A41L encodes a CC 
chemokine binding protein (Ng et al., 2001; Clark et al., 2006; Bahar et al., 2008), 
gene B8R encodes an IFN-γ receptor (Alcami & Smith, 1995) and gene B15R encodes 
an IL-1R (Smith & Chan, 1991; Alcami & Smith, 1992; Spriggs et al., 1992a). The 
A40R ORF is 480 bp long and is predicted to encode a 159 aa protein with a mass of 
18.1 kDa. Bioinformatic analysis showed A40 WR is identical to proteins encoded by 
many strains of VACV including Lister and RPXV Utrecht. In other VACV strains or 
orthopoxviruses there are closely related proteins that have variations near the C –
terminus and some additional amino acid substitutions. For instance, the VACV 
Copenhagen A40 protein shares 80 % aa identity with VACV WR but differs in the last 
22 aa where these residues are replaced with 31 distinct residues due to a frameshift 
mutation. Whilst VACV A40 WR differs in aa sequence from these strains, the A40 
from WR represents the majority species and so justifies why this strain was studied 
rather than Copenhagen. The Ab raised against the VACV strain WR A40 protein 
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expressed in bacteria, detected the A40 protein in cells infected by all the VACV 
strains tested that encode an identical A 40 protein. In addition, this Ab detected 
slightly different A40 proteins made by other VACV strains including Copenhagen. 
The ability of this Ab to detect VACV Copenhagen A40 shows that the A40 variants 
made by VACV strains WR and Copenhagen are stable. Although VACV WR & 
Wyeth are both derived from NYCBH, the Wyeth strain does not express A40 
recognised by this polyclonal Ab. The reasons for this are unclear, but possible 
explanations could be a promoter or frameshift mutation.  
 The characteristics of the A40 protein defined by Wilcock et al., (1999) were 
verified and A40 was shown to be expressed early in infection appearing within 2 h p.i. 
This is logical for its role in modulating the innate immune response to infection. Its 
expression prior to viral DNA replication would allow it to interact with the host 
immune system before late viral proteins are expressed and enable it to either prevent 
or delay the host response to infection. The A40R gene product is heavily glycosylated 
with the unglycosylated 18.1 kDa protein representing only a small fraction of the A40 
protein produced during infection. Proteins ranging from ~25 – 40 kDa are the major 
forms produced during infection and these were shown to be glycosylated because 
treatment of infected cells with tunicamycin, or digestion of A40 protein with the 
endoglycosidase PNGase F, caused reduction in A40 size. The use of PNGase F to 
verify the post-translational glycosylation was necessary because tunicamycin can 
induce ER stress and consequently the production of unmodified A40 might have been 
due to disruption of the host cell translation and modification machinery. In addition to 
being glycosylated, analysis of A40 by native PAGE and SDS-PAGE in the absence of 
β-ME, indicated that A40 can form oligomers, predominantly dimers. The 
oligomerisation of the glycosylated A40 may allow to A40 to bind to its ligand with 
higher affinity as exemplified by C-type lectins. The stalk region of C-type lectins, such 
as DC-SIGN, is important for oligomerisation and this enhances Ag binding (Feinberg 
et al., 2005). In DC-SIGN, repeats of 23 amino acids form an extended neck region. 
The regions nearest the CRD stabilise the dimer while the regions near the N terminus 
are needed to stabilise a tetramer. A40 only contains 20 amino acids in the possible 
stalk region. This region may be able to stabilise oligomers by forming a coiled-coil 
and thereby increase the affinity for binding. 
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 While most characterised VACV immunomodulators are either secreted or 
intracellular, the localisation of A40 at the cell surface with type II topology suggests it 
modulates the immune response from this location. The type II topology means that the 
CLECT domain is exposed on the cell surface in a position to interact with other host 
cells.  
 The expression and purification of recombinant A40 from E. coli enabled the 
production of another Ab that was very valuable for this project. The new Ab 
recognised denatured A40 in immunoblots but also native A40 by immunofluorescence 
and thus allowed the study of A40 localisation within infected or transfected cells. The 
antibody was raised against the C-type lectin domain and therefore its recognition of 
A40 on live (non-permeabilised) cells confirmed the type II membrane topology of 
A40. This knowledge was essential in focusing the project towards binding studies 
using recombinant A40, rather than focusing on A40 with the infected cells. The 
recombinant A40 produced in E. coli was also used in crystallisation studies. The 
microfluidic trials produced crystals which diffracted to 8 Å. This was a good step 
forward, considering the protein was denatured from inclusion bodies and then refolded 
but needs to be improved. The use of selenomethionine to label the recombinant protein 
was tried but the yields were too low to be efficient by this mechanism and so the 
structure of A40 remains unsolved.  
 
7.3 Role of A40 in the intradermal immune response 
 Although the sequence of A40 from VACV strains WR and Copenhagen 
differ, the fact that deletion of the A40R gene from VACV strain WR resulted in virus 
attenuation and alteration in the immune response to infection, indicated that the WR 
A40 protein is functional. It was interesting that vΔA40 was attenuated in the i.d. but 
not i.n. infection model (Wilcock et al., 1999; Tscharke et al., 2002). In this regardA40 
is not alone in influencing infection in one model but not another (Tscharke et al., 
2002). The comparison of the response to infection by wild type or deletion mutant can 
be used to dissect the role of a particular protein even if a difference is seen in only one 
model. A40 may have a measurable effect on the i.d. but not i.n. model because of the 
difference in cell populations within the two areas. In the i.n. model, the outcome of 
infection can be measured by studying the weight change and infiltration of leukocytes 
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into the lungs or spleen. Within both the i.n. and i.d. model, T lymphocytes are 
recruited to the sites of infection by day 7 p.i and αβ-TCR+ T cells predominate over 
γδTCR+ T cells. In contrast to leukocyte recruitment in the i.d. model, neutrophils 
comprise <10% of the cells recruited to the lungs in an i.n. infection (Reading & Smith, 
2003a; Jacobs et al., 2006).  
 In the i.d model the loss of A40 caused an increase in the recruitment of 
macrophages and T cells early in infection. The increase in γδTCR cells in the absence 
of A40 in the i.d. model indicates this could be true as γδTCR cells are a large 
subpopulation with the skin. The local increase in MHC class II
+ 
cells following i.d. 
infection with vA40R compared to WT virus would attract more CD4+ T cells and 
these would produce cytokines that help attract CD8
+
 T cells and other leukocytes to 
target the infected cell and clear the host of VACV. This correlates with the observed 
slight increase in CD4
+
 T cells at day 2 p.i., which is followed at day 4 p.i. by an 
increase in CD8
+
 T cells.  
 The increase in macrophages seen in the absence of A40 allows the immune 
system to detect the infection earlier and this detection would allow APCs to return to 
the lymph nodes and interact with T cells, thereby increasing the response to the 
infected area. The macrophages would also help with the clearance of infected cells. 
Activation of tissue macrophages would result in secretion of IL-12 and TNF-α. IL-12 
induces differentiation of naive T cells to Th1. This promotes the production and 
release of IFNγ, which in turn promotes IL-12. This feedback loop maintains the 
activation and infiltration of further macrophage and NK cells. The Th1 response is 
important in clearing the virus. Collectively, these observations might suggest that A40 
is skewing the immune response towards a Th2 biased response. 
 The recruitment of leukocytes to the skin depends on cytokine and chemokines 
especially CCL2 & CCL3 (MCP-1 & MIP-1α) which recruit macrophages and T cells. 
When VACV strain WR gene B14R was deleted, there was also an increase in 
macrophage and T cell numbers in the infected tissue after i.d. infection (Chen et al., 
2008). This was explained by the ability of B14 to inhibit activation of IκB kinase and 
thereby the downstream pathway leading to NF-B activation. NF-B activation is 
needed for the production of many pro-inflammatory cytokines that are needed for 
leukocyte recruitment. While A40 could not function in this way because it is 
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expressed on the cell surface, it might interact with either macrophages or NK cells and 
thereby modulate the activation of these cells. In turn this would affect the production 
of cytokines and the consequent recruitment of more cells. 
 Although there was no significant difference in NK cell number when A40 was 
absent, A40 could still influence NK function by affecting the activation state of the 
infiltrating NK cells. Whilst no difference was seen in the cytolytic activity of NK or 
CTL cells extracted from infected ears, there may be a difference at earlier time-points 
that was not seen due to the low numbers of cells present. These cells may have been 
too few to give reproducible data within a cytotoxicity assay. In vitro, it was observed 
that infection of NK cells prior to incubation with uninfected target cells activated the 
NK cells and increased their cytotoxicity. This does not correlate with data from 
Kirwan et al., 2006 and these authors concluded that VACV infection of NK cells 
inhibited their ability to kill target cells. A plausible explanation is that the extent to 
which the NK cells are infected determines whether they are activated or rendered non-
functional. A higher m.o.i., or infection for longer duration, would tend to render the 
cells non-functional, whereas a lower m.o.i., or infection for a shorter time might 
merely activate the cells. The in vitro cytotoxicity assays demonstrated that A40 was 
produced in infected NK cells. This could be of advantage to the virus by allowing 
infected NK cells to further modulate the immune response even if viable virus progeny 
are not produced from these cells. The effect of A40 in vivo on cytotoxicity could be 
masked by the function of another, yet unidentified, VACV protein or the effect may 
not be significant at the particular time-points or p.f.u. used in these assays. 
 The in vitro cytotoxicity assays using the vΔA40 and vTAPA40 to infect target 
cells prior to incubation with NK cells, showed that the presence of A40 affects the 
ability of NK cells to lyse infected cells. VACV infection in the absence of A40 
slightly increased the ability of NK cells to recognise and kill infected cells. 
Conversely, in an infection where A40 was over-expressed, the ability of NK cells to 
kill these infected cells was diminished. This correlates with the ability of recombinant 
A40 to bind to NK cells. In vivo, the ability of NK cells to recognise infected tissue and 
lyse target cells as well as the activation and the resultant recruitment of further 
leukocyte populations is important in the clearance of infection. Whilst this ability to 
modulate NK killing was not seen in the extracted cells, this may be due to the time-
points analysed and the number of cells able to be extracted. Even if A40 does not 
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affect the number of NK cells recruited to the site of infection, an ability to modulate 
the activation of the NK cells that are recruited would be advantageous to VACV. By 
inhibiting NK activation and consequential release of cytokines, A40 would help mask 
the presence of VACV within the infected tissue, for at least a while, allowing the virus 
to replicate unhindered by the response mounted by the immune system.  
 As outlined in section 1.8.3.2, different OPVs affect NK cell function in 
different ways and A40 could have a novel function not yet seen in these viruses. 
Whilst MPXV does not affect MHC class I expression greatly, it does encode a protein 
that down-regulates T cell recognition, needs direct cell-cell contact and is MHC I & II 
independent (Hammarlund et al., 2008). In contrast, the CPXV protein CPV203 retains 
MHC class I molecules in the ER, thereby modulating the recognition of infected cells 
through presented viral peptide surveillance(Byun et al., 2007). Other genes of viruses 
such as the RCMV encode a PKR-P homologue thereby modulating NK recognition 
(Voigt et al., 2007). RCMV infection shuts off the expression of Clr-b, leaving infected 
cells sensitive to NK killing. By acting as a decoy ligand, the RCMV protein RCTL 
subverts the immune system‟s MHC-independent „self-nonself‟ surveillance. Could 
A40 act in a similar fashion to the RCMV protein RCTL which protects infected cells 
from NK killing by it interaction with NKR-P1B?  
 The modification of VACV strains to generate a better vaccine against smallpox 
and also to allow VACV to be used as a vector to express foreign antigens for 
vaccination against other diseases such as HIV or malaria is at the forefront in the study 
of VACV proteins and their interactions with the host. The consequence of the removal 
of A40R from VACV WR on virus immunogenicity was analysed by challenging 
animals that had been immunised with WT, deletion or revertant viruses 28 days 
previously with VACV WR i.n. This showed that animals immunised with vA40 lost 
less weight upon challenge and so were better protected. This indicates that the removal 
of A40 would beneficial for vaccine development. Many studies focus on the use of 
VACV strain MVA, due to its loss of many immunomodulators and its good safety 
profile, even in immunocompromised individuals. MVA still contains the A40R gene, 
but the protein has a different C-terminal sequence to VACV WR and this could affect 
function. However, the effect of this difference remains to be characterised. It remains 
possible that deletion of A40 from MVA might improve immunogenicity.  
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 The potential for A40 to interact with a ligand on the surface of another cell was 
investigated by a cell binding assay using recombinant A40 protein fused to BAP. This 
protein was produced in a mammalian system, allowing it to be glycosylated in the 
same way that it is during VACV infection. The biotinylation is highly specific and 
produces a ratio of one biotin molecule per recombinant protein molecule. This allows 
the molarity of the recombinant proteins to be determined using a known biotinylated 
standard. As the interaction between biotin and its ligand avidin is specific and high 
affinity (Kd = 10
-14
), and avidin and its derivatives are tetrameric, this provides a 
method for multimerising proteins and increasing the avidity for binding studies 
(Hanke et al., 1999). The biotinylated A40 proteins were bound to avidin-coated 
fluorescent beads and screened against different cell types. This screen revealed that 
both recombinant forms of A40 (with or without stalk region between the membrane 
and CRD) were able to bind some cell types but not others. Epithelial cells such as 
HeLa, HEK 293T and BS-C-1 cells did not bind A40, but some NK, B and T cells 
(NK92MI, RAW 246.7, AK31 and B3Z cells) did. Generally, the binding of A40 
containing the stalk region was higher than binding of A40 lacking this domain. When 
this study was expanded to include human PBMCs, recombinant A40 bound 
preferentially to populations enriched in monocytes. This is consistent with the binding 
seen to RAW 246.7 cells. CD8
+
 T cells express NK cell associated molecules like Ly49 
and NK1.1 upon activation and this might explain why A40 bound to certain T cells 
types in culture but not others. The ability of A40 to bind to immune cells and not 
epithelial cells indicates its function involves the modulation of the immune response 
not the surrounding epithelial cells or infected cell in which it was produced.  
 This binding to immune cells suggests that VACV A40 WR belongs to the 
expanding group of VACV immunomodulators that are not secreted and not involved 
in intracellular signalling and have been identified in other viruses such as the MHC 
class I mimics of CMV. In VACV, the group could be said to include VACV B18 and 
CrmE. While both proteins are present in a soluble form, they also have a 
transmembrane form which either block IFN-α transmembrane signalling (Colamonici 
et al., 1995; Alcami et al., 2000)or sequester TNF to prevent TNF-mediated 
killing(Saraiva & Alcami, 2001; Reading et al., 2002). 
 The nature of the molecule(s) bound by A40 remain unknown but this (these) 
includes a protein component because trypsin treatment prevented A40 binding. While 
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it is possible that the CRD of A40 is binding to carbohydrate attached to a protein 
backbone, and the trypsin treatment removed this backbone, it seems unlikely that A40 
interaction with cells is by carbohydrate alone. This is because all cells have 
carbohydrate on their surface, yet A40 bound to some cells and not others. A40 lacks 
the final conserved cysteine found in classical C-type lectins and that is required for 
carbohydrate binding (Drickamer, 1989). This might suggest that A40 is not a 
carbohydrate binding lectin. However, other lectins such as Clr lack a conserved 
cysteine and yet recognise certain GAGs in a Ca
2+ 
independent manner (Plougastel et 
al., 2001; Carlyle et al., 2004). 
 
7.4 Future work 
 The limitations of time meant that while the characterisation of A40 was 
advanced in this study, many questions are still unanswered. Using the reagents 
generated in this project, the study of A40 can be continued and the function of A40 in 
an immune response investigated further. 
 Expansion and refinement of the co-immunoprecipitation studies using 
membrane preparations from positive-binding cell types is a priority for this study. 
 The analysis of leukocyte infiltration could be expanded to investigate the 
activation state of the cells recruited in the presence and absence of VACV WR A40. 
Focusing on early time-points p.i., the recruitment and binding of A40 to other APCs, 
including DCs, could be investigated. In vivo, the analysis of leukocyte recruitment by 
flow cytometry could be focused on days 0-4 and on particular subsets of cells. In 
particular, cells which were relatively rare in the previous samples analysed, which 
would include but are not limited, to DCs. In vitro, the cell-binding assay could be 
expanded to include DCs cultured from mouse samples in collaboration with Dr 
Nathalie Jacob, University of Liege. Focusing on these cell types in i.d. murine samples 
may overcome the limiting sensitivity of the assay and the rarity of these cells in the 
previously performed wider screen. 
 To investigate in greater detail the host response to infection in the presence or 
absence of A40, the levels of cytokine expression could be measured by RT-PCR using 
RNA extracted from infected tissue, especially early after infection (day 0 -7). An 
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increase in pro-inflammatory cytokines might be anticipated in vΔA40 infected tissues 
that would recruit the increased number of macrophages and T cells to the site of 
infection. Primers have already been designed to encompass a variety of cytokines and 
chemokines thought to be important in the recruitment of leukocytes and the response 
to virus infections. For instance, transforming growth factor (TGF)-β is a 
chemoattractant for macrophages and it would be interesting to see if levels are 
elevated in after infection with vΔA40 compared to WT and Rev. Similarly, it would be 
interesting to investigate if IL-8 was increased after infection by vΔA40. IL-8 attracts 
neutrophils to sites of infection just before macrophages, which then produce TNF & 
IL-12. 
 So far the consequences of immunization with a virus lacking A40 have been 
investigated focusing on early time points (up to day 10 p.i.) by looking at the cellular 
response to infection and late time points (28 day p.i.) by evaluating the protection this 
immunisation provides. But there has been no measurement of antibody responses or 
the memory T cell response to VACV antigens. These parameters need investigation, 
for example by measurement of Ab levels and IFN-γ levels in vaccinated mice samples 
by ELISA. 
 Using the His-BAP-tagged A40 produced from the baculoviruses generated in 
this project, the question of whether the glycosylation of A40 affects its binding affinity 
or range could be investigated. Alternatively, binding studies with de-glycosylated A40 
proteins produced in mammalian cells could be performed. To perform these tests 
efficiently, larger quantities of the mammalian protein should be produced and purified 
from the stable cell lines grown in multi-flask culture systems. This was not preformed 
due to time limitations and would only be prioritised after identification of A40‟s 
ligand (s). 
 In summary, the most important task remaining is the identification of ligands 
for A40 on the surface of specific cells of the immune system. The identification of 
these ligands is key to understanding the mechanism of action of A40. The 
identification of such ligands might improve our understanding of the immune system 
and as precedent for this, the study of the HCMV UL18 protein and its ligands resulted 
in the discovery of the leukocyte immunoglobulin-like receptor (LIR)-1 (Cosman et al., 
1997).  
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